Index to Volume 48 - Cancer Research · thylpsoralen, 2015 Aneuploidy sequential development â€¢¿y-glutamyltransferase,skin papillo-mas, 3253 Anorexia cancer tumor necrosis factor

Index to Volume 48

Subject Index

Abclscm virus-infected promonocytic leukemia cells

viral oncogene expression, 1702Accessory cells

T helper cells andtumor-specific CTL generation, 1422

A-431 cellsAh receptor analysis, 2388isolation and characterization

epidermal growth factor, stimulation,2377

Acetaldophosphamideleukemic progenitor cell effects

bone marrow purging, 339Acetone

-inducible cytochrome P-450benzene metabolism, liver micro-

somes, 53872-Acetylaminofluorene

carcinogenesispremalignant hepatic nodules, DNA

adducts, 5270depletion of adenosine diphosphate-ribo-

syl transferasc in rat liver, 3581Acidification: see pHAcidosis

effect on cytotoxicityplatinum complexes, 2342

Acivicindipyridamole and

biochemical assessment, 5591inhibited nucleoside salvage, Phase I

clinical trial, 5585Aclacinomycin

enhanced activity of peritoneal cellsrespiratory burst, 3440

Acodazole hydrochloridePhase I trial

pharmacokinetics, cardiotoxicity, 44234'-(<>-Acridinylamino )nii'thanesulfon-Af-an-

isididcmethotrexate and

metabolic interaction, 5106Acrolein

enhancement of murine immune responses, 41

pathobiological effectshuman bronchial epithelial cells, 1717

Actinpolymerization in HL-60 cells, 6721

Actinomycin Dquantification by ELISA

ff-D-galactosidase label, 4843Adenine nucleotides

poly(ADP-ribose) metabolism alterationhyperthermia, 4233

Adenocarcinomabladder

epidemiological characteristics, 3853c-myc and c-fos differential expression

familial polyposis coli, 4855cervical

monoclonal antibody, immunodi-agnostic potential, 6565

coloniec-myc expression, recurrence and sur

vival, 1350DNA lesions, leucovorin-5-fluoropyr-

imidine, 4153effect, voluntary exercise, 7079glyceraldehyde-3-phosphate dehydro-

genase gene expression, 6354growth inhibition, methotrexate or 5-

fluorodeoxyuridine, 3319localization, radiolabeled monoclonal

antibodies, 4324mitoxantrone, Phase I study, 5874monoclonal antibody binding, cell sur

face antigen, 6573mono-, di-, and tri-O-acetylated sialic

acids, 483plasminogen activator profiles, 4520platelet-aggregating factor, mono

clonal antibodies, 6411pulmonary metastasis, mechanism of

inhibition, 3728restoration of differentiation, polyeth

ylene glycol, 2498xenografts, folate pools, 3062

colorectalcathepsin B-like proteinase, 6855serum, natural killer cell activity, 2596

endometrialheterogeneity, progesterone receptor

distribution, 1889gastric

xenograft growth, a-difluoromethylor-nithine, 3265

humanprostaglandin biosynthesis, 4770

interferon interactionshalogenated pyrimidine antimetabo-

lites, 4868lung

expression of a-amylase, 3292( rMâ€¢¿�ganglioside residue disrimination,

monoclonal antibodies, 6154incidence by histolÃ³gica!type, popula

tion-based registry, 6580risk factors, personal and family his

tory, 7279significance, K-ras activation, 5730thromboxane biosynthesis, 2674

mammarycell growth, semisolid clonogenic me

dium, 3995-deazaaminopterin, 5-alkyl deriva

tives, 5686differential expression, WDNM1 gene,

5203insulin effects, phosphatidylinositol ki-

nase, 6727insulin receptor kinase, diabetes and

sex steroids, 3742lymphatic metastasis, soybean agglu-

tinin binding cells, 1451overgrowth of primary tumors, genetic

evidence, 6109photosensitization, plasma membrane

enzymes, 3360suppression, genetic factor, 2204suppressor lymphokine production, T-

cells, 943ovarian

aromatization, testosterone, 6491characterization and properties, 6166effect, sodium butyrate, 6161

mitoxantrone, Phase I study, 5874pancreatic

glyceraldehyde-3-phosphate dehydro-genase gene expression, 6354

prostaticmetastatic potential, cell mol Â¡litv.

4312renal

anticarcinoma activity, rhodamine123,2061

salivary glandras p21, cAMP levels, 2898

sporadic amplification of HER2/neuprotooncogene, 1517

uterine cervixhuman papillomavirus types, 993

Adenocarcinoma cellshuman salivary

growth inhibition, normal human lÃ¬broblasts, 2819

Adenoma cellsgrowth of neoplastic thyroid cells

epidermal growth factor receptor,3652

Adenosine dialdehydeinhibitory effect

neuroblastoma growth, 5933Adenosine diphosphate-ribosyl transferase

depletion in liverexposure, ./V-2-acetylaminofluorene,

3581inhibitors

enhanced cytotoxicity, 6-thioguanine,5650

Adenosine 3':5'-monophosphate, cyclic

cellular proliferation and ras p21salivary gland adenocarcinoma, 2898

-dependent protein kinasesphorbol ester effect, teratocarcinoma

cells, 3993postconfluence growth arrest

lOT'/i fibroblasts, 1874site-selective analogues

cancer control, 1642vasoactive intestinal peptide receptors

breast cancer cells, 5079Adenosine triphosphatase

P-glycoproteinsmuitidrug resistance, K562/ADM

cells, 4926Adenosine triphosphate

anthracycline cardiotoxicity model, 5222flavone acetic acid-induced modulation

tumor physiology, NMR spectroscopy,4749

leukemia 1,1210 cell linesresistance, ribonucleotide reducÃasein

hibitors, 8395-Adenosylmethionine

formation in liverchronic feeding, Di.-ethionine, 4464

properties of LI210 resistant cellsa-difluoromethylornithine, 2678

Adi-novirus-12human bronchial epithelial cells

T-antigen transformation, 1904selective cytotoxicity

phospholipids, diacylglycerols, 578Adenoviruses

7401

Research. on December 5, 2020. © 1988 American Association for Cancercancerres.aacrjournals.org Downloaded from

http://cancerres.aacrjournals.org/

SUBJECT INDEX TO VOLUME 48

DNA amplificationcellular genotoxic stress, 3123

typeSmethyl methanesulfonate effect, libro

blast cells, 3050Adenylate cyclase

cellular processingvasoactive intestinal peptide, 6201

tumorigenicityS49 wild-type and eye" lymphoma,

641Adhesion

laminin-dependent and laminili inde

pendentsulfatides, melanoma cells, 3367

Adjuvantsactive specific immunotherapy

melanoma. Phase I trial, 5883contribution of medicine

primary treatment, breast cancer, 2314Adrenal cortex

strong expressionM, 170,000-180,000 P-glycoprotein,

4611Adrenal glands

regulation of mammary tumorigenesis,3801, 3808

Adriuimi-in: see also Doxorubicinantitumor activity of MX2

murine tumor cells, 6653cardiotoxicity

free radical formation, 4766doxycycline in combination chemother

apyleukemia, 6686

enhancement of antitumor activitypolymethacrylate nanospheres, U937

cells, 1835flow cytometric localization

isolation of viable cells, 5742glutathione contents

human and rodent tumor cells, cellcycle phases, 3661

increased levels in hepatic implantscarcinoma from regional infusion,

4584intrinsic drug resistance

possible link, detoxification mechanism, 3025

iron andreappraisal of association, 5645

liposome-encapsulated Adriamycin oralterations, murine host defense func

tions, 130multifactorial resistance

P388 leukemia, 3595potentiation of cytotoxicity

dipyridamole, HeLa and sarcoma 180cells, 1208

recurrent tumor sensitivityrat model, mammary tumors, 4549

resistance and sensitivitymetallothionein induction, prostatic

carcinoma, 4503-resistant cells

85-kDa protein, 7082vinculin phosphorylation. protein ki-

nase C role in HL-60 cells, 3324therapy effect

monocyte activation, liposome-encapsulated immunomodulators, 5256

tolerance in Chinese hamster ovary cellsantioxidant defenses, glutathione,

4493

Aflatoxinphotoactivated

DNA strand scission, apurinic sites,3070

Aflatoxin B,adduction of active genes, 7146-dichloride DNA adducts

structural characterization, calf thymus DNA, 5391

DNA binding and glutathione conjugation

effects, butylated hydroxyanisole, 2688effect on glucocorticoid receptors

tyrosine aminotransferase, Reuberhepatoma cells, 5188

immunological detection of adductsin vivo formation, 6328

influence on duck liversduck hepatitis B virus infection, 1559

Agingdistribution of Wilms' tumor, 1653

DNA replication in hepatocytesunscheduled DNA synthesis, 1618

growth of Sinclair swine melanoma,1708

Aircarbon dioxide mixture or

pH mollificai ion. hydralazine and glucose, 1543

Albumindifferential regulation of Â«,-fetoprotein

hepatocyte hybrids, 6371embryonic liver epithelial cell lines, 4909lack of

marker of preneoplastic hepatocytes,albumin-positive liver, 387

Alcoholbreast cancer epidemiology, 5615comparative epidemiology of cancer

United States, Italy, 7285consumption

risk of breast cancer, 2284drinking and smoking

oral and pharyngeal cancer, 3282esophageal carcinoma, 3843

Aldehyde dehydrogenasecytosolic

characterization, LI210 cells, 2963deficient carboxyphosphamide excretion

cyclophosphamide administration,cancer patients, 5167

role in survival of progenitorsmurine blast cell colonies, 4-hydrope-

roxycyclophosphamide, 1223tumor-associated

gene expression, hepatoma, 7009Alkaline phosphatase

uptake of WR-2721 derivativestransported form of drug, 3634

WR-2721radioprotection of cells, 3641

Alkylating agentsantitumor effects of pentoxifylline

thiotepa, human cancer cells, 4375chemosensitization by misonidazole,

3528chemotherapy of medulloblastoma cell

linestransplantable xenografts, 4189

cytotoxicityinduction, sister chromatid exchange,

3100m-diamminedichloroplatinum(Il) and

gene expression, Escherichia coli, 4823

effect of doseclinical correlation, 6417

ethacrynic acid and piriprostcytotoxicity effect, 3622

point mutation of ras protooncogenesacute nonlymphocytic leukemia, 1812

(f-propiolactoneH-ras oncogene activation, mouse car

cinoma, 556protection of Ehrlich ascites tumor cells

nitrogen mustard, 5-jV^V-dimethylami-loride, 2454

06-Alkyldeoxyguanosinedetection by "P-postlabeling

nucleotide Chromatographie analysis,2156

Alkylglycerolsactivation of macrophages

cancerous tissues, 604406-Alkylguanine-DNA alkyltransferase

inactivationnitrosourea potentiation, leukemic

cells, 1521regeneration in lymphocytes

nitrosourea exposure, 5368secondary leukemia. 3084

Alkyl lysophospholipidmodification of cell surface carbohy

dratesinvasive behavior, 977

reduction of epidermal growth factorbinding

breast cancer cell lines, 6033Aluminum:nickel alloy

decontamination and disposalosoureas, related A'-nitroso compounds,

522Alveolar nodules

hyperplastictransplantation, gland-free fat pads,

3197Alveolar type II cells

origin of papillary lung tumorsA'-nitrosoethylurea-induced, 148

Amino acidsbranched chain

pan-literal nutrition, Yoshida sarcoma,2698

4-c/i-hydroxy-L-prolinegrowth sensitivity, transformed rodent

cell lines, 24839-Aminoacridines

DNA damage and cell kill, 8607-Aminoactinomycin D

activation of B-cellseliminatili structure, flow cytometry,

67084-Aminobiphenyl

cigarette-induced bladder cancereffects of timing, tobacco type, 3849

DNA adductsimmunochemical quantitation, 6336

6-Aminohexanoic acidinduction of differentiation

HL-60 cells, 36137a-(4'-Amino)phenylthio-4-androstene-

3,17-dioneeffect on mammary carcinoma, 6808

Aminopterin8-deaza analogues

cytotoxicity, polyglutamate formation,1481

1-Aminopyrene1-nitropyrene derivatives and

7402




carcinogenic activities, 4256Ammonium acetate

effects on colon carcinogenesisA'-methyl-Ar'-nitro-/V-nitrosoguani-

dine-induced, 3035Amonafide

limited sampling modelspharmacokinetics, 4127

AmsacrineDNA damage and cell kill

9-aminoacridines, 860production of protein-associated DNA

breaksLI210 cells, PZE, 1404

resistance of noncycling cells, 310Amsacrine analogues

Phase I trial of CI-921, 6593a-Amy lase

expression in human lung cancers, 3292Anchorage independence

cancer suppressor genegenetic assessment, hamster cells, 46

requirement for transformationtumor promoter exposure, 7126

Anchorage-independent growthcomparison of growth requirements

monolayer and soft agarose, colon carcinoma, 2469

reversible inductionepidermal keratinocytes, 1566

Androgenaromatization of testosterone

ovarian epithelial tumor cells, 6491conjugate content in breast cyst fluid

epidermal growth factor, 5860-dependent Shionogi carcinoma

early phases of regression, geneexpression, 6309

estrogen-stimulated hormone receptorprofiles

prostatic carcinoma, 3077-independent prostate carcinoma

testosterone, 5a-dihydrotestosterone,609

-responsive and -unresponsive cellsautocrine growth factor, paracrine

mechanism, 4904testosterone effect on B16 melanoma

imidazole-induced tyrosinase expression, 3586

AnemiaFanconi's

repair of DNA damage, 4,5',8-trime-

thylpsoralen, 2015Aneuploidy

sequential developmentâ€¢¿�y-glutamyltransferase,skin papillo-

mas, 3253Anorexia

cancertumor necrosis factor as mediator,

4567Anthracycline

cardiotoxicity modeladenosine triphosphate/protein ratios,

5222hemin-induced cell protection

hemopoietic cells, 3566morpholinyl

selective inhibition, ribosomal genetranscription, 4101

partial reversal of doxorubicin resistanceforskolin, murine sarcoma S180 var

iants, 539

second-generationinteraction with polynucleotides, 6962

Anthroneschrysarobin

epidermal polyamine levels, DNA synthesis, 6390

Anthropometrybreast cancer risk assessments, 5363

Antiantibodytumor targeting

human colonie tumor xenografts, 2005Antibodies: see also specific type

antiidiotypicmonoclonal antibody, carcinoem-

bryonic antigen, 4002anti tumor

diffusion and binding, spheroids, 4032methotrexate conjugate, nature of

linkage, 3330Andes trogens

growth inhibitionbreast cancer, 6819

regulation of growth and invasivenessMCF-7 cells, 6764

tamoxifen and hydroxytamoxifenv.v.estradici effects, normal breast

cells, 7193Antifolates

interactions, 2421lipophilic

trimetrexate transport, lymphoblastoidcells, 6986

Antileukemia agentseffects on nuclear matrix-bound DNA

replicationCCRF-CEM leukemia cells, 1850

Antineoplastic agentsplatinum(rhodamine-l 23)2

m-diamminedichloroplatinum(II),squameHIScell carcinoma, 5101

Antiobesity drugsnovel dehydroepiandrosterone analogues

enhanced biological activity, reducedside effects, 4817

Antioxidant enzymesxeroderma pigmentosum fibroblasts,

2132Ant Â¡tumoractivity

Adriamycinpolymethacrylate nanospheres, U937

cells, 1835antibody-dependent cellular cytotoxicity

LAK cells, 1173augmented effect of interleukin-la

indomethacin, 584COS 16949A

hormone-dependent and -independenttumors, 834

m-diamminedichloroplatinum(II) andanalogues

myelotoxic concentrations, 3135deglycosylated ricin A-chain immunotox-

inshindered disulfide linkages, 6396

enhancement of l-hexylcarbamoyl-5-fluorouracil

hyperthermia, Ehrlich ascites tumor,3977

FK973, 1166interleukin 2

interferons, syngeneic murine tumors,260

tumor necrosis lac tor ri, 4011LAK cell generation from blood

glioblastoma patients, 6069quinocarmycin

leukemia, lymphoma cell lines, 6029ricin A chain-containing immunotoxins

clinical trial evaluation, CD 19 andCD22 antigens, 2610

saporin immunotoxinshepatotoxicity, 7072

somatostatin analoguesoncological applications, 6977

12-O-tetradecanoylphorbol-13-acetateoleanane-type triterpenoid compounds,

5210Antitumor agents

FK973DNA cross-linking, LI210 cells, 5172

MX2murine tumor cells, 6653

polyamine metabolismneoplastic growth, chemotherapy, 759

testing ofsnail neurons, side-effects, 7184

Antitumor drugsditercalinium

loss, mitochondria! DNA, 4982quinone

resistance, L5178Y murine lympho-blasts, 1727

AphidicolinDNA repair as mechanism of acquired

resistancecisplatin, ovarian cancer, 5713

1-/3-D-ArabinofuranosyIcytosineclinical pharmacology

effect of tetrahydrouridine, 13372',2'-difluorodeoxycytidine and

comparison, toxicity, 4024doxycycline in combination chemother

apyleukemia, 6686

effects of incorporation on elongationDNA polymerase 0, 1494

flow cytometric localizationisolation of viable cells, 5742

5-hydroxymethyl-2'-deoxyuridine

promyelocytic leukemia cells, 3117influence of lipid conjugates

growth and metastasis, Lewis lung carcinoma, 826

in vivo pharmacodynamicssynergy, m-diamminedichloropla-

tinum(II), 117metabolic activation

bromodeoxyuridine enhancement, HL-60 cells, 517

modulation of arabinonucleoside metabolism

arabinosylnucleotides, 329vincristine and methotrexate combina

tionacute lymphoblastic leukemia, 351

L-Arabinoseresistance test with Salmonella typhimu-

riumprimary tool, carcinogen screening,

907Arabinosyl-5-azacytidine

preclinical pharmacologynonhuman primates, 4294

9-/3-D-Arabinosylguaninemodulation of antibody response

natural killer cell activity, purine mi -cleoside analogues, 4799

Arabinosylnucleoside

7403




modulation of metabolismhuman leukemia cells, 329

Arachidonic acidenhanced activity of peritoneal cells

aclacinomycin, respiratory burst, 3440evidence for thromboxane biosynthesis

lung adenocarcinomas, 2674linoleic acid and

thymidine incorporation, hepatoma,3106

metabolite releasebryostatins and phorbol esters, C3H

10T'/2 cells, 3702

profiles of prostaglandin biosynthesisnormal lung and tumor tissue, lung

cancer patients, 3140A roma tase

antitumor effects of CGS 16949Ahormone-dependent and -independent

tumors, 834inhibitor

effects on mammary carcinoma, 6808ovarian epithelial tumor cells, 6491

ArylaminesÂ¿V-hydroxyderivatives

DNA repair, urinary bladder epithelialcells, 4227

Aryl hydrocarbon hydroxylasel/i receptor analysis

A43I squamous cell carcinoma, 2388mono- and bifunctional enzyme inducers

in liver, 4776Asbestiform minerals

induction of ornithine decarboxylase activity

trachea! epithelial cells, 709Asbestos

diet and mesotheliomacase-control study in Louisiana, 2911

-induced mesotheliomaschromosomal translocations, specific

breakpoints, 6455occupational risk factors

laryngeal cancer, Texas Gulf Coast,1960

Ascitesfibrin-fibronectin degradation

ovarian carcinoma, 3507hepatoma cells

factor with antiinvasive potential fromrat liver, 3760

pantropic killer cellsadoptive immunotherapy, OK-432,

4163predictive value

in vitro clonogenic assays, 5447Ascitic fluid

growth factorovarian cancer, 1066

pleural effusions andinterleukin 2-inducible killer cells,

6321i.-Ascorbic acid

amplification of second-stage bladdercarcinogenesis

promotion by NaHCOi, 6317Aspartate carbantoyltransferase

A'-(phosphoacetyl)-i--aspartate biochemistry, 4441

Aspirinrisk of colorectal cancer, 4399

Assaysaffinity chromatography

target proteins, Bowman-Birk protease

inhibitor, 1798antibodies against 7-methyldeoxyguano-

sine, 5065benzo(a)pyrene

anticarinogen detection, natural products, 6257

bromodeoxyuridine/DNAmethotrexate effects, LI210 cells,

4288bromodeoxyuridine labeling method

analysis, chromosomal DNA replication pattern, 219

capillary human tumor clonogenic celloptimization, characterization, 715

chemotherapeutic drug sensitivitycolon carcinomas, monolayer culture,

3236clonogenic

growth requirements, acute lympho-blastic leukemia cells, 5901

prediction, response to tumors, 5447purging regimens, mice, 3394vital cell counting and, 5722

comparative light microscopic, ultra-structural, and immunohistochemi-cal

alveolar type II cell origin, papillarylung tumors, 148

dextran-coated charcoalSAMBA 200 analysis of estrogen re

ceptors, breast carcinoma, 1578differential hybridization analysis

fibronectin messenger RNA, prostaticcancer, 2042

differential responsiveness of breast cancer cells

growth factors, 17/3-estradiol, 4083DNA precipitation and alkali unwinding,

6444dual label fluorescence technique

monoclonal antibody-drug conjugates,6211

ELISAactinomycin D quantification, /3-D-ga-

lactosidase label, 4843extracellular matrix invasion

protein gels, 6933fluorescence-detected antibody binding

tumorigenicity, murine lymphomas,270

genotoxicity of jV-nitroso compoundshepatocytes, 4144

immunoassayshuman chorionic gonadotropin, detec

tion of antigens in urine, 1361immunoenzymatic

cathepsin D, breast cancer cytosols,462

limited sampling modelsaim mat ule pharmacokinetics, 4127

Luria-Delbruck fluctuation analysispitfalls and practice, 1060

microculture tetrazoliumfeasibility of drug screening, panels of

human tumor cell lines, 589monoclonal antibodies as immunotoxins,

1119multiparametric (SAMBA)

anti-Ki67, breast carcinoma, 4368new medium-term bioassays

development of, carcinogens, 5051"P-postlabeling and nucleotide Chro

matographiedetection of Â¿T'-alkylguanosine,2156

purification and characterization of P-52normal and preneoplastic liver nod

ules, 2805quantitative studies

tumor transplant ahi Iit) in mice, 6510quantitative transplantation

spontaneous tumors, C3H mouse,4525

repair of i^-methylguanineoligodeoxynucleotides, 1184

semisolid clonogenic mediumgrowth, mammary adenocarcinoma

cells, 399soft-agar clonogenic

tumor cell viability, inoculum density,3944

soluble tetrazolium/formazanevaluation of, human and other tumor

cell lines, 4827tumor-associated galactosyltransferase

isozyme II, 5325, 5335tumorigenicity

activated ras genes, human melanomas, 950

two-dimensional gel electrophoreticanalysis

Friend erythroleukemia cells, 1110visual grading system

metastatic potential, cell motility,4312

Astrocytomatreatment-induced changes in sensitivity

multiclonal tumor mixture model,2749

Ataxia-telangiectasia cellscancer in homozygotes and hÃ©tÃ©rozy

gotes of patients in Britain, 2929heterogeneity in chromosome damage

repair rates, bleomycin, 276impaired glutathione biosynthesis, 5374

Australiacancer in migrants, 751

Autoanti bodiesantigen expression

paraneoplastic dorsal root gangliono-pathy, small cell lung carcinoma,430

Autocrine growth factorandrogen-responsive and -unresponsive

cellsparacrine mechanism, 4904

pre-B-cell stimulating activitymalignant pre-B-cell lines, 6438

regulation of epidermal growth factor receptor

1,25-dihydroxyvitamin D.i, breast cancer cells, 2734

response of lung carcinoma cell line,4976

transferrin-likeT-lymphoma cells, normal prolifera

tion, 3425Autocrine growth inhibitor

transforming growth factor-|8ER-negative breast cancer cells, 3898

AutoradiographyM, 97,000 to 250,000 protein antigen

concentrations, melanoma, 54755-Azacytidine

therapy by directing differentiation, 19965-Aza-2 '-deoxycytidine

phenotypic changes in neoplastic cells,2440

Azoxymethane

7404




aberrant crypts as preneoplastic lesions,6187

-induced colon carcinogenesisdietary eicosapentaenoic acid, effect,

4790a-difluoromethylornithine, growth in

hibition, 6498effects of voluntary exercise, 7079inhibition, dietary ethanol, 3313omega-3 fatty acids, 6642oncogene expression, retroviral-like se

quences, 3964

B

Bacteriamammalian cells and

mutagenicity, CC-106S and analogues,32

significance of floralung mÃ©tastases,3031

BALB/c 3T3 cellsgap-junctional communication

cell transformation, 3490p32 cDNA clone isolation, 4795uniqueness of spontaneous transformant,

2512Basement membrane

bile duci ular epithelial cell cultures, 6145interaction of intravascular tumor cells

endothelial cells, subendothelial matrix, 4065

invasion by metastatic cellseffects of inhibitors, 3307

B-cellsactivation of

chromatin structure, flow cytometry,6708

chronic lymphocytic leukemiadistribution, doxorubicin metabolites,

5031,25-dihydroxyvitamin D} receptor

modulation, myeloma cell line, 1213pre-

autocrine production, 6438T-cell receptor gene rearrangements

immunoglobulins, Hodgkin's disease,

3591Benoxaprofen

phagocytes andDNA damage, 3094

Benz(a)anthraceneAh receptor analysis

A431 squamous cell carcinoma, 2388Benzene

-inducible cytochrome P-450metabolism, liver microsomes, 5387

metabolitesoxygen radicals, induced DNA dam

age, 4762Benzo(a)pvrene

assay for detection of anticarcinogensnatural products, 6257

-induced skin tumorigenesisprotection, tannic acid, 2361

species differences in DNA adduct formation

dermal fibroblasts, 7132systemic effects

ultraviolet irradiation, 620Benzo(<i)pyrene diol-epoxide

resistance of mitochondria! DNA to inutagenesis

HeLa cells, 4578Benzodiazepine

bindingisoquinoline, glioma imaging, 5837

Benzotriptgastrin antibodies

colon carcinoma, 7179Bile

human4-hydroxy-JV-desmethyltamoxifen me

tabolite, tamoxifen, 2304Bile acids

biliary metabolites of fluoropyrimidines,2010

Bile ductepithelial cells

cultures, extracellular matrix substitutes, 6145

tumor markers CA 19-9 and CA-50carcinoembryonic antigen, pancreatic

neoplasms, 1985Biochanin A


Biological response modifiersOK-432

adoptive immunotherapy, pantropickiller cells, 4163

Biotechnology productsin cancer therapy, 223

Bis-chloroethylnitrosoureaD,L-buthionine-S,/Ã®-sulfoximineeffect

cytotoxicity, human melanoma cells,19

l,3-Bis(2-chloroethyl)-l-nitrosoureaeffect of thymidine on activity, 4272tumor bioenergetics and histology

nuclear magnetic resonance spectros-copy, 676

yV,/V'-Bis(2-chloro)-/V-nitrosourea

effect of alkylating agent doseclinical correlation, 6417

CM-Bis-neodecanoato-frani-Ã„,Ã„,-l,2-diaini-nocyclohexaneplatinum(II)

cellular pharmacology, 1300entrapment in multilamellar lipid vesi

cles(â€¢/s-diamminedichloroplatinum(II) cy

totoxicity, 4509Bladder

carcinogenesisNaHCOj promotion, ascorbic acid

amplification, 6317Bladder neoplasms

antitumor effects of pentoxifyllinethiotepa, human cancer cells, 4375

cigarette-inducedeffects of timing, tobacco type, 3849

comparative carcinogenesisnitrosomethylalkylamines, 6648

differential repair of platinum-DNA ad-ducts, 3019

glycosyltransferases, 4427increased levels

fibroblast growth factor-like activity,2083

malignant properties of sublinesactivated c-Ha-ros oncogene, 4993

motor exhaust-related occupations, 1989photodynamic effect

hematoporphyrin derivative, 6115quantitation of DNA adducts

4-aminobiphenyI, 6336relation to cigarette smoking, 4405site-specific analysis of total serum cho

lesterol

incident cancer, National Health andNutrition Examination Survey, 452

transplan tablemetallopurpurin derivatives, photody

namic therapy, 194Blast cells

acute myeloblastic leukemia cellsproduction, growth potentiating fac

tors, 6424effect of 4-hydroperoxycyclophospham-

idehemopoietic progenitors, 1223, 2348

Bleomycinbromodeoxyuridine and

cytotoxicity and DNA strand breaks,tumor cells, 4244

effect on murine tumor cellselevated temperatures, pH values, 615

elimination of T-suppressor activity,6658

heterogeneity in chromosome damageand repair

ataxia-telangiectasia cells, 276hyperthermia and radiation

combination therapy development,6291

phleomycin andinternucleosomal cleavage, yeast, 6837

vincristine and methotrexate combination

acute lymphiÂ»hlasiicleukemia, 351Blood

hyperlipemicthymidine incorporation, hepatoma,

3106LAK cell generation and antitumor ac

tivity in glioblastoma, 6069Blood-brain barrier

delivery of monoclonal antibodies, 4725disruption

methotrexate, rat brain tumors, 694Blood flow

elimination of 5-fluoro-2'-deoxyuridine

in liver, 3561monoclonal antibody uptake

Clouser and renal cell xenografts, 188systemic hemodynamics

galactose injection, 1476tumor

determinants of, 2641measurement, NMR spectroscopy,

3449venous pH and

Walker 256 carcinoma, hyperglycemia,1201

Blood group antigensgene-encoded glycosyltransferases

normal and malignant bladder urothe-lium, 4427

germ cell neoplasms, 5342IgG3 monoclonal antibody

Tn antigen, 4361Le" antigens

comparison between human colon andpancreas, 3834

Lex and Le>

human pancreatic cancer, 475pancreatic cancer cells, 5422related antigens in human urothelium,

4113serum type 1 chain antigens, 3856structural variation of A antigens

normal colon and carcinomas, 181Bloom's syndrome

7405




relation to human fibroblast strain46BR, 6343

Bombi-silismall cell lung carcinoma

antagonists, effects on growth, 4783exogenous administration, effects on

growth, 1439-stimulated gastrin

gastric cancer, 2296Bone

metastasismurine model. 6876

-resorbing activityinterleukin-1Â«,adult I cell leukemia,

4284Bone marrow

5-bromo-2'-deoxyuridine incorporationpharmacodynamics, VX-2 tumors,

6900diethyldithiocarbamate inhibition of tox-

icitycu-diamminedichloroplatinum(II),

5708a-difluoromethylornithine

methylglyoxal bis(guanylhydrazone)and. Phase I study, 1367

DNA cross-linkinginfluence of WR2721, nitrogen mus

tard, 6002growth requirements

acute lymphoblastic leukemia cells,clonogenic assay, 5901

i.-histidinol effect5-fluorouracil metabolism, murine tu

mor system, 6664interleukin 1 secretion

â€¢¿�y-interferon,1,25-dihydroxyvitaminD,, 1740

macrophagescytotoxin release, 7-interferon, 1808

metastasismurine model, 6876

Ph-positive myelocytic leukemiasister chromatid exchange, 745

progenitor cellsprotein synthesis, thermotolerance,

3630radiobiological features, acute lympho

blastic leukemia, 5788purging

clonogenic assays in mice, 3394leukemic progenitor cell effects, acetal-

dophosphamide, 339soybean agglutinin, breast cancer cell

removal, 4573review of hemopoietic growth factors,

5624Bone marrow cells

cytotoxic effects of iodobenzylguanidineneuroblastoma cell lines, 2993

Boronneutron capture therapy

murine melanoma, 6313Bowman-Birk protease inhibitor

potential intracellular target proteinsaffinity chromatography, 1798

Braincytotoxicity of alkylating chemothera-

peutic agentsinduction, sister chromatid exchange,

3100human malignant glioma

two types of receptor, insulin-likegrowth factors, 1233

human neuroblastomaidentification, guanine nucleotide-

binding protein, 2756metastasis

highly pigmented melanoma variant,4897

osmotic blood-brain barrier disruptionmonoclonal antibody delivery, 4725

site-specific metastasismelanoma and fibrosarcoma, 3478

transplantability of tumorsquantitative studies, 6510

Brain neoplasmsadoptive immunotherapy

LAK cells, 2047antiproliferative effect of verapamil,

3617fetal forebrain transplants

iV-nitrosoethylurea induction, oligo-dcndrogliomas, 2871

glioblastoma multiformeselective amplification, epidermal

growth factor receptor, 2711malignant

interleukin 2, LAK cells, 5011pediatrÃ¬e

chromosome abnormalities, 175Breast

antiestrogens and, 7193cancer

antiestrogen-induced growth inhibition, 6819

cyst fluidepidermal growth factor, 5860

epithelial cellsgrowth factor and oncogene expres

sion, 7041localization of estrogen receptor, 6517neoplastic tissues

11Pmagnetic resonance profiles, 5112

Breast cancer cellsdegradation of extracellular matrix

cathepsin D, 3688differential responsiveness

growth factors, 17/3-estradiol, 4083effects of steroid hormones

peptide growth factors, c-fos expression, 802

endocytosis and intracellular routingantibody-ricin A chain conjugate, 3822

epidermal growth factor gene expressionregulation by progestins, 4555

estrogen receptor-negativebiological activity, transforming

growth factor-/3, 3898glucose metabolism

magnetic resonance spectroscopy, 870interaction of phenol red

estrogenic and antiestrogenic action,3693

precursor of cathepsin Dmonoclonal antibodies, 3709

proliferation effects of melatonin, 6121regulation of epidermal growth factor re

ceptor1,25-dihydroxyvitamin D.,, 2734

regulation of growth and invasivenessantiestrogens, 6764

removal ofsoybean agglutinin, model for purging

marrow, 4573steroid insensitivity

genetic instability, 4340vasoactive intestinal peptide receptors,

5079VP-16-induced DNA strand breaks

mechanism of action, 5096Breast neoplasms

alcohol consumption and risk, 2284bromine-80m-labeled estrogens

therapy, ER-positive cancers, 899cancer families

susceptibility to neoplasia, 5381cancer in migrants to Australia, 751cathepsin D in cystosols

immunoenzymatic assay, 462c-erbB-2 gene copy number and protein,

1238detection of chromosome aneuploidy

interphase nuclei, 5825detection of mammary serum antigen in

seramonoclonal antibodies, 7060

epidemiology, 5615estrogen-induced potentiation

DNA damage, topoisomerase 11-inter-active antitumor drugs, 297

estrogens as cause of human cancer, 246gross cyst disease

proteases, cyst fluid, 6379growth

Gompertzian model, 7067heterogeneous populations

kinetic and morphometric responses,3276

human breast epithelial cellsphenotypical changes, carcinogens,

2837human-human hybridomas

monoclonal antibodies, 3208insulin-like growth factor

mRNA expression, 6691receptors, 6429

interleukin 2-inducible killer cellsascitic fluid, pleural effusions, 6321

malecase-control study, 1326

metastaticcomparison, CAI5-3 and carcinoem-

bryonic antigen, 4107model for survival, 5565iV-nitrosomethylurea-induced

polyamines, progesterone, 3058plasminogen activators

relation, estrogen and epidermalgrowth factor, 6603

premenopausalendocrinology, tamoxifen, 1026

primary treatmentcontribution of medicine, 2314

progesterone receptor localizationanti-receptor monoclonal antibodies,

6462radioimmunotherapy

monoclonal antibodies, human milkfat globule, 4664

receptors of EGF and insulin-like growthfactor I

relation to steroid receptors, 1343reduction of epidermal growth factor

bindingalkyl-lysophospholipid, 6033

risk assessed by anthropometry, 5363risk factors

Chinese women in Shanghai, 1949synergistic inhibition of growth

cyclic AMP analogues, 1642tissue-type plasminogen activator

7406




new prognostic marker, 1348tumor growth

disparate actions, tamoxifen, 812xenografts

metabolism in vivo, 7264Bromine-80m

-labeled estrogenstherapy, ER-positive cancers, 899

radiotoxicityestrogen receptor-directed therapy,

Auger electrons, 5805Bromodeoxyuridine

bleomycin andcytotoxicity and DNA strand breaks,

tumor cells, 4244cell kinetics in human malignancies

flow cytometry, 6238cytokinetic effects of methotrexate

L1210 cells, 4288enhancement of l-/3-r>arabinofuranosyl-

cytosinemetabolic activation, HL-60 cells, 617

labeling methodchromosomal DNA replication pat

tern, 219Schwannian cell differentiation

human neuroblastoma cell lines, 25315-Bromo-2'-deoxyuridine

incorporation into DNAtissue-specific pharmacodynamics,

VX-2 tumors, 6900induction of S-100 protein

neuroblastoma cells, 170Bromosulfopht halcin

-sensitive efflux route for methotrexatevincristine action, LI210 cells, 5995

Bryostatin 1-induced phosphorylation pattern mim

icryphorbol ester, HL-60 cells, 5984

phorbol 12,13-dibutyrate andinhibition of cell-cell communication,

epidermal cells, 447protein kinase C as receptor

phorbol ester tumor promoters, 1Bryostatins

phorbol esters, effects on C3H lOT'/zcells, 3702

Buccal cellsplatinum-DNA adducts

cancer patients, 5597Busulfan

induction of sister chromatid exchangechronic myeloid leukemia, 3435

Butano!cell surface cathepsin B-like activity,

1416extraction of tumor-specific antigens

fibrosarcoma, ultraviolet light-induced,7004

Buthionine sulfoximinecytotoxicity effect and DNA cross-link

ingcytostatic drugs, human melanoma

cells, 19-mediated glutathione depletion

enhanced melphalan cytotoxicity, me-dulloblastoma xenograft, 2764

n-Butyl alcoholtumor antigen characterization

autologous cytotoxic T-cell clone,3892

Butylated hydroxyanisolehepatic aflatoxin B, DNA binding

glutathione conjugation, 2688Butyrate

epidermal growth factor bindingDNA synthesis, hepatocytes, 6560

Cachectintumor necrosis factor as mediator

cancer anorexia, 4567Cachexia

alterations in protein synthesisNovikoff hepatoma, Yoshida sarcoma,

1554body composition changes

improvement, exogenous insulin, 2784branched chain amino acids

parenteral nutrition, Yoshida sarcoma,2698

noncachectic sarcoma patientsaltered leucine metabolism, 1374

whole body protein turnover rateresting energy expenditure, cancer pa

tients, 2590Cadmium

carcinogenesisdose-response, prostate and testes,

4656Caerulein

enhancement of gastric carcinogenesis,6332

Caffeic acidinhibition of TPA-induced tumor promo

tion in mouse skin, 5941Caffeine

breast cancer epidemiology, 5615cytogenetic damage and antineoplastic

effectEhrlich ascites tumor cells, cyclophos-

phamide, 1129influence of consumption

mammary gland development, 2078mammary tumorigenesis

unsaturated fat, 2074Calcitonin

gene-related peptidemolecular forms in human medullary

thyroid carcinoma, 2412transcriptional and posttranscriptional

modulationsodium n-butyrate, medullary thyroid

carcinoma, 2096Calcium

antiproliferative effect of verapamil,3617

behavior of murine epidermal cell linesinitiated and noninitiated skin, 435

-binding proteinpurification, multidrug resistance,

3173biomarkers of increased susceptibility

gastrointestinal neoplasms, cancer prevention, 235

bone-resorbing activityinterleukin-la, adult T-cell leukemia,

4284channels

u>-conotoxin and adenosine, Lambert-Eaton myasthÃ©niesyndrome, 4719

cholesterol sulfate accumulationesophageal epithelial cells, 5289

diet and high risk of stomach cancer inChina, 3518

inhibition of chemotactic peptide-in-duced elevation

phorbol 12-myristate 13-acetate, HL-60 cells, 2707

new growth factor in ascitic fluidovarian cancer. 1066

Phase 1clinical trial of carbetimer, 5353protein kinase C and

alteration, LAK cell activity, 635Calcium eliminati-

genotoxicity of chromÃ¢tesmouse embryo cells, 5280

Calmidazolium12-0-tetradecanoylphorbol-l 3-acetate

anddifferentiation modulation, colonie

cancer cells, 6173Calmodulin

antagonistsenhancement of immunotoxin activity

in ovarian and epidermoid carcinoma, 3919

inhibitorsgrowth inhibition, colon adenocarci-

noma, 3319cAMP: see Adenosine 3':5'-monophos-

phate, cyclicCamptothecin

identification of mammalian DNA topo-isomerase I

drug target, 1722-resistant CHO cell mutants, 6404

Canceretiology

rare events as clues, 3544families: see also Cancer family syndrome

susceptibility to neoplasia. 5381head and neck

Clq binding macromolecules, immunecomplexes, 5868

cytotoxicity, natural killer cells, 5017pharmacokinetics. m-diamminedichlo-

roplatinum(Il), 3869migrants to Australia, 751nonrandomness of chromosome aberra

tions, 7120risk associated with

adult stature, 1658Cancer family syndrome

normal ( > chromosomal radiosensitivitycell survival, 2579

twenty-four kindreds. 5358Cancer suppressor genes: see GenesCarbetimer

Phase I clinical trial, 5353Carbogen

breathingfluosol-DA (20%), hypoxia, 3350

Carbohydrate antigen 15-3carcinoembryonic antigen comparison

metastatic breast cancer, 4107Carbohydrate antigen 19-9

CA-50 andpancreatic cancer and benign diseases,

1985comparison of sialylated Le" antigens

colon-rial and pancreatic tissues, 3834DU-PAN-2 and

expression in tumor tissue and serum,pancreatic cancer, 1435

expressiongastrointestinal tumor-associated gly-

coprotein, 1505Carbohydrate antigen 125

tumor marker expressionovarian carcinoma, glucocorticoids,

7407




3502Carbohydrate antigens

serum type 1 chain antigens, 3856Carbohydrates

cell surfacemodification and invasive behavior, al-

kyl lysophospholipid, 977metabolizing enzymes

profiles, hepatocellular carcinoma, 467Carboxyphosphamide

deficient urinary excretioncyclophosphamide administration to

cancer patients, 5167Carcinoembryonic antigen

antiidiotype antibodiesmonoclonal antibody, cancer patients,

4002CA 15-3 and

comparison, metastatic breast cancer,4107

CA 19-9 and CA-50tumor markers, pancreatic cancer and

benign diseases, 1985cell surface glycoprotein expression

colorectal carcinoma, 7257chromosomal localization of gene family

differential expression, various tumors,2550

DNA hypomethylationcorrelation, colon carcinoma, 5674

growth potential of human colorectalcarcinomas, 1689

protein secretiontransforming growth factor-/3, colon

carcinoma, 4059radioimmunotherapy

colonie cancer xenografts, 3270radiolocalization

polyclonal and monoclonal antibodies,1823

transcription of genesmalignant and nonmalignant human

tissues, 3153Carcinogenesis

2-acetylaminofluorenepremalignant hepatic nodules, DNA

adducts, 5270adult stature and risk of cancer, 1658antioxidant enzymes

xeroderma pigmentosum fibroblasts,2132

azoxymethane-induced colonieomega-3 fatty acids, 6642

bladderNaHCO, promotion, ascorbic acid

amplification. 6317cadmium

dose-response, prostate and testes,4656

cancer suppressor genegenetic assessment, hamster cells, 46

chemicalcytochrome P-450 enzymes, cancer

chemotherapy, 2946Sudan Ill-induced prevention, mecha

nism, 254systemic effects, ultraviolet irradiation,

620colonie

effects of ammonium acetate and sodium cholate, 3035

effects of voluntary exercise, 7079inhibition by ethanol, azoxymethane,

3313

inorganic selenium, effect of dietaryexcess, 1777

comparativenitrosomethylalkylamines, 6648

earlymucin-associated oncofetal antigen,

1571environmental

cancer prevention, changing concepts,1381

gastriccaerulein enhancement, 6332human model, 3554

human bronchial epithelial cellspathobiological effects, acrolein, 1717T-antigen transformation, 1904

lack of methapyrilene bindingrat liver DNA, 6475

liver and thyroidcytochrome P-450 induction, hydan-

toins, 2492low serum uric acid levels, 2916mammary

induction, effect of exercise, 2720Â¿V-methyl-jV-nitro-W-nitrosoguanidine

proliferative response, gastric mucosa,5275

molecular mechanismscancer prevention and treatment, 4135

oxygen-free radicals, 3882protein kinase C down-regulation

Ha-ros transfection, C3H 10T'/2 cells,6535

renalinhibition, tamoxifen, 779

resistance to nickel(II) ionscharacterization, mouse cell lines,

6850skin

transcriptional control, keratin geneexpression, 3245

Syrian hamster cheek pouchDNA adduct formation, 7,12-dimeth-

ylbenz(a)anthracene, 2025transforming activity of papillomavirus

isolation, new type, 7164tumor progression in SENCAR mice

papillomas, 7048tumor-promoting activity

teleocidins A and B, 4211two-stage

clonogenic keratinocytes, 6285U.S.-Japan Cooperative Cancer Re

search Program Conference, 6249Carcinogenicity

deuterium-labeled 1,2-dimethylhydra-zine, 2162

hydroxyalkylnitrosaminesF344rats, 1533

oxidation of frans-3,4-dihydrodiol metabolites

7,12-dimethylbenz(a)anthracene, 1227Carcinogens

aberrant cryptspreneoplastic lesions, colon, 6187specificity study, colon, 6183

aflatoxin B, adductioneliminatili, active genes, 7146

4-aminobiphenylquantitation, DNA adducts, 6336

behavior of murine epidermal cell linesinitiated and noninitiated skin, 435

chemicalmitochondria! DNA mutagenesis,

HeLa cells, 4578comparative properties

altered hepatocyte foci, hepatic tumors, 4171

cytogenetic changesneoplastic progression, trachea! epi

thelial cells, 702development

medium-term bioassays, 5051Ar-2-fluorenylacetamide

late target protein, liver, 6745inhibition of 0-propiolactone-induced

neoplasia4-mercaptobenzene, forestomach and

large bowel, 27403-(methylnitrosoamino)propionitrile

DNA cyanoethylation, 6780W-[4-(5-nitro-2-furyl)-2-thiazolyl]form-

amideeffect of peroxidase inhibitors, 304

A'-nitrosomethylbenzylaminediallyl MIItide chemoprevention,

esophageal cancer, 6872phenotypical changes

human breast epithelial cells, 2837polycyclic aromatic hydrocarbon-DNA

adductswhite blood cells of foundry workers,

2288rare events as clues to cancer etiology,

3544rat urinary bladder carcinomas

conversion from low grade to highgrade, 1265

screeningi.-arabinose resistance test, Salmonella

typhimurium, 907selective killing of transformed cells

intercellular communication, therapeutic applications, 3203

sodium bisulfitechromosome transformation, Syrian

hamster cells, 7246transformation

differentiation-induced Mil cells,4389

Carcinomahuman TSP-180 complex

quantitation, normal and tumor tissue,816

radiation-induced injurytumor bed strÃ¶ma. 2116

Syrian hamster cheek pouchDNA adduct formation, 7,12-dimeth-

ylbenz(o)anthracene, 2025transplan table

loss of M, 78,000 marker, 2265tumor progression in SENCAR mice

initiator dose, papilloma, 7048tumors as caricatures

process of tissue renewal, 1996Carcinoma, adenosquamous

uterine cervixhuman papillomavirus types, 993

Carcinoma, bladderhuman papillomavirus type 16

mild immunodeficiency, 7207Carcinoma, breast

anionic form of glutathione transferasepresence, human tumors and cell lines,

527antagonism of progestin action, 5071cancer family syndrome, 5358c-erbB-2 gene amplification

7408




correlation, nodal status and nucleargrading, 1238

effect of alkyhiting agent doseclinical correlation, 6417

epidermal growth factor receptorgene amplification, overexpression,

161infiltrating ductal

genomic status, c-myc status, 199keratins 13 and 16

differential expression, 5831latent transformed growth-inhibiting fac

tor, 418localization of estrogen receptor, 6517milk fat globule membrane-associated

antigenendocytosis, monoclonal antibody,

3188Phase I trial

hexamethylene bisacetamide, 7304restricted specificity for tumor-associated

antigenmonoclonal antibody, 4543

SAMBA analysisanti-Ki67, 4368estrogen receptors, 1578

stremai fibronectin staining patternmetastatic ability, 6227

transformation of mammary epithelialcells

oncogenic retroviruses, 4689Ar,Ar',W-triethylenethiophosphoramide

cyclophosphamide, combination in vitro and in vivo, 94

Carcinoma, cervicalcinnamaldehyde with rÃ³-diamminedi-

chloroplatinum(II), 938oral contraceptives and

case-control study in Chile, 1011papilloma early gene expression

correlation, altered growth properties,3780

papilleimavirus type 16immortalization, exocervical epithelial

cells, 4620transformation, C127 mouse fibro-

blasts, 2505papillomavirus type 18

identification, E6 proteins, 2969immortalization, exocervical epithelial

cells, 4620Carcinoma, colonie

alterations of biological characteristicscolon-derived substrata material, 2825

antibody-mediated killingattached effector cells, 624

cell line markers, 1936cellular processing

vasoactive intestinal peptide, 6201c-myc and c-fos differential expression

familial polyposis coli, 4855comparison of growth requirements

monolayer and soft agarose, 2469cytogenetic and phenotypic analysis

resistance, mitoxantrone, 1882DNA hypomethylation

expression, carcinoembryonic antigen,5674

drug sensitivity assaymonolayer culture, 3236

enhanced cytotoxicitynoncompeting monoclonal antibodies,

6303expression of epidermal growth factor,

137nastrili receptor antagonists

antibodies, 7179gene transcription

carcinoembryonic antigen family, 3153heterogeneous responses

hexamethylene bisacetamide, 5487induction of carcinoembryonic antigen

secretionfibronectin expression, transforming

growth factor-/3, 4059levels of urokinase and its receptor, 3112metastatic

sialoglycoprotein expression, 2353modulation of cytotoxic effect of 5-fluo-

rouracilJV-methylformamide, 6193

orthotopic implantation, 6863recurrence and survival

relationship with c-myc expression,1350

selection of highly metastatic cellssurgical specimens, 1943

structural variationblood group A antigens, 181

transfection with foreign geneinduction, immunogenic tumor var

iants, 2975transforming growth factor-/3-resistant

subclonescharacterization, 7120

Carcinoma, colorÃ©ela!expression of cell surface glycoprotein,

7257growth potential

carcinoembryonic antigen, 1689localization

radiolabeled monoclonal antibodies,4324

mucinous variantcell culture, 3751

nerve growth factor receptorschromai in, melanoma cells, 7200

neuroendocrine markers, 4078Phase I trial

hexamethylene bisacetamide, 7304Phase II trial

7-interferon, mAb CO 17-1A, 2568variants of phosphohexose isomerase

isoelectric focusing patterns, 2998Carcinoma, embryonal

effects of dietary retinoidsgrowth and differentiation, 3772

Carcinoma, endometrialhyperplastic and neoplastic endometria

progesterone receptors, 6132modulation of plasminoceli activator ac

tivitygrowth factors, 6384

new hypodiploid human cell lineUM-EC-1, 1864

progesterone receptor structureprotease activity, 1143

reproductive factorsrisk of cancer, uterine corpus, 6217

Carcinoma, epidermoidenhancement of immunotoxin activity,

3919Carcinoma, esophageal

tobacco and alcoholdiet and occupation, 3843

Carcinoma, gastricbinding of gastrinl7, 932expression of epidermal growth factor,

137variants of phosphohexose isomerase

isoelectric focusing patterns, 2998Carcinoma, gastrointestinal

-associated glycoproteinCA 19-9 expression, 1505

phosphohexose isomerase characterization

neuroleukin relationship, 7018Carcinoma, hepatocellular

disulfated glycosphingolipidmonoclonal antibodies, 6769

dolichol kinase and phosphatase, 3418in vitro translation analysis, 2382increased Adriamycin levels

regional infusion, 4584isolation of hepatoma nuclear proteins

monoclonal antibodies, 5495non-A/non-B hepatitis-associated, 7294preneoplastic liver and

carbohydrate-metabolizing enzymes,profiles, 467

prognostic factors, 7314putative premalignant hepatic nodules

DNA adducts, 2-acetylaminofluorene,5270

Carcinoma, lungantibody-mediated killing

attached effector cells, 624autocrine growth factor response, 4976comparison of intrathoracic models,

2880Lewis: see Lewis lung carcinoma tumor

Carcinoma, mammaryeffects of aromatase inhibitor, 6808epithelial-like markers

class I MHC, 7237fibrinogen influx and accumulation

cross-linked fibrin, 1920heat-induced vascular damage

thermosensitivity, 7226medroxyprogesterone acetate effect

proliferation, cell cycle kinetics, 5084metastasis and intercellular communica

tion, 5129miicin like1carcinoma antigen

monoclonal antibodies, 6799phospholipids and phorbol ester binding,

1528spontaneous tumors

quantitative transplantation assays,C3H mouse, 4525

Ar,A",A'"-triethylenethiophosphoramide

cyclophosphamide, combination in vitro and in vivo, 94

tumorigenesisinfluence of caffeine, coffee consump

tion, 2068variants of phosphohexose isomerase

isoelectric focusing patterns, 2998xenotransplanted

effect of retinoids, athymic mice, 3733Carcinoma, medullary thyroid

estrogen receptorhormone responsiveness, 2760

modulation of calcitonin gene expressionsodium n-butyrate, 2096

N-njyc expressionneoplasia, thyroid C-cells, 4073

regulatory peptides, 2412Carcinoma, nasopharyngeal

preserved foodscase-control study in China, 1954

Carcinoma, non-small cell lung

7409




flow eytometryprognostic factors for survival, 2923

Carcinoma, ovarianCA 125 tumor marker expression

hormonal regulation, 3S02enhancement of immunotoxin activity,

3919epithelial

aromatization of testosterone, 6491steroid receptors, survival, 6222

fibrin-fibronectin degradation, 3507fibrinogen influx and accumulation

cross-linked fibrin. 1920sensitive and resistant cells

accumulation of m-diamminedichloro-platinum(II), 68

Carcinoma, pancreaticfetal pancreatic protein as marker, 6906loss of M 78,000 marker, 2265

Carcinoma, prostaticandrogen-independent

testosterone, 5Â«-dihydrotestosterone,609

antiinvasive activity of estramustine,1842

constitutive productionplatelet-derived growth factor, 1930

estrogen-stimulated hormone receptorprofiles, 3077

evaluationcytotoxic activity, diethylstilbestrol,

2867metallothionein induction and deinduc-

tionAdriamycin resistance and sensitivity,

4503partial inhibition of growth

Sandostatin, 4651restricted specificity for tumor-associated

antigenmonoclonal antibody, 4543

variation in tumor yield3,2 '-dimethyl-4-aminobiphenyl, 4629

visual grading systemmetastatic potential, cell motility,

4312Carcinoma, renal cell

activated 11 ra.\ oncogenes, 5251cancer families

susceptibility to neoplasia, 5381clinical and immunological effects

interleukin 2, repetitive weekly cycles,2561

Clouser xenograft andmonoclonal antibody uptake, blood

How, 188cytogenetic analysis

tumor aggressiveness, 28871,25-dihydroxyvitamin D3 receptor

measurement, 2458nonfamilial

ultrastructure, 2890recurrent or metastatic

prognostic factors for survival, 7310transplantation in mice

erythropoietin-induced polycythemia,3430

tumor spread and DNA content, 3165Carcinoma, Shionogi

androgen-responsive and -unresponsivecells

autocrine growth factor, paracrinemechanism, 4904

early phases of regression

gene expression, 6309Carcinoma, small cell lung

antagonism of voltage-gated calciumchannels

w-conotoxin, Lambert-Eaton myasthÃ©niesyndrome, 4719

antigen expressionparaneoplastic dorsal root gangliono-

pathy, 430combined modality treatment

thymosin fraction V, 1663<7Vili:iinmiili-difilli)ropl;ilinn nil II) ac

quired resistance, 6803distinct sublines, 2544effects of bombesin on growth, 1439erA/4-related sequence coding

deleted gene, 682membrane sialoglycoprotein

lgG2a antibody, 4318specificity of monoclonal antibody, 7319

Carcinoma, squamous cellactivation of ornithine decarboxylase ac

tivityguanosine triphosphate, 1252

l/i receptor analysis, 2388biosynthesis and secretion of laminin

keratinocytes, 5193m-diamminedichloroplatinum(II) resist

anceeffect, hyperthermia, 5101

epidemiological characteristics, 3853esophageal

cross-contamination, DNA fingerprintanalysis, 5660

GM: ganglioside residue discriminationmonoclonal antibodies, 6154

head and necktwo new cell lines, 2858

larynxoccupational risk factors, Texas Gulf

Coast, 1960lung

incidence by histolÃ³gica!type, population-based registry, 6580

mechanism of H-ras oncogene activation, 556

pharmacokineticsm-diamminedichloroplatinum(II),

3869spontaneous tumors


tumor transplantabilityquantitative studies in mice, 6510

Carcinoma, transitional cellpapillary and nodular

relationship, human urinary bladder,2299

polyamine synthesis and interconversionresponse to blockade, normal and ma

lignant urothelium, 357Carcinoma, urothelial

blood group-related antigens, 4113conversion from low grade to high grade,

1265Carcinoma-associated antigen

mucin-likemonoclonal antibodies, 6799

Carcinoma cellscytotrophoblasts and

epidermal growth factor, receptor synthesis, 1105

endocytosis and intracellular routingantibody-ricin A chain conjugate, 3822

growth of neoplastic thyroid cellsepidermal growth factor receptor,

3652second generation monoclonal antibodies

radioimmunolocalization of xeno-grafts, 4597

tumor-associated glycoprotein 72 antigen, 4588

Cardiopulmonary toxicityinterleukin 2

continuous vs. bolus infusion in sheep,2221

Cardiotoxicityacodazole hydrochloride

Phase I trial, 4423Adriamycin-induced

free radical formation, 4766anthracycline model

adenosine triphosphate/protein ratios,5222

0-Carotenediet and high risk of stomach cancer

case-control study in China, 3518dietary

cancer of the prostate, Japan, 1331risk factors for lung adenocarcinoma

personal and family history, 7279Carrageenan

importance of Lyt-2* T-cells

tumor rejection, 4834Castanospermine

inhibition of tumor growthv-/ms-induced, 1091

Catalaseeffect on Adriamycin tolerance

Chinese hamster ovary cells, 4493peroxisomal /^-oxidation mRNAs

rat tissues, 5316xeroderma pigmentosum fibroblasts

antioxidant enzymes, 2132Catechol

yV-methyl-iV'-nitro-A'-nitrosoguanidinestomach carcinogenesis, phenolic an-

tioxidants, 5310Catechol analogues

cytotoxicity against malignant melanomastructure-activity relationships, 5178

Cathepsin B-like activity

cell surface, murine melanomas and 11brosarcomas, 1416

-like proteinasebiochemical study, colon cancer, 6855

Cathepsin Dbreast cancer cytosols

immunoenzymatic assay, 462carbohydrate moiety

increased mannose-6-phosphate, human hepatoma, 362

degradation of extracellular matrixbreast cancer cells, 3688

M, 52,0000 precursormonoclonal antibodies, breast cancer

cells, 3709CC-1065 analogues

mutagenicitymammalian cells and bacteria, 32

U-71,184 and otherscell survival and cycle, Chinese ham

ster ovary cells, 109C-cells

thyroidneoplasia, N-myc expression, 4073

CCRF-CEM cells

7410




resistanceimpaired polyglutamylation of metho-

trexate, 2149Cell-cell communication

contrasting duration of inhibitionepidermal cells, phorbol 12,13-dibutyr-

ate and bryostatin 1, 447Cell culture

bile ductular epithelial cells, 6145comparison of monolayer and soft aga-

rosegrowth requirements, colon carci

noma, 2469DNA fingerprint analysis

cross-contamination, squamous cellcarcinoma, 5660

enhancement of LAK cell cytolysisincreased yields to cancer patients,

5696growth in apar

tumor cell viability, inoculum density,3944

markers of colonie cell lines, 1936vital cell counting r.v.clonogenic assay,

5722Cell cycle

assessment of durationsister chromatid exchanges, somatic

and spermatogonial cells, 5953cell growth response

interleukin 1 binding correlation, 5455cell survival and

U-71,184, CHO cells, 109changes in glycosphingolipids

differentiation, squamous SQCC/Y1cells, 2121

changes in maturing III .-60 cellsretinoic acid, 5989

cytokinetic effects of methotrexateL1210 cells, 4288

deferoxamine effectshematopoietic progenitor cells, 3571

m-diamminedichloroplatinum(II)-in-duced cytotoxicity

mechanism of, 4484early G, phase

proliferation-associated antigen, 1244effects of /V-methylformamide

glutathione status, lymphoma cells,3389

inhibitory effects of prostaglandin \HL-60 cells, 2813

isolation of viable cellsdrug-treated cultures, 5742

kineticsmedroxyprogesterone acetate, mam

mary carcinoma, 5084normal G2 chromosomal radiosensitivity

cancer family syndrome, 2579phorbol ester-induced (â€¢delay

time lapse photography, HeLa cells,1759

premature chromosome condensationnuclear fragmentation, CHO cells,

6478progression

m-diamminedichloroplatinum(II),CHO cells, 6703

proliferation-dependent regulationDNA topoisomerase II, cultured hu

man cells, 3230radiosensitivity

normal human fibroblasts, 4535resistance of noncycling cells to amsa-

crine, 310ribonucleotide reducÃaseM l subunit

proliferation, differentiation, 5151transient exposure to hydroxyurea

DNA replication, Syrian hamster cells,6298

various phasesglutathione, human and rodent tumor

cells, 3661Cell density

regulatory effectsgrowth factor binding, 4266

Cell morphologyloss of metastatic responsiveness

B16 melanoma adhesive cell variant,1258

Cell motilityvisual grading system

metastatic potential, 4312Cells: see specific type of cellCepharanthine

lysosomal function, 1307Cerebrospinal fluid

penetration of active metabolitescyclophosphamide and ifosfamide,

2113Cervical neoplasms

analysis of human papillomavirus sequences, 324

human chorionic gonadotropinnew marker, 1356

papillomavirus types 16 and 18 DNAimmortalization, exocervical epithelial

cells, 4620transforming activity of papillomavirus

isolation of a new type, 7164CGS 16949A

antitumor effectshormone-dependent and -independent

tumors, 834Chemoembolization

collagenm-diamminedichloroplatinum(II),

liver and kidney, 2446Chemoimmunothcrapy

interleukin 2 continuous administrationtransplantation antigen, cyclophospha

mide, 101Chemoprevention


iV-nitrosomethylbenzylamine-inducedesophageal cancer

diallyl sulfide, 6872Chemosensitization

misonidazoleenhancement of melphalan activity,

3528Chemotactic activity

endothelial cell-derived interleukin 1tumor cells, 7041

Chemotactic peptideactin polymerization in HL-60 cells,

6721-induced elevation of intracellular cal

ciuminhibition in HL-60 cells, phorbol es

ter, 2707Chemotherapy

bifunctional alkylating agentsmedulloblastoma, transplantable xeno-

grafts, 4189breast cancer growth

Gompertzian model, 7067

cell kinetics in human malignanciesbromodeoxyuridine, flow cytometry,

6238combination

doxycycline, leukemia, 6686combined modality treatment

thymosin fraction V, small cell lungcancer, 1663

Clq binding macromoleculesimmune complexes, head and neck

cancer, 5868tic novo guanylate synthesis

commitment to replication, hepatoma3924A cells, 507

a-difluoromethylomithine-inducedgrowth inhibition

azoxymethane-induced colonie neoplasms, 6498

disorganizing-overstabilizing drugscell proliferation, 4892

drug sensitivity assaymonolayer culture, colon carcinomas,

3236effect of galactose on systemic hemody-

namicsblood flow rate, normal and tumor tis

sues, 14765-fluorouracil metabolites in plasma and

urinewith and without methotrexate, 1680

interleukin 2 andpulmonary tumors in mice, 122

neoplastic growthpolyamine metabolism, 759

nucleic acid flow cytometrylarge cell lymphoma, 6614

oligonucleotidesinhibitors, gene expression, 2659

phenotypic changes in neoplastic cells5-aza-2 '-deoxycytidine, hydroxyurea,

2440prevention of induced testicular injury,

4354recurrent tumor sensitivity

rat model, mammary tumors, 4549roles of cytochrome P-450 enzymes

chemical carcinogenesis, 2946snail neurons as model

neurotoxic side-effects. Vinca alkaloids, 7184

surgery andtiming of, osteosarcoma model, 5533

therapeutic and pharmacological studiestetrachloro(i/, Â¡-trans)1,2-diamino-

cyclohexane platinum (IV), 1745Chile

oral contraceptives and cervical carcinoma, 1011

Chinadiet and high risk of stomach cancer,

3518preserved foods and nasopharyngeal car

cinomacase-control study, 1954

women in Shanghairisk factors, breast cancer, 1949

Chinese hamster ovary cells: see Ovarycells, Chinese hamster

Chlorambucilethacrynic acid and piriprost

cytotoxicity effect, 3622|4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio|

acetic acidperoxisome proliferation and DNA syn-

7411




thesishepatocarcinogenesis, 6739

Chloroacetaldehyde-treated DNA

interstrand cross-links, ethidium bromide fluorescence, 4804

Chloroaluminumsulfonated phthalocyanine

biological effects, transplantable tumors, 3040

l-{2-Chloroethyl)-3-cyclohexyl-l-nitrosou-rea

-resistant Mer* tumor cells

thermal sensitization, 1086H2-Chloroethyl)-3-(4-methylcyclohexyl)-l-

nitrosoureatreatment-induced changes in sensitivity


2-Chloroethyl(methylsulfonyl)methanesulfonate

DNA interstrand cross-link formationeffect, C^-methylguanine, 3606

ChloroethylnitrosoureaDNA interstrand cross-link formation

effect, 06-methylguanine, 3606

nitroimidazoles andmixed-function drugs. Mer cells, 798

-treated glioma cellsDNA alkylation products, 4489

3'-|3-(2-Chloroethyl)-3-nitrosoureido|-3'-

deoxythymidineeffect of thymidine

nitrosourea activity, 4272Chlorogenic acid

inhibition of TPA-induced tumor promotion in mouse skin, 5941

Cholesterolalteration of biosynthetic pathways

polycyclic aromatic hydrocarbons,2555

glucocorticoid effectslipopolysaccharide, B-cell leukemia 1

cells, 59site-specific analysis of serum


Cholesterol sulfateaccumulation

esophageal epithelial cells, 5289Choline

-deficient dietmodulation, epidermal growth factor

receptors, 1162protection of Ehrlich ascites tumor cells

nitrogen mustard, S-^V^V-dimethylami-loride, 2454

Chondroitin sulfatedifferentiation-associated changes

U937 cells, 6103Choriocarcinoma

gestationalcase-control study, 1004

kinetics of cell intoxicationricin and ricin A chain immunotoxin,

806Chromatin

activation of B-cellsflow cytometry, 6708

aflatoxin It, adductionactive genes, 7146

melanoma cellsnerve growth factor receptors, colorec-

tal carcinoma, 7200

modifications/V-methylformamide-induced radiosen-

sitization, 5669Chromatograph)

affinitytarget proteins, Bowman-Birk protease

inhibitor, 1798Chromium

effects on liver epithelial cell linesrelevance, in vitro transformation,

6484Chromogranin A

neuroendocrine markersendocrine and nonendocrine tumors,

4078Chromosome 7

cytogenetic analysisrenal cell carcinoma, 2887

Chromosome 11sialyltransferase expression, 1491

Chromosomesaberrations

antitumor topoisomerase II inhibitors,Chinese hamster cells, 512

nonrandomness, 7120primary neoplasia related, 7115radiosensitivity, normal human libro â€¢¿�

blasts, 4535abnormalities

malignant human gliomas, 405pediatrie brain neoplasms, 175

analysis of sixteen human rhabdomy-osarcomas, 983

aneuploidyinterphase nuclei, breast tumors, 5825

cytogenetic instabilityuroepithelial cells, SV40-transformed,

3215damage and repair rates

bleomycin, ataxia-telangiectasia cells,276

DNA ligase deficiencyassociation, T cell acute leukemia,

4038DNA replication pattern

analysis, bromodeoxyuridine labelingmethod, 219

frequent nonrandom abnormalitieslarge cell and immunoblastic Km

phoma, 5557genetic assessment

cancer suppressor gene, hamster cells,46

genetic convergence and divergencetumor progression, 5911

induction of sister chromÃ¢tid exchangechronic myeloid leukemia, 3435

infrequent loss of heterozygosityhuman stomach cancer, 2988

internucleosomal cleavage in yeastbleomycin, phleomycin, 6837

in vitro transformationsodium bisulfite, Syrian hamster cells,

7246irradiation-induced markers

metastasizing murine tumor, 999localization of carcinoembryonic antigen

gene familydifferential expression, various tumors,

2550loss

role in ros/m^c-induced Syrian hamster tumors, 1623

malignancy by cell fusion, 3302

molecular cloning of ME491early stages, melanoma tumor progres

sion, 2955molecular mechanisms of carcinogenesis

cancer prevention, treatment, 4135nonrandom alterations

human malignant mesothelioma, 142organization of amplified genes

mult Â¡drug-resistam Chinese hamstercells, 3179

Philadelphiaacute lymphoblastic leukemia, molecu

lar heterogeneity, 866acute lymphoblastic leukemia, break

point cluster region, 2876point mutation of ras protooncogenes

acute nonlymphocytic leukemia, 18123p21-3p25

deletion in small cell lung carcinoma,erM-related sequence, 682

premature condensationnuclear fragmentation, heat shock in

CHO cells, 6478reorganization

retinoblastoma susceptibility gene, os-teosarcoma development, 3939

solid tumors, 1049translocations with specific breakpoints

asbestos-induced mesotheliomas, 6455Chronopharmacology

circadiani rhythm and 5-fluorouracil concentrations, 1676

Chrysarobinalterations in epidermal polyamine levels

DNA synthesis, 6390C3H 10T'/2 cells

differential effects of bryostatinsphorbol esters, arachidonic acid re

lease, 3702Ar-methyl-A"-nitro-A'-nitrosoguanidine

spontaneous transformation, 5977partial protein kinase C down-regulation

Ha-ros oncogene, fibroblast transfec-tion, 6535

spontaneous transformation, 5969transformation to focus formation

lead enrÃ³mate, 5280CI-921

Phase I trial, 6593Cigarette smoking

bladder cancereffects of timing, tobacco type, 3849motor exhaust-related occupations,

1989relationship in a case-control study,

4405comparative epidemiology of cancer

United States, Italy, 7285detection of O6-methyldeoxyguanosine

human placenta! DNA, 4184drinking and

oral and pharyngeal cancer, 3282incidence of lung cancer

histolÃ³gica!type, population-basedregistry, 6580

laryngeal canceroccupational risk factors, Texas Gulf

Coast, 1960long-lasting effects

pulmonary drug-metabolizing enzymes, 4695

lung adenocarcinomarisk factors, personal and family his

tory, 7279

7412




significance, K ra\ activation, 5730lung cancer

effects in women, 6951tumoricidal activity, alveolar macro

phages, 3949nasal diseases and maxillary sinus cancer

case-control study of past history inJapan, 1651

preserved food and nasopharyngeal carcinoma

case-control study, 1954-related tumors

lung and pancreas, rats, 6912site-specific analysis of total serum cho

lesterolincident cancer, National Health and

Nutrition Examination Survey, 452squamous cell carcinoma

bladder adenocarcinoma, 3853Cimetidine

influence on anticarcinogenic effectgastrin, 1591

Cinnamaldehydecu-diamminedichloroplatinum(ll) and

Synergist Â¡ccell inactivation, NHIK3025 cells, 938

Orcadian rhythm5-fluorouracil concentrations, 1676

Cirrhosisinsulin-like growth factor II mRNA

expression, 6844preneoplastic liver

profiles, carbohydrate-metabolizingenzymes, 467( 'Â¡spiatili:see c/'i-Diamminedichloropla-

tinum(II)Cifrai

oxidation of retino! to retinole acidepidermis, 7038

CL 259,763restoration of cytolytic T-lymphocyte re

sponse, 2135Clowes Memorial Award Lecture, 4135c-myc

amplificationperipheral T-cell lymphoma, 4959

cellular distribution of transcriptschemical hepatocarcinogenesis, 5522

c-fos anddifferential expression, familial poly-

posis coli, 4855colon carcinoma

recurrence and survival, 1350DNA amplification

small cell lung cancer, 5163enhanced expression

epidermal growth factor receptor,renal cancer, 6753

expression in HL-60/MRI cells, 6733gene abnormality

xenotransplantability, lung cancers,6025

inhibitory effects of prostaglandin A.cell cycle progression, HL-60 cells,

2813N-myc expression

neoplasia, thyroid C-ceIIs, 4073protooncogene expression

normal and leukemic erythroid cells,3972

sublines of small cell lung carcinoma,2544

Coffee consumptioninfluence of caffeine

mammary gland tumorigenesis, 7,12-dimethylbenz(a)anthracene-induced,2068

squamous cell carcinomabladder adenocarcinoma, 3853

Colchicineeffect on microtubules

cell proliferation, 3T3 cells, 4892Collagen

chemoembolizationcis-diamminedichloroplatinum(II),

liver and kidney, 2446Collagenase

blocking of secretionestramustine, tumor cell invasion,

6262effects of inhibitors

basement membrane invasion, meta-static cells, 3307

lytic activity in host and tumor cellsmacrophage and lymphocyte potentia-

tion, 6832regulation of growth and invasiveness

antiestrogens, MCF-7 cells, 6764Colon

aberrant cryptsinduction of, specificity study, 6183potential preneoplastic lesions, 6187

biomarkers of increased susceptibilitygastrointestinal neoplasms, cancer pre

vention, 235carcinogenesis

effect of dietary eicosapentaenoic acid,4790

effects of ammonium acetate and sodium cholate, 3035

effects of voluntary exercise, 7079inorganic selenium, effect of dietary

excess, 1777oncogene expression, retroviral-like se

quences, 3964comparison of sialylated Le" antigens,

3834-derived substrata material

effect, colon carcinoma cell line, 2825human neoplastic tissues

plasminogli activator profiles, 4520marker for early carcinogenesis

iiHH-in associali-ii oncofetal antigen,

1571normal and neoplastic

mono-, di-, and tri-O-acetylated sialicacids, 483

structural variationblood group A antigens, 181

Colonie cellsstimulation of proliferation

structural requirements, oxidized fattyacids, 1771

Colonie mucosapattern of epithelial cell proliferation,

4121Colonie neoplasms

azoxymethane-inducedo-difluoromethylornithine, growth in

hibition, 6498cathepsin B-like proteinase

biochemical study, 6855characterization of mucin

xenografts, 6678human xenografts

tumor targeting, second antibody,2005

hypotheses for origin, 7323

inhibited nucleoside salvagedipyridamole and acivicin, Phase I

clinical trial, 5585inhibition

dietary omega-3 fatty acids, 6642inhibition of colonie carcinogenesis

dietary ethanol, azoxymethane, 3313intrinsic drug resistance


modulation of differentiationcalmidazolium, 12-O-tetradecanoyI-

phorbol-13-acetate, 6173prostaglandin biosynthesis, 4770radioimmunotherapy of xenografts

monoclonal antibodies, carcinoem-bryonic antigen, 3270

reduced genomic 5-methylcytosine content, 1159

role of fecapentaenesmutagenicity, 7324

synergistic inhibition of growthcyclic AMP analogues, 1642

Colony-forming unitsenhancement by monoclonal antibody

treatmentpulmonary endothelial cells, 4964

granulocyte-macrophageeffects, hematopoietic suppressor mol

ecules, 1548role for aldehyde dehydrogenase

survival of progenitors, 4-hydroperox-ycyclophosphamide, 1223

uniqueness of spontaneous transformantclone of BALB/c 3T3 cells, 2512

Colony-stimulating factorgranulocyte-macrophage

intravenous administration, monocyteactivity, 2604

mitogenic responsiveness, HL-60 cells,2683

jV-nitrosomethylurea-induced mammarytumor growth

polyamines, progesterone, 3058production of growth potentiating fac

torsblast cells, acute myeloblastic leukemia

cells, 6424review of hemopoietic growth factors,

5624therapy by directing differentiation in

carcinoma, 1996Colorectal neoplasms

Cora antigen expressiontissue distribution, 2198

modulation of cytotoxic effect of 5-fluo-rouracil

yV-methylformamide, 6193risk

chronic illnesses, operations and medications, 4399

site-specific analysis of total serum cholesterol


tumor detection with human monoclonalantibodies, 4348

whole body protein turnover rateresting energy expenditure, cancer pa

tients, 2590Colorectal polyps

prevention of recurrencevitamins C and E, 4701

Complements

7413




Clqimmune complexes, head and neck

cancer, 5868Conjugates

methotrexate conjugated with antitumorantibodies

nature of linkage, mode of action,3330

u-Conotoxinantagonism of voltage-gated calcium

channelssmall cell carcinoma, Lambert-Eaton

myasthÃ©niesyndrome, 4719Contraceptives: see Oral contraceptivesCora antigen

differential expressionmalignant and benign gastrointestinal

epithelia, 2198Crisnatol

Phase I and clinical pharmacology, 4706CSF: see Colony-stimulating factorCurcumin

inhibition of TPA-induced tumor promotion in mouse skin, 5941

2-CyanoethyldiazohydroxideDNA

3-(methylnitrosoamino)propionitrile,6780

Cyanomorpholinyldoxorubicininhibition of ribosomal gene transcrip

tion, 4101Cyclic AMP: see Adenosine 3':5'-mono-

phosphate, cyclicCyclooxygenase

enhanced activity of peritoneal cellsaclacinomycin, respiratory burst, 3440

Cyclophosphamideactive metabolites

cerebrospinal fluid penetration, 2113combined with interferon-a/j3

response of P388 leukemia, 2329contribution of medicine

primary treatment, breast cancer, 2314cytogenetic damage and antineoplastic

effectcaffeine. Ehrlich ascites tumor cells,

1129deficient carboxyphosphamide excretion

cancer patients, 5167effect on pathophysiology

solid tumors, 4206gonadotoxicity

luteinizing hormone-releasing hormone agonist, 2174

low doseeffects on immune system of cancer

patients, 1671metabolite of

acrolein, enhanced immune responses,41

-resistant L1210 cellscharacterization, cytosolic aldehyde

dehydrogenase, 2963response of radiation-induced fibrosar

coma-1"P NMR spectroscopy, 4736

A',Ar',Ar"-triethylenethiophosphoramide

andcombination in vitro and in vivo, 94

tumor specific transplantation antigenand

interleukin 2, active specific chemoim-munotherapy, 101

whole-body hyperthermia and

natural killer cell activity, erythroleu-kemia, 4561

Cyproterone acetateoptimal medical castration in male rats,

6063Cytidine S'-triphosphate

-dependent dolichol kinasedolichol phosphatase and, human lu

pai omas. 3418Cytochrome P-448

Sudan Ill-induced preventionchemical carcinogenesis, mechanism,

254Cytochrome P-450

benzene-induciblemetabolism, liver microsomes, 5387

c and d genesventral prostate and liver, 3045

induction by 5-ethyI-5-phenylhydantointumor promotion, liver and thyroid,

2492interferon-mediated depression

role of xanthine oxidase, 2107isozyme specificity

metabolic activation, 2-amino-3-meth-ylimidazo[4,5-/]quinoline

metabolic activationspecificity, Cytochrome P-450 iso-

zymes, 4513oxidative metabolism of l nitropy rene

liver microsomes, 4261roles of enzymes in chemical carcinogen

esiscancer chemotherapy, 2946

Cytokeratindiagnostic and therapeutic monoclonal

antibodiesmesothelioma cell lines, 5228

different types of human lung cancerchain-specific monoclonal antibodies,

3221embryonic liver epithelial cell lines, 4909

Cytokines: see also specific typecirculating

interleukin 2 and LAK cells, metastatic cancer, 5864

heterogeneous distributionmonoclonal antibodies, interstitial

pressure, 7022modulation of major histocompatibility

antigens, 5818Cytomegalovirus

oncogenes of DNA tumor viruses, 493Cytoplasm

accumulation of ditercaliniummitochondria! damage, hepatocytes,

6542DNA cross-linking by FK973

L1210 cells, 5172suppression of tumorigenicity

reconstructed mouse cells, 830tissue distribution and cellular localiza

tionhuman monoclonal antibodies, 7273

Cytoskeletoncell deformability and metastatic poten

tialcorrelation, melanoma cell variants,

5124tumor cell

platelet adhesion role, platelet aggregation, 3787

Cytosolendocytosis and intracellular routing

antibody-ricin A chain conjugate, 3822Cytotoxic granules

isolation and characterizationLAK cells, 4681

Cytotoxicityantibody-dependent cellular

antitumor effect, LAK cells, 1173noncompeting monoclonal antibodies,

colon carcinoma, 6303â€¢¿�y-interferonand mAb CO 17-1A,

Phase II trial, 2568antitumor topoisomerase II inhibitors

sister chromatid exchange, Chinesehamster cells, 512

m-diamminedichloroplatinum(II)-in-duced

mechanism of, 4484DNA damage and cell kill

9-aminoacridines, 860DNA strand breaks and

bromodeoxyuridine and bleomycin, tumor cells, 4244

generation in LAK cellstumor necrosis factor, interleukin 2,

788hyperthermic

effect, topoisomerase II inhibitors,3932

â€¢¿�y-interferontherapyhuman peripheral blood monocytes,

1042melphalan

glutathione depletion, medulloblas-toma xenograft, 2764

natural killer cellshead and neck cancer, 5017

proliferation-dependenteffect of methotrexate in leukemia,

5638synergistic effect

tumor necrosis factor, hyperthermia,650, 654

6-thioguaninesynergistic enhancement, ADP-ribosyl-

transferase, 5650Cytotoxic T-lymphocytes

augmentation of activity7-interferon gene transduction, 4730

autologous clonetumor antigen characterization, Â«bu

tyl alcohol, 3892clone specific for stable antigen

LI210 cells, 6450glioma spedile

immunoregulatory effects, interleukin2 and interferon, 2981Lyt-2' and L3T4~

recognition, melanoma antigen, 2730modulation of antibody response

natural killer cell activity, purine micleoside analogues, 4799

restoration of responseCL 259,763, mice, 2135

tumor-specific generationT helper cells and accessory cells,

1422Cytotoxin

augmentation of releasebone marrow macrophages, 7-inter

feron, 1808Cytotrophoblasts

A431 carcinoma cells andepidermal growth factor, receptor syn

thesis, 1105

7414




D

Daunorubicininteraction with hepatoma

compromised DNA synthesis, 2404-monoclonal antibody immunoconjugate

acid-labile, compared to free drug,6097

vincristine and methotrexate combination

acute lymphoblastic leukemia, 3515-Deazaaminopterin

5-deazamethotrexate andS-alkyl derivatives of, methotrexate

comparison, 56868-Deaza analogues

methotrexate and aminopterincytotoxicity, polyglutamate formation,

14813-Deazaguanine

DNA-directed actions, 2774Deferoxamine

cell cycle effectshematopoietic progenitor cells, 3571

inhibition of neuroblastoma viabilityproliferation, 7189

Dehydroepiandrosteronegene for ovarian granulosa cell tumor

susceptibility, 5092induction of ovarian granulosa cell tu

mors, 2788novel analogues

enhanced biological activity, reducedside effects, 4817

Dehydroepiandrosterone-sulphatebreast cyst fluid

epidermal growth factor, 58604-Demethoxydaunorubicin

Phase I clinical trialchildren with refractory leukemia,

5348Deoxyadenosine

inhibited DNA damage repairchronic lymphocytic leukemia cells,

39812'-Deoxycoformycin

inhibition of DNA damage repairchronic lymphocytic leukemia cells,

3981Deoxycytidine

thymidine kinase deficiency andsubstrate cycles, deoxyribonucleosides,

36814'-Deoxydoxorubicin

Phase I evaluationleukemia, 5580

DeoxyguanosineI,.V -clhcnodeoxygiiunosiiH' as marker

DNA adduci formation, trans-4-hy-droxy-2-nonenal, 320

12-Deoxy- 16-hydroxyphorbolseed oil ofJatropha curcas, 5800

Deoxyribonucleosideseffects of deoxycytidine

thymidine kinase deficiency, substratecycles, 3681

Desmopressingrowth-promoting activity

leukemia cells, 7055Deuterium

-labeled 1,2-dimethylhydrazinecarcinogenicity in mice, 2162

nuclear magnetic resonance spectroscopymeasurement, tumor blood flow and

perfusion, 3449

Dexamethasonegap-junctional intercellular communica

tiontransformed foci, BALB/c 3T3 cells,

3490induction of neoplastic transformation

Fujinami sarcoma virus, chick embryomodel, 7231

interferons andtumoricidal effects, human leukocyte

cell lines, 567rat ductular oval cells

promotion of growth, primary culture,368

Diabetesinsulin effects

phosphatidylinositol kinase, mammarytumors, 6727

sex steroid hormones andinsulin receptor kinase, mammary ade-

nocarcinoma, 3742squamous cell carcinoma

bladder adenocarcinoma, 3853Diacylglycerols

growth-promoting activity of desmopres-sin

leukemia cells, 7055phospholipid toxicity

adenovirus 12 transformant, 578protein kinase C as receptor

phorbol ester tumor promoters, 1Diallyl sulfide

chemopreventionA'-nitrosomethylbenzylamine-induced

esophageal cancer, 6872effect on liver microsomal nitrosamine

metabolismother monooxygenase activities, 5937

1,2-Diaminocyclohexanecarrier ligand in LI210 cells

intracellular biotransformation, platinum compounds, 5136

cii-DiammineU.l-cyclobutanedicarboxy-lato)platinum(II)

diethyldithiocarbamate inhibitionbone marrow toxicity, 5708

m-DiamminedichloropIatinum(II)acquired resistance in vitro

characterization, small cell lung carcinoma, 6803

alkylating agents andgene expression, Escherichia coli, 4823

D,L-buthionine-5,Ã„-sulfoximine effectcytotoxicity, human melanoma cells,

19cinnamaldehyde and

synergistic cell inactivation, M lIK3025 cells, 938

collagen chemoembolizationliver and kidney, 2446

combined with X-raytherapeutic gain, 3158

cross-resistanceX-ray and, human tumor cell lines,

5133cytotoxicity

cw-bis-neodecanoato-frans-/?./?-1,2-diaminocyclohexaneplatinum(II),multilamellar lipid vesicles, 4509

mechanism of, 4484ci'.v-di;unininr( 1,1-cyclobutanedicarboxy-

lato)platinum(II)DNA interaction products, cancer pa

tients, 5597

diethyldithiocarbamate inhibitionbone marrow toxicity, 5708

differential repair of platinum-DNA ad-ducts

bladder and testicular tumors, 3019drug sensitivity assay

monolayer culture, colon carcinomas,3236

effect of alkylating doseclinical correlation, 6417

effects on kidneyrenal proximal tubule cells, 2538

hyperthermia andeffect, resistant cell line, 5101hypoxia and acidosis, cytotoxicity,

2342protection from renal injury, o-(ÃŸ-hy-

droxyethyl)-rutoside, 2239radiation and tumor growth delay, fi

brosarcoma, 2693rhodamine 1233, 2335whole body, effect on renal injury, 440

increased resistance in NIH 3T3 cellsraÃoncogenes, 793

-induced DNA adductsformation and repair, fibroblasts, 6058

influence on DNA synthesiscell cycle progression, CHO cells,

6703mitomycin C and

inferieron action, human mesotheli-oma xenografts, 64

model for nephrotoxicitythiol rescue agents, 6017

myelotoxic concentrationsantitumor activity, 3135

pharmacokineticshead and neck cancer patients, 3869

platinum analogues andaccumulation, murine leukemia cells, 9

ovarian neoplasmsaccumulation, sensitive and resistant

cells, 68mechanism of acquired resistance,

DNA repair, 5713resistant sublines, 3355

synergy with 1-/3-D-arabinofuranosylcyto-sine

in vivo pharmacodynamics, 117therapeutic and pharmacological studies

tetrachloro(</,/-/ran.j) 1,2-diaminocy-clohexane platinum (IV), 1745

Diazacholesterolalteration of cholesterol biosynthetic

pathwayspolycyclic aromatic hydrocarbons,

2555Diaziquone

sister chromatid exchange inductionhuman and mouse lymphocytes, 27

Dibutyryl cyclic adenosine 3':5'-monophos-

phateactin polymerization in HL-60 cells,

6721gap-junctional intercellular communica


3490cu-Dichloro-bis-isopropylamine plati-

num(II)identification of iproplatin metabolite,

3533Dicoumarol

modulation of mitomycin C cytotoxicity

7415




mammary tumor cells, 54715,10-Dideazatetrahydrofolic acid

antifolate drug interactions, 24211,9-Dideoxyforskolin

partial reversaldoxorubicin resistance, murine sar

coma S180 variants, 539Diet: see also Nutrition

comparative epidemiology of cancerUnited States, Italy, 7285

effect of excessinorganic selenium, colon carcinogene-

sis, 1777esophageal carcinoma, 3843fat and caloric restriction

exercise, mammary tumorigenesis,4276

high risk of stomach cancer in China,3518

ingestion of cod with vegetablesurinary level, A'-nitrosothioproline,

4049mesothelioma and

case-control study in Louisiana, 2911sodium-deficient diet

restriction, tumor growth, 3445Dietary fat


vention, 235breast cancer epidemiology, 5615

10-|Diethylaminopropylamino)-6-methyl-5//-pyrido|3',4':4,5|pyrrolo(2,3-g)-

isoquinoline: see PZEDiethyldithiocarbamate

inhibition of bone marrow toxicityfii-diamminedichloroplatinum(II),

5708Di(2-ethylhexy)phthalate

peroxisome proliferation and DNA synthesis

hepatocarcinogenesis, 67395,5-Diethylhydantoin

cytochrome P-450 inductiontumor promotion, liver and thyroid,

2492Diethylnitrosamine

comparative propertiesaltered hepatocyte foci, hepatic tu

mors, 41711.2 \ r/Mdimot liyIhylira/i IK-and

hepatocyte initiation, 988Diethylstilbestrol

breast cancer epidemiology, 5615estrogen-stimulated hormone receptor

profilesprostatic carcinoma, 3077

evaluation of cytotoxic activityprostatic carcinoma cells, 2867

-induced pituitary neoplasmsglandular kallikrein, prolactin, 4158

role of metabolism and DNA adduct formation

sister chromatid exchange, lymphocytes, 335

Differentiation antigensCD3

endocytosis and degradation, I colls,2249

CDSradioimmunotoxins, nude mouse

model, 7107CD19andCD22

clinical trial evaluation, ricin A chain-

containing immunotoxins, 26102',2'-Difluorodeoxycytidine

comparison, toxicity, 4024a-Difluoromethylornithine

combined with Â«2a-interferonPhase I study, 6584

gastric adenocarcinoma xenograftgrowth, 3265

-induced inhibition of growthazoxymethane-induced colonie tumors,

6498methylglyoxal bis(guanylhydrazone) and

Phase I evaluation, hematological malignancies, 1367

properties of LI 210 resistant cells, 2678DL-2-Difluoromethylornithine

curative effectmutant LI210 leukemia cells, 4807

/nin.v-3,-4-1)ih>Urodiolmetabolitesoxidation of 7,12-dimethyl-

benz(a)anthracene3a-hydroxysteroid-dihydrodiol dehy-

drogenase, 1227Dihydrofolate reducÃase

antifolate drug interactions, 24215a-Dihydrotestosterone

testosterone-mediated increaseandrogen-independent prostate carci

noma, 6091,25-Dihydroxyvitamin I),

receptor measurementrenal cell carcinoma, 2458

receptor-mediated modulationhuman myeloma cell line, 1213

regulationepidermal growth factor receptor,

breast cancer cells, 27345-/V,/V-Dimethylamiloride

protection of Ehrlich ascites tumor cellsantiproliferative effect, nitrogen mus

tard, 24543,2'-Dimethyl-4-aminobiphenyl

variation in tumor yieldprostate and other target organs, 4629

7,12-Dimethylbenz(a)anthraceneestrogen-like effects

anterior pituitary dopamine receptors,6434

mammary adenocarcinogenesissuppression, genetic factor, 2204

mammary neoplasmsdietary flavonol quercetin, 5754effects, aromatase inhibitor, 6808glucocorticoids, growth alterations,

7212mammary tumorigenesis

influence of caffeine, coffee consumption, 2068

adrenal regulation, 3801, 3808oxidation of irans-3,4-dihydrodiol me

tabolites3a-hydroxysteroid-dihydrodiol dehy-

drogenase, 1227rapid induction of ovarian granulosa cell

tumorsneonatally estrogenized mice, 425

skin tumorigenesisprotection, fannie acid, 2361

1,2-Dimethylhydrazinedeuterium-labeled

carcinogenicity, 2162diethylnitrosamine and

hepatocyte initiation, 9883,7-Dimethyl-2,6-octadienal: see Cifrai

Dimethyl sulfoxideeffect of sodium butyrate

ovarian adenocarcinoma, 6161induction of erythropoietin receptor

murine erythroleukemia cells, 1818mitogenic responsiveness to GM-CSF

HL-60 cells, 2683soluble tetrazolium/formazan assay

cell growth and drug sensitivity, 48273',5'-Dioctanoyl-5-fluoro-2'-deoxyuridine

selective accumulation of prodrug, 41791,2-Dioctanoyl-^n-glycerol

inhibition of MCF-7 cell growthprotein kinase C activity, 6943

Diphenylmethaneantiestrogen binding site ligands

antiproliferative action, 3954Dipyridamole

acivicin andbiochemical assessment, 5591inhibited nucleoside salvage, Phase I

clinical trial, 5585intraperitoneal administration

pharmacokinetics, cancer patients, 215potentiation of Adriamycin cytotoxicity

I loi.a and sarcoma 180 cells, 1208Ditercalinium

cell treatmentloss of mitochondrial DNA, 4982

cytoplasmic accumulationmitochondrial damage, hepatocytes,

6542DNA

accumulation of strand breaksmethotrexate, A^-propargyl-S.S-didea-

zafolic acid, 2036aldehyde dehydrogenase gene expression

hepatoma, 7009alkylation

A'-(2-chloroethyl)-A'-nitrosourea,glioma cells, 4489

estrous cycle modification, jV-methyl-A'-nitrosourea, 3090

4-(ALmethyl-ALnitrosamino)-l-(3-pyri-dyl)-l-butanone, lung, 4215

A'-nitrosomethyl-(2-hydroxy-ethyl)amine, 1537

thymidine effect, nitrosourea activity,4272

amplificationadeno-associated virus, cellular geno-

toxic stress, 3123myc family, small cell lung cancer,

51631-jS-D-arabinofuranosylcytosine

5-hydroxymethyl-2'-deoxyuridine,HL-60 cells, 3117

binding of progesterone receptormodulation, polyamines, 1217

5-bromo-2'-deoxyuridine incorporationtissue-specific pharmacodynamics,

VX-2 tumors, 6900chromosomal replication pattern

bromodeoxyuridine labeling method,219

chromosome-specific repetitive probesinterphase nuclei, breast tumors, 5825

cisplatin-induced adductsformation and repair, fibroblasts, 6058

cleavageinternucleosomal, bleomycin and

phleomycin in yeast, 6837phorbol ester-induced changes in leu

kemia cells, 6625

7416




resistance, DNA topoisomerase II,3537

complementaryCTL activity, 7-interferon gene trans-

duction, 4730p32 clone isolation, 4795

compromised synthesisdaunorubicin interaction, hepatoma,

2404content

tumor spread, renal cell carcinoma,3165

content and proliferative activityclinical outcome, non-Hodgkin's lym-

phoma, 6608cyanoethylation


-directed actions of 3-deazaguanine,2774

double-strand breaksm-diamminedichloroplatinum(II), cy-

totoxicity, 4484effect of hyperthermia

cw-diamminedichloroplatinum(II),rhodamine 1232, 2335

elevated sister chromatid exchangesethylene oxide-exposed primates, 5045

fingerprint analysiscross-contamination, esophageal squa-

mous cell carcinoma, 5660flow cytometry

advanced germ cell cancer, survival,3864

fragmenting activitiestumor necrosis factor, 6006

galactoside-binding lectinsshared sequence homology, 645

glycosylasemutagenicity, 5-hydroxymethyl-2 ' -

deoxyuridine, 5466granulocyte

iododeoxyuridine incorporation, fluo-rodeoxyuridine, 2933

hepatocellular carcinomanon-A/non-B hepatitis association,

7294hypomethylation

carcinoembryonic antigen, colonie carcinoma, 5674

inhibition of ionizing radiation recoveryprocesses

polyamine-depleted Chinese hamstercells, 4881

in situ hybridizationhuman papillomavirus types, uterine

cervix adenocarcinoma, 993interaction of second-generation anthra-

cyclines with, 6962integration by type 5 adenovirus

methyl methanesulfonate effect, libroblast cells, 3050

interaction of melphalan in lymphocyteschronic lymphocytic leukemia, 1972

-interactive agentsether lipid analogues and, antiprolifer-

ative activity, 1788lesions

doxorubicin content, myeloma cells,6360

growth inhibition, colon adenocarcinoma, 3319

leucovorin-5-fluoropyrimidine, colonadenocarcinoma, 4153

ligase activityheme effect, erythroleukemia cells,

6278ligase deficiency

association with acute T-cell leukemia,4038

mammalian topoisomerase Idrug target, camptothecin, 1722

methylbenzylnitrosamine-induced formation

esophageal O6-methylguanine, ellagic

acid, 7088mitochondria!

loss of, ditercalinium treatment, 4982resistance to mutagenesis, Ik-la cells,

4578molecular mechanisms of carcinogenesis

cancer prevention, treatment, 4135nuclear matrix

antileukemia agents, CCRF-CEM leukemia cells, 1850

papillomavirus types 16 and 18immortalization, exocervical epithelial

cells, 4620placenta!

detection, O'-methyldeoxyguanosine,

4184ploidy

flow cytometry, canine mammary neoplasms, 3411

polymerase chain reaction analysisparaffin-embedded thin-tissue sections,

4564precipitation

alkali unwinding assays, 6444protection of Ehrlich ascites tumor cells

nitrogen mustard, 5-7VyV-dimethylami-loride, 2454

PZE-induced breaksLI210 cells, 1404

rat liverlack of binding, methapyrilene, 6475

reactivity with basesSalmonella typhimurium, methylchry-

sene diol epoxide enantiomers, 1781replication in Syrian hamster cells

transient exposure to hydroxyurea,6298

sodium chromate-induced lesionspolyadenosine diphosphoribose stimu

lation, V79 cells, 1100strand break formation

bromodeoxyuridine and bleomycin, tumor cells, 4244

strand scissionapurinic sites, photoactivated afla-

toxin, 3070tumor virus oncogenes, 493

DNA adductsaflatoxin K,

chromatin, active genes, 7146effect of butylated hydroxyanisole,

2688in vivo immunological detection, 6328

aflatoxin B,-dichloridestructural characterization, calf thy

mus DNA, 5391antibodies against 7-methyldeoxyguano-

sine, 5065benzo(a)pyrene

species formation differences, dermalfibroblasts, 7132

7,12-dimethylbenz(a)anthraceneSyrian hamster cheek pouch epithe

lium, 20251Â»A^-ethenodeoxyguanosineas marker

ÃraÂ«Ã-4-hydroxy-2-nonenal,320immunochemical quantitation

4-aminobiphenyl, 6336levels

inhibition of renal carcinogenesis, ta-moxifen, 779

8-methoxypsoralenflow cytometry, keratinocytes, 7013

4-nitroquinoline 1-oxide andcell sensitivity, hereditary cutaneous

malignant melanoma, 5145platinum

cancer patients, 5597repair, bladder and testicular tumors,

3019polycyclic aromatic hydrocarbons

white blood cells, foundry workers,2288

putative premalignant hepatic nodules2-acetylaminofluorene carcinogenesis,

5270sister chromatid exchanges

diethylstilbestrol, lymphocytes, 335DNA cross-linking

acquired cisplatin resistance in vitrocharacterization of small cell lung car

cinoma, 6803D,L-buthionine-S')/?-sulfoximine effect on

cytotoxicitycytostatic drugs, human melanoma

cells, 19chloroacetaldehyde

ethidium bromide fluorescence, 4804effect of O'-methylguanine

chloroethylnitrosoureas, 3606FK.973

L1210 cells, 5172influence of WR2721

nitrogen mustard, bone marrow andleukemia cells, 6002

DNA damagebenoxaprofen and phagocytes, 3094cell kill produced by 9-aminoacridines,

860DNA precipitation and alkali unwinding

assays, 6444estrogen-induced potentiation

breast cancer cells, topoisomerase II-interactive antitumor drugs, 297

flavone acetic acid-inducedGlasgow osteogenic sarcoma, 1279

genotoxicity of W-nitroso compoundshepatocytes, 4144

inhibition of repair2'-deoxycoformycin, chronic lympho

cytic leukemia cells, 3981repair of 4,5',8-trimethylpsoralen dam

agenormal and Fanconi's anemia cell

lines, 2015role of oxygen radicals in induction

benzene metabolites, 4762VP-16-induced

mechanism of action, breast tumorcells, 5096

DNA ligase Irelation of fibroblast strain 46BR

Bloom's syndrome, 6343

DNA methylationexpression of rat pepsinogen gene, 1603organ and cell specificity

A'-nitrosomethylamylamine, 5482

7417




DNA polymerase ÃŸ1-0-D-arabinofuranosyltransferase

effects on incorporation, elongation,1494

DNA repairdefect

ultraviolet light response, trichothiod-ystrophy, 6090

domain-orientedxeroderma pigmentosum cells, 844

effect of thymidinenitrosourea activity, 4272

enhancement of 6-thioguanine cytotoxic-ity

ADP-ribosyltransferase inhibitors,5650

genotoxicity of yV-nitroso compoundshepatocytes, 4144

mechanism of acquired resistancem-diamminedichloroplatinum(II),

ovarian cancer, 5713multifactorial resistance to Adriamycin,

3595normal <. â€¢¿�chromosomal radiosensitivity

cell survival, cancer family syndrome,2579

regeneration of 0"-alkylguanine-DNA al-

kyltransferasenitrosourea exposure, lymphocytes,

5368urinary bladder epithelial cells

W-hydroxy derivatives, arylamines,4227

DNA synthesisalterations in epidermal polyamine levels

chrysarobin, 6390butyrate effects

epidermal growth factor receptor binding, hepatocytes, 6560

gallium effecthuman T-cell lymphoblasts, 3014

influence of c/5-diamminedichloropIa-tinum(II)

cell cycle progression, CHO cells,6703

growth andoxygen-dependent regulation, Ehrlich

ascites tumor cells, 2053peroxisome proliferation

hepatocarcinogenesis, 6739replicative

reduction of potential, hepatocytes,1618

DNA topoisomerase IIdamage and cell kill

9-aminoacridines, 860low levels

resistance, leukemic and normal lymphocytes, 3537

proliferation-dependent regulationcultured human cells, 3230

strand breaksreduced doxorubicin cytotoxicity, oua-

bain, 725Dodecylglycerol

activation of macrophagescancerous tissues, 6044

Dolichol kinasedolichol phosphatase and

microsomal fractions, human hepato-mas, 3418

i -Dopa decarboxylaseneuroendocrine markers

endocrine and nonendocrine tumors.

L-DOPA, 4078L-DOPA methyl ester

cytotoxicity of catechol analogueshuman malignant melanoma, 5178

Dopaminereceptors

7,12-dimethylbenz(<z)anthracene, anterior pituitary, 6434

Dorsal rootparaneoplastic ganglionopathy

antigen expression, small cell lung carcinoma, 430

Doxorubicin: see also Adriamycinconcentration in multidrug-resistant

myeloma cells, 6360differing mechanisms of resistance

human tumor cell lines, 2793distribution of metabolites

B-cells, chronic lymphocytic leukemia,503

escalating dose concurrently with <>.-in-terferon

Phase I trial, 2574lysis of drug-resistant tumor cells

activated lymphocytes, 2372partial reversal of resistance

forskolin, murine sarcoma S180 variants, 539

reduction of cytotoxicity by ouabain, 725reversal of resistance by verapamil

multidrug-resistant myeloma cells,6365

tolerated doseICRF-187 pretreatment, 6918

Doxycyclinecombination chemotherapy of leukemia,

6686Drinking

smoking andoral and pharyngeal cancer, 3282

Drug-antibody conjugatesendocytosis of monoclonal antibody

MCF-7 cells, 3188gallium-labeled antibodies

immunoscintigraphy, 1189Drug resistance

Adriamycin-resistant cells85-kDa protein, 7082

antitumor activity of MX2murine tumor cells, 6653

detection ofenzymatic amplification, human tu

mors, 5775cÃº-diamminedichloroplatinum(II) and

platinum analoguesaccumulation, murine leukemia cells, 9sensitive and resistant cells, ovarian

carcinoma, 68doxorubicin

differing mechanisms, tumor cell lines,2793

etoposide-resistant human KB cell linescombined modalities of resistance,

5956glucose metabolism in breast cancer cells

magnetic resonance spectroscopy, 870lysis of tumor cells

activated lymphocytes, 2372molecular mechanisms

ribonucleotide reducÃase,2029possible link

colon tumors, detoxification mechanism, 3025

reversal of resistance to vincristine

quinacrine, 2064treatment-induced changes in sensitivity


tumor cellsflow cytometric enumeration, 6037

U.S.-Japan Cooperative Cancer Research Program Conference, 6249

Drug screeningpanels of human tumor cell lines

microculture tetrazolium assay, 589DU-PAN-2

CA 19-9 andexpression in tumor tissue and serum,

pancreatic cancer, 1435Dysplastic nevi

association with multiple primary melanoma, 1016

E

Effector cellsantibody-mediated killing

human tumor cells, 624isolation and reactivity

concomitant tumor immunity, 1153LAK cells

administration, interleukin 2, 1965phenotype in rats, 884subset of giant autofluorescent lym

phocytes, 2184local interleukin 2 therapy

mouse mammary tumors, various inimunogenicities, 2193

tumor rejectiondelayed-type hypersensitivity, T-cells,

5922Effusions

human malignantmultiplicity, transforming growth fac

tors, 1792prognosis and tumor burden

marker, transformiing growth factor-o,5023

Ehrlich ascites tumor cellsantitumor effects of l-hexylcarbamoyI-5-

fluorouracilhyperthermia, Nakahara-Fukuoka sar

coma cells, 3977circulating glutamine

contribution by host tissues, 1551cytogenetic damage and antineoplastic

effectcaffeine, cyclophosphamide, 1129

DNA synthesis and growthoxygen-dependent regulation, 2053

protection against antiproliferative effectnitrogen mustard, 5-AVV-dimethylami-

loride, 2454zinc metabolism, 3381

Eicosanoidsprostaglandin production

therapeutic response predictor, indomethacin, 3002

Eicosapentaenoic acideffect on colon carcinogenesis

azoxymethane-induced, 4790Electromagnetic fields

low energy microwave fieldsornithine decarboxylase activity, phor-

bol ester, 4222Electron microscopy

ultrastructureCALLA-positive myeloma, 6234

Ellagic acid

7418




methylbenzylnitrosamine-induced formation

esophageal O^-methylguanine, 7088

Embryo cellsmouse

genotoxicity of chromÃ¢tes,5280EMT6 tumors cells

modulation of mitomycin C cytotoxicitydicoumarol, 5471

Endocrine therapyresponse of rat mammary tumors

nuclear magnetic resonance spectros-copy, 89

Endocrine tissuetumor-associated Ewing's sarcoma anti

gen, 6127Endocytosis

intracellular routing andantibody-ricin A chain conjugate, 3822

monoclonal antibodymilk fat globule membrane-associated

antigen, MCF-7 cells, 3188Endometrial neoplasms


new hypodiploid human cell line I'MEC-1, 1864

Endometriumdisparate actions of tamoxifen

breast tumor growth, athymic mouse,812

hyperplastic and neoplasticprogesterone receptors, 6132

Endothelial cells-derived interleukin 1

chemotactic activity, tumor cells, 7041differential photosensitivity

porphyrin photodynamic therapy,4539

effects of hyperthermia on cell survivalprotein synthesis patterns, 2101

heat-induced vascular damagerelationship to thermosensitivity, 7226

interaction of intravascular tumor cellssubendothelial matrix, 4065

mechanism of injuryLAK cells, 5528

proliferating area of human gliomaintercapillary distance, 2938

pulmonary capillarylung tumor colony formation, mono

clonal antibodies, 4964Enrichment

lymphatic metastasis of mammary ade-nocarcinoma

soybean agglutinin binding cells, 1451Enterobacter cloacae

significance in inhibition of lung mÃ©tastases, 3031

Environmentmolecular mechanisms of carcinogenesis

cancer prevention, treatment, 4135rare events as clues to cancer etiology,

3544Enzymes

mono- and bifunctional inducers in liver,4776

pulmonary drug-metabolizinglong-lasting effects, tobacco smoking,

4695Epidermal cells

behaviorinitiated and noninitiated skin, 435

cell line development

papillomas in skin grafts, ras"', 165

contrasting actions of staurosporine onneutrophils, 4646

inhibition of cell-cell communicationphorbol 12,13-dibutyrate, bryostatin 1,

447modulation of transglutaminases

TPA, retinole acid, 74Epidermal growth factor

amplification of receptor geneesophageal cancers, 5119

amplified and overexpressed receptorgene

breast carcinoma, 161antagonism of progestin action

breast carcinoma cells, 5071breast cyst fluid

cation and androgen conjugate content, 5860

cepharanthine and lysosomal function,1307

differential regulationplasminogen activators, urothelium,

5552effects of bryostatins and phorbol esters

arachidonic acid release, C3H lOT'/icells, 3702

gene expressionprogestins, breast cancer cells, 4555

growth modulation of mouse keratino-cytes

transforming growth factors, 1596-induced mitogenesis

kidney epithelial cells, 4886nerve growth factor receptors

chromatin, melanoma cells, 7200oncogenes of DNA tumor viruses, 493pro-l andpro-2 transfectants

tumor promoters and antipromoters,mouse cells, 6076

receptoramplification, human glioma xeno-

grafts, 2231c-myc expression, renal cancer, 67531,25-dihydroxyvitamin Dj, breast can

cer cells, 2734glioblastoma cells, 5433growth of neoplastic thyroid cells,

3652human gastric and colonie carcinomas,

137lung cancer cell line, 1132modulation, liver tumor promoters,

1162plasminogen activators, human breast

cancer, 6603relation to steroid receptors, breast

cancer, 1343restriction fragment length polymor

phisms, 4045selective amplification, glioblastoma

multiforme, 2711reduction of binding

alkyl-lysophospholipid, breast cancer,6033

regulatory effects of cell density, 4266reversible induction of anchorage-inde

pendent growthnormal mouse keratinocytes, 1566

stimulationcharacterization, A-431 cells, 2377cytotrophoblasts, A-431 cells, 1105

transforming growth factor-ahamster oral keratinocytes, 3130

variants in urine of rats bearing humantumors, 1428

Epidermal neoplasmsclonogenic keratinocytes

two-stage carcinogenesis. 6285Epidermis

oxidation of retinol to retinoic acid,7038

phosphorylation of M, 34,000 to 40,000proteins

protein kinase C, 4018Epirubicin

Phase 111 studymultiple myeloma, 6246

Epithelial cellsbile ductular cell culture, 6145breast

phenotypical changes, carcinogens,2837

bronchialacrolein, pathobiological effects, 1717differentiation, oxygen radicals, 816T-antigen transformation, 1904

embryonic liverdifferentiation patterns, 4909

esophagealcholesterol sulfate accumulation, 5289

exocervicalimmortalization, papillomavirus DNA,

4620expression of fibronectin

tumor line, mouse alveolus. 4933keratin subtypes

small cell lung cancer, 2724kidney

epidermal growth factor, mitogenesis,4886

liverchromium effects, transformation,

6484transforming growth factors, 850

mammarygrowth factor expression, oncogenes,

7041transformation, oncogenic retrovi-

ruses, 4689mammary and urinary bladder

DNA repair, arylamine metabolites,4227

pattern of proliferationcoleircela I mucosa, 4121

Epithelial neoplasmsbiosynthesis and secretion of laminin

cultured human keratinocytes, 5193keratin-like antigen

monoclonal antibodies, 4969Epithelium


vention, 235epithelial-like markers

class I MHC, mammary carcinoma,7237

gastrointestinaldifferential expression, Cora antigen,

2198human breast

keratins 13 and 16, 5831reconstitution of site preference

mammary tumors, 3698Syrian hamster cheek pouch

DNA adduci formation, 7,12-dimeth-ylbenz(<z)anthracene, 2025

thymic

7419




analysis of tumors, PE-45 monoclonalantibody, 1896

Epitopescarbohydrate

human squamous lung cancer, 2125Epoxide hydrolases

metabolizing enzymes in mammarygland and liver

effects of inducers, 1390Epstein-Barr virus

oncogenes of DNA tumor viruses, 493Erythrocytes

aflatoxin II, adductionchromatin, active genes, 7146

Erythroleukemiamaturation

Superoxide dismutase, 6674protooncogene expression, 3972whole-body hyperthermia and cyclophos-

phamidenatural killer cell activity, 4S61

Erythroleukemia cellsheme effect

DNA ligase activity, 6278murine

erythropoietin receptor induction,1818

Erythropoietin-induced polycythemia

transplantation, renal carcinoma, 3430induction of receptor

murine erythroleukemia cells, 1818Escherichia coll

yV-ethyl-yV-nitrosourea-induced lesionsneighboring base sequence, distribu

tion and repair, 4455gene expression

alkylating agents, cu-diamminedichlo-roplatinum(II), 4823

Esophageal cellsDNA fingerprint analysis

cross-contamination, squamous cellcarcinoma, 5660

Esophageal neoplasmsamplification

epidermal growth factor receptor gene,5119

A'-nitrosomethylbenzylamine-induced

chemoprevention of, diallyl sulfide,6872

EsophagusBarrett's

ornithine decarboxylase, polyaminelevels, 3288


vention, 235DNA cyanoethylation


epithelial cellscholesterol sulfate accumulation, 5289

hydroxy metabolites of methyl-n-amylni-trosamine, 5663

precancerous lesionsvitamin intervention, 2280

EsorubicinPhase I evaluation in leukemia, 5580

Estradioleffects on estrogen receptor in mela

noma, 3720-induced kidney tumors

biochemical analysis of development,971

insulin-like growth factor I receptors inbreast cancer, 6429

long-term antiestrogen administrationtamoxifen-stimulated growth, MCF-7

tumors, 5183vs. tamoxifen

effects on normal breast cells, 719317/3-Estradiol

differential responsivenessgrowth factors, breast cancer cells,

4083growth of estrogen receptor-positive mel

anoma, 7093Estramustine

antiinvasive activitymalignant MO., mouse cells, human

prostate carcinoma, 1842-binding associated protein

expression, lung cancer cell lines, 4615tumor cell invasion

blocking of collagenase secretion, 6262Estrogen

action of 2-phenylindole derivatives, 784aromatization of testosterone

ovarian epithelial tumor cells, 6491bromine-80m-labeled

therapy in ER-positive cancers, 899bromine-80m radiotoxicity

receptor-directed therapy, Auger electrons, 5805

case-control study of male breast cancer,1326

cause of human cancer, 246differential responsiveness of breast can

cer cellsgrowth factors, 17/3-estradiol, 4083

effects of phenol redbreast cancer cell growth, 3693

epidermal growth factorinsulin-like growth factor I, breast can

cer, 1343hepatic effects of steroids

structure-activity studies, 2462-induced kidney tumors

drug metabolism enzymes, 5726-induced pituitary neoplasms

glandular kallikrein, prolactin, 4158-induced renal carcinogenesis

inhibition by tamoxifen, 779interactions with intracellular receptor

complexmouse Leydig cells, preneoplastic hy-

perplasia, 14-like effects

7,12-dimethylbenz(a)anthracene, anterior pituitary dopamine receptors,6434

neonatally estrogenized micerapid induction, ovarian granulosa cell

tumors, 425plasminogen activators

human breast cancer, 6603potentiation of DNA damage and cyto-

toxicitybreast cancer cells, topoisomerase II-

interactive antitumor drugs, 297receptor

antiestrogen growth regulation, MCF-7 cells, 6764

hormone responsiveness, medullarythyroid carcinoma, 2760

localization, human breast tissue, 6517SAMBA 200 analysis, breast carci

noma, 1578

receptor concentrationbreast cancer survival model, 5565

receptor-negative breast cancer cellsbiological activity, transforming

growth factor-/3, 3905receptor status

cathepsin D, breast cancer cytosols,462

replacement therapybreast cancer epidemiology, 5615

-sensitive proliferation patternkidney tumor cells, 3676

steroid insensitivitybreast cancer cells, 4340

-stimulated hormone receptor profilesprostatic carcinoma, 3077

Estrous cyclemodification by ALmethyl-/V-nitrosourea

rat mammary gland DNA alkylation,3090

Ethacrynic acidpiriprost and

cytotoxicity effect, 3622Ethanol

esophageal carcinoma, 3843-inducible cytochrome P-450

benzene metabolism, liver micro-somes, 5387

inhibition of colonie carcinogenesishigh-dose azoxymethane, 3313

1,iV''-Mllicnudfiiv yijiiiiiiiisiiiv

potential marker for DNA adduci formation

rrufls-4-hydroxy-2-nonenal, 320Ether lipid analogues

DNA-interactive agents andantiproliferative activity, human tumor

cells, 1788Ethidium bromide

fluorescencechloroacetaldehyde-DNA, 4804

Ethinylestradiolmetabolism and binding

a-naphthoflavone, hepatocarcinogene-sis, 5460

Di.-Ethionineformation of 5-adenosylethionine in

liver, 446410-Ethyl-lO-deazaaminopterin

Phase I trialadvanced cancer, 5573

Ethylene oxide-exposed primates

elevated sister chromatid exchanges,5045

Ethylmethane sulfonateresistance of mitochondrial DNA to mu-

tagenesisHeLa cells, 4578

yV-Ethyl-W-nitrosourea-induced lesions in Escherichia coli

neighboring base sequence, distribution and repair, 4455

-induced tumorigenesismouse major histocompatibility com

plex (H-2), 6634tumor size and morphology

gestational development, lung tumors,379

5-EthyI-5-phenylhydantoincytochrome P-450 induction

tumor promotion, liver and thyroid,2492

Etoposide

7420




DNA strand breaksmechanism of action, breast tumor

cells, 5096metabolism and excretion

rat liver models, 5692-resistant human KB cell lines

combined modalities of resistance,5956

topoisomerase H-interactive drugsestrogen and DNA damage, breast

cancer cells, 297Etoposide glucuronide

major metabolite of etoposiderat and rabbit, 1829

Exercisemammary carcinogenesis

effect on induction, 2720mammary tumorigenesis

dietary fat, caloric restriction, 4276voluntary

effects on colon carcinogenesis, 7079Exotoxins


Extracellular matrixassay for tumor cell invasion

protein gels, 6933bile duct Â»lar epithelial cell cultures, 6145collagen-binding glycoproteins

MDAY-D2 tumor cells, 4743degradation with cathepsin D

breast cancer cells, 3688interaction of melanoma with murine

mesentery, 5296platelet-derived growth factor-like pro

teinsconstitutive production, prostate carci

noma, 1930Extravasation

interaction of intravascular tumor cellsendothelial cells, subendothelial ma

trix, 4065

Fab fragmentsantibody-guided targeting

non-small cell lung cancer, 1977monoclonal antibody delivery

osmotic blood-brain barrier disruption,4725

monoclonal antibody Mel-14glioma localization, 5701

Factor Xloss of activator capabilities

vitamin K, Lewis lung carcinoma,6504

Familial polyposis colic-myc and c-fos differential expression,

4855Fat

bladder cancermotor exhaust-related occupations,

1989mammary tumorigenesis

caffeine and, 2074caloric restriction, voluntary exercise,

4276prostate cancer

dietary /3-carotene, case-control study,1331

Fatty acidsomega-3

colon tumor inhibition, 6642oxidized

colonie cell proliferation, structural requirements, 1771

Fecapentaenescolon cancer

hypotheses for origin, 7323role in mutagenicity, 7324

Ferritineffects of hematopoietic suppressor mol

eculesgranulocyte-macrophage progenitor

cells, 1548Fertility

gestational choriocarcinomacase-control study, 1004

Ferulic acidinhibition of TPA-induced tumor promo

tion in mouse skin, 5941a-Fetoprotein

differential regulationhepatocyte X hepatoma hybrids, 6371

embryonic liver epithelial cell lines, 4909lack of mRNA expression

peroxisome proliferators, liver tumors,4919

rat ductular oval cellspromotion of growth, primary culture,

368Fibrin

coagulationprotection against cytotoxic cells,

5216-fibronectin degradation

ovarian carcinoma, 3507Fibrinogen

influx and accumulationcross-linked fibrin, mouse carcinoma,

1920Fibroblast growth factor

-like activityincreased levels in urine, bladder or

kidney cancer, 2083modulation of plasminogen activator ac

tivityendometrial adenocarcinoma cells,

6384regulatory effects of cell density, 4266

Fibroblastsdermal

DNA adduci formation,benzo(a)pyrene, 7132

effects of SV40 transformationintercellular gap junctional communi

cation, 3485fetus-derived

identification, transformation-associated cell surface antigen, 2798

formation and repair of cisplatin-DNAadducts, 6058

1la-iuv transfectionprotein kinase C down-regulation,

C3H 10T'/2 cells, 6535invasiveness in monolayers

metastatic potential, T-cell hybrido-mas, 3405

malignancy by cell fusion, 3302methyl methanesulfonate effect

type 5 adenovirus DNA integration,3050

normal humangrowth inhibition, salivary adenocarci

noma cells, 2819radiosensitivity, 4535

proliferation-dependent regulationDNA topoisomerase II, 3230

src oncogene expressionreversal of transformed phenotypes,

1587strain 46BR

relation to Bloom's syndrome, 6343lOT'/i

postconfluence growth arrest, cAMP,1874

transformation by human papillomavirus16, 2505

-tumor cell interactionenhancement, metastatic capacity,

1456xeroderma pigmentosum

antioxidant enzymes, 2132Fibronectin

colon carcinomacarcinoembryonic antigen secretion,

transforming growth factor-/3, 4059effect, colon-derived substrata mate

rial, 2825down modulation of messenger RNA

prostatic cancer, 2042enhanced receptor expression

sarcoma virus-induced tumors, 5510epithelial cell strains, 4933receptors

alteration of, phorbol ester-treatedpromonocytic cell lines, 5730

stromalstaining pattern and metastatic ability,

breast carcinoma, 6227Fibrosarcoma

cell surface cathepsin B-like activityidentification, butano! extraction,

14165-deazaaminopterin

5-alkyl derivatives, methotrexate comparison, 5686

effect of interferon-aA/Dtumor cell growth, 2366

elimination of T-suppressor activitybleomycin, tumor-bearing rats, 6658

growtheffects, glucocorticoid receptor, 2703

laser Doppler flowhyperglycemia, murine tumors, 7102

metastasis marker polypeptides in cancer, 572

metastaticstimulation, transforming growth fac

tor-/?, 6999platelet aggregation in metastasis, 1460role of serotonin

antitumor effects, tumor necrosis factor-Â«,4250

site-specific brain metastasis, 3478spontaneous tumors


tumor growth delay and cell survivaltrimodality therapy, 2693


ultraviolet light-inducedbutano! extraction, tumor-specific an

tigens, 7004Fibrosarcoma-1

radiation-inducedcyclophosphamide response, "P NMR

spectroscopy, 4736Fibrosarcoma cells

glucocorticoid-induced alterations ofgrowth

7421




mammary tumor, 7212Fish

ingestion of cod with vegetablesurinary level, A'-nitrosothioproIine,

4049progressive growth of tumors

transplantation, thymus-aplastic mice,741

FK973antitumor activity

hematotoxicity, 1166DNA cross-linking, 5172

Flavone acetic acidDNA damage

Glasgow osteogenic sarcoma, 1279modulation of tumor physiology

NMR spectroscopy, 4749Phase I study, 5878

Flavonol quercetin7,12-dimethylben7(u)anthracene induced

mammary cancer, 5754Flow cytometry

activation of B-cellschromatin structure, 6708

advanced germ cell cancerproliferative activity, survival, 3864

analysis of DNA ploidycanine mammary tumors, 3411

cell cycle and viable cell isolationexposure to cytotoxic agents, 5742

cell kinetics in human malignanciesbromodeoxyuridine, 6238

compared to clonogenic assaydrug testing, 5722

cytogenetic and ultrastructural studiesnonfamilial renal carcinoma, 2890

cytokinetic effectsmethotrexate, L1210 cells, 4288

enumeration of drug-resistant tumorcells, 6037

8-methoxypsoralen-DNA photoadductskeratinocytes, 7013

nucleic acidlarge cell lymphoma, 6614

prognostic factors for survivalnon-small cell lung carcinoma, 2923

protein-tyrosine kinase activitypp60' "' expression, 4633

Fluctuation analysisLuria-Delbruck

pitfalls and practice, 1060Fluocinolone acetonide

gap-junctional intercellular communication

transformed foci in BALB/c 3T3 cells,3490

Fluoranthene-hemoglobin adductsisolation and characterization, 4756

/V-2-Fluorenylacetamidelate target protein in liver, 6745

Fluorescencegiant autofluorescent lymphocytes

LAK cells as subset, 21842-Fluoro-0-alanine

biliary metabolites in liver, 201016a-Fluoro-5-androsten-17-one

novel dehydroepiandrosterone analoguesenhanced biological activity, reduced

side effects, 48175-Fluoro-2-deoxyuridine

biliary metabolites of fluoropyrimidines,2010

elimination by liver, 3561growth inhibition

colon adenocarcinoma, 3319incorporation of iododeoxyuridine

granulocyte DNA, Phase I study, 2933recurrent tumor sensitivity

rat model, mammary tumors, 45495-Fluoroorotate

liposome-based therapyhuman ovarian cancer, 5237

S-Fluoropyrimidineincreased levels of DNA lesions

colon adenocarcinoma, 41535-Fluorouracil

circadian rhythm, 1676contribution of medicine

primary treatment in breast cancer,2314


3236folate pools

xenografts, colon adenocarcinoma,3062

formation of conjugates5-fluoro-^-alanine, bile acids, 2010

i.-histidinolmetabolism, murine tumor system,

6664specificity, proliferation dependence,

1470leucovorin and

disseminated cancer treatment, pancreas, 5570

mechanisms of innate resistancethymidylate synthase inhibition, 5894

metabolites in plasma and urinewith or without methotrexate, 1680

modulation of cytotoxic effectA'-methylformamide. colon carcinoma,

6193pharmacokinetics

mass spectrometry, 6956maximum tolerated dose, continuous

venous infusion, 459yV-(phosphonacetyl)-i.-aspartate

biochemistry, 4434prognostic factors

hepatocellular carcinoma, 7314Fluosol-DA

photodynamic therapy-induced hypoxiacarbogen breathing, 3350

Folateeffects of deficiency

metastatic potential, melanoma cells,4529

mechanisms of innate resistancethymidylate synthase inhibition, 5894

Folie acidantagonists in chemotherapy, 4131

Folylpolyglutamate synthetaseregulation

methotrexate, hepatoma cells, 2426Forebrain

fetal transplantsA'-nitrosoethylurea induction, oligo-

dendrogliomas, 2871Forestomach neoplasia

/3-propiolactone-inducedinhibition, 4-mercaptobenzene, 2740

Formaldehydeingestion of cod with vegetables

urinary level, A'-nitrosothioproIine,4049

Formylmethionylleucylphenylalaninephorbol ester inhibition

chemotactic signals, HL-60 cells, 2707Forskolin

partial reversaldoxorubicin resistance, murine sar

coma S180 variants, 539Friend erythroleukemia

electrophoretic analysis, 1110protooncogene expression, 3972

Friend virus complexpolycythemia-inducing strain

curative effect, irradiation, 2399Fucosyltransferase

Le* and Le* antigen expression

human pancreatic cancer, 475a-2-i-Fucosyltransferase

significance of altered levelsserum, leukemic patients, 3998

Galactosebinding activity

ricin-monoclonal antibody conjugates,4469

effect on systemic hemodynamicsblood flow rate, 1476

/J-D-Galactosidasequantification of actinomycin D by

ELISA, 4843Galactoside

-binding lectinsshared sequence homology, 645

Galactosyltransferase isozyme IItumor-associated

immunoassay, 5325, 5335Gallbladder

tumor markers CA 19-9 and CA-50carcinoembryonic antigen, pancreatic

neoplasms, 1985Gallium

effect on DNA synthesishuman T-cell lymphoblasts, 3014

-labeled antibodiesimmunoscintigraphy, drug-antibody

conjugates, 1189Gangliosides

detection of monosialogangliosidemonoclonal antibody, tumor-infiltrat

ing macrophages, 2524GMÃ•

residue discrimination, monoclonalantibodies, 6154

inhibited melanoma growthIgG3 monoclonal antibody, GM.<lac-

tone immunization, 5680melanoma-associated

fish genus Xiphophorus, 3454neosynthesis

transfection, Gardner-Arnstein strainfeline sarcoma virus-DNA, 1753

Gap junctionc-raf protooncogene expression

7-glutamyltranspeptidase, liver neoplasms, 1610

intercellular communicationeffects, SV40 transformation, 3485transformed foci, BALB/c 3T3 cells,

3490metastatic capacity

mammary carcinoma, 5129selective killing of transformed cells

therapeutic applications, 3203Garlic

diallyl suItidechemoprevention, carcinogen-induced

7422




esophageal cancer, 6872liver microsomal nitrosamine metabo

lism, 5937Gastric mucosa

differential proliferative responsecarcinogenesis, /V-methyl-Ar'-nitro-Ar-

nitrosoguanidine, 5215Gastric neoplasms

human model of gastric carcinogenesis,3554

Gastrinbombesin-stimulated

gastric cancer, 2296receptor antagonists

antibodies, colon carcinoma, 7179Gastrin,7

binding to human gastric carcinoma celllines, 932

Gastrin-releasing peptideeffects of bombesin antagonists

growth, small cell lung cancer, 4783molecular forms

human medullary thyroid carcinoma,2412

Gastrointestinal neoplasms-associated glycoprotein

CA 19-9 expression, 1505biomarkers of increased susceptibility

cancer prevention, human subjects,235

cancer in migrants to Australia, 751Cora antigen expression, 2198monoclonal antibody reaction

high-molecular-weight glycoprotein,4053

Gastrointestinal tractintervention of T-cells in transportation

mouse mammary tumor virus, mammary gland cells, 6555

Gel electrophoresis: see AssaysGenes

amplifiedchromosomal organization, multidrug-

resistant Chinese hamster cells,3179

cancer suppressorassessment, hamster cells, 46

EIAphospholipid toxicity, adenovirus 12

transformant, 578galactoside-binding lectins

shared sequence homology, 645hepatocellular carcinoma

in vitro translation analysis, 2382human a-interferon

coding, functional properties of proteins, 1763

multidrug resistanceRNA detection, in situ hybridization,

4334NM2ÃŒ

RNA levels in metastasis, 6550oligodeoxynucleotides

inhibitors of expression, 2659pro

transfer of promotion sensitivity, 1195specific chromosomal abnormalities

malignant human gliomas, 405WDNM1

differential expression, mammary ade-nocarcinoma cells, 5203

Geneticsrare events as clues to cancer etiology,

3544

GenotoxicitychromÃ¢tesin mouse embryo cells, 5280

Germ cell neoplasmsadvanced

proliferative activity, survival, 3864blood group-related antigens, 5342estrogens as cause of human cancer, 246stage migration

complete responders, 3524Germinal cell aplasia

procarbazine-inducedpartial prevention, testosterone, 4354

Gestational choriocarcinomacase-control study, 1004

Glia maturation factortherapy by directing differentiation in

carcinoma, 1996Glioblastoma

analysis of lymphoid infiltrates, 6926I AK cell generation and antitumor ac

tivity, 6069multiforme

selective amplification, epidermalgrowth factor receptor, 2711

Glioblastoma cellsexpression of altered epidermal growth

factor receptor, 5433Glioma


blood-brain disruptionmethotrexate, rat brain tumors, 694

diagnostic imagingisoquinoline, benzodiazepine binding,

5837expression of mRNAs

platelet-derived growth factor, transforming growth factor-a, 3910

humanproliferation, intercapillary distance,

2938receptor expression, insulin-like

growth factors, 1233specific chromosomal abnormalities,

405human xenografts

amplification, epidermal growth factorreceptor gene, 2231

antiglioma monoclonal antibody, therapeutic efficacy, 559

intrue-ranial. radioimmunotherapy,

2904localization

monoclonal antibody fragment, 5701malignancy stages

clonal genomic alterations, 5546-specific cytotoxic T-lymphocytes

immunoregulatory effects, interleukin2 and interferon, 2981


Glioma cellsyV-(2-chloroethyl)-./V-nitrosourea-treated

DNA alkylation products, 4489plasminogen activator

modulation, sodium butyrate, 291Gliosarcoma

new cell linebiological and karyotypic characteriza

tion, 731nuclear magnetic resonance spectros-

copy, 5610tumor bioenergetics, histology, 676

0-1,3-Glucan

lentinandenaturation and renaturation, T cell

responses, 671Glucocorticoids

CA 125 tumor marker expressionovarian carcinoma, 3502

-induced alterationsfibrosarcoma growth, mammary tu

mor, 7212lipid lateral diffusion and membrane

compositionlipopolysaccharide, B-cell leukemia 1

cells, 59mammary tumorigenesis

adrenal regulation, 3808receptor

effects, fibrosarcoma growth, 2703protein level, 2636tyrosine aminotransferase modulation,

Reuber hepatoma cells, 5188Glucose

blood flow and venous pHWalker 256 carcinoma, hyperglycemia,

1201-deprived L929 cells

nucleoside-restored heat resistance,suppressed protein synthesis, 1442

diffusivitymulticellular tumor spheroids, 3905

energy substrate utilizationMorris hepatoma 7777 cells, 602

estrogen-induced kidney neoplasmsdrug metabolism enzymes, 5726

hydralazine andpH modification, air or carbon dioxide

mixture, 1543metabolism in breast cancer cells

magnetic resonance spectroscopy, 870metabolism in vivo

human breast cancer xenografts, 7264role of hypovolemic hemoconcentration

flow decline, 7102tumor metabolic changes

â€¢¿�"Pnuclear magnetic resonance, 5917Glucose-6-phosphate

mitochondria! bound hexokinasehepatoma cells, 913

/3-Glucuronidascidentification of etoposide glucuronide

major metabolite, rat and rabbit, 1829Glutamine

circulationcontribution by host tissues. Ehrlich

asdics tumor cells, 1551energy substrate utilization

Morris hepatoma 7777 cells, 602Glutamylation

role of folylpolyglutamate synthetasemethotrexate, hepatoma cells, 2426

7-Glutamyltransferasesequential development of aneuploidy

skin papillomas, 3253â€¢¿�v-Glutamyltranspeptidase

estrogen-induced kidney neoplasms,5726

expression of c-ra/protooncogeneliver neoplasms, 1610

lack of mKNA expressionperoxisome proliferatoÂ», liver tumors,

4919Glutathione

acquired cisplatin resistance in vitrocharacterization, small cell lung carci

noma, 6803

7423




buthionine sulfoximine-mediated depletion

enhanced melphalan cytotoxicity, me-dulloblastoma xenograft, 2764

cellular levelsrodent and human tumor cells, 3657

depletionheat shock protein synthesis, Chinese

hamster ovary cells, 7033elicci on Adriamycin tolerance

Chinese hamster ovary cells, 4493growth and cell cycle

yV-methylformamide effects, lym-phoma cells, 3389

human and rodent tumor cellsvarious phases of cell cycle, 3661

impaired biosynthesisataxia-telangiectasia cells, 5374

levels in medulloblastomamelphalan transport, glutathione-51-

transferase, 5397resistance to quinone antitumor agents

characterization, L5178Y murine lym-phoblasts, 1727

Glutathione peroxidaseeffect on Adriamycin tolerance

Chinese hamster ovary cells, 4493Glutathione transferase

anionic formpresence in human tumors and cell

lines, 527estrogen-induced kidney neoplasms,

5726multifactorial resistance to Adriamycin,

3595Glutathione 5-transferase

conjugation and aflatoxin H, I )\A binding

effects, butylated hydroxyanisole, 2688U.S.-Japan Cooperative Cancer Re

search Program Conference, 6249Glutathione-5-transferase P

lack of mRNA expressionperoxisome proliferators, liver tumors,

4919purification and characterization

normal and preneoplastic liver nodules, 2805

Glyceraldehyde-3-phosphate dehydrogenaseincreased gene expression

pancreatic adenocarcinoma, 6354Glycolipids

lactoneotetraosylceramidedetection in patients with cancer, 1512

neutralmonoclonal antibody, HTLV-I and

adult T cell leukemia, 3148sulfated

thrombospondin binding, melanoma,6785

Glycoproteinscell surface

colorectal carcinoma, 7257collagen-binding

MDAY-D2 tumor cells,4743gp70

mutagen-treated murine tumor cells,1137

gploOradioimmunotherapy, lung cancer cell

lines, 2768high-molecular-weight

monoclonal antibody reaction, gastrointestinal cancer, 4053

IRGpIIb/IIIatumor cell cytoskeleton, platelet adhe

sion, 3787lamÃnin-associated

biosynthesis and secretion, keratino-cytes, 5193

M, 95,000melanocytes and melanomas, mAb,

1286mucin

monoclonal antibodies, sera frombreast cancer patients, 2138

serum type 1 chain antigens, 3856Glycosphingolipid

changes accompanying differentiationhuman squamous SQCC/Y1 cells,

2121disulfated

monoclonal antibodies, hepatocellularcarcinoma, 6769

Glycosylationgene transcription

carcinoembryonic antigen family, 3153sialosyl-Tn epitope

monoclonal antibody preparation,2214

Glycosyltransferaseseffect of hyperthermia

Chinese hamster ovary cells, 5717human blood group gene-encoded

normal and malignant bladder urothe-lium, 4427

Glycyrrhetinic acidantitumor promotion by oleanane-type

triterpenoids12-0-tetradecanoylphorbol-13-acetate,

5210Gompertzian model

breast cancer growth, 7067Gonadotoxicity

cyclophosphamideluteinizing hormone-releasing hor

mone agonist, 2174Gonadotropin-releasing hormone

analogueoptimal medical castration, male rats,

6063partial prevention

germinal cell aplasia, procarbazine-in-duced, 4354

Granulocytesheat shock and differentiation

HL-60 cells, 6715incorporation of iododeoxyuridine into

DNAfluorodeoxyuridine modulation, 2933

maturationl\rosine phosphorylation in HL-60

cells, 52Granuloma

imeobaclcrmni induced infectiousXenopus, 958

Granulosa cell neoplasmsgenetics

dehydroepiandrosterone, 5092Granulosa cells

inhibition of thymidine uptakeLHRH agonist, 7252

Great Britaincancer in homozygotes and hÃ©tÃ©rozy

gotesataxia-telangiectasia, xeroderma pig-

mentosum, 2929Griseofulvin

effect on microtubulescell proliferation, 3T3 cells, 4892

Growth factorautocrine

lung carcinoma cell lines, 4976differential responsiveness

17/3-estradiol, breast cancer cells, 4083hemopoietic, 5624expression in mammary epithelial cells

oncogenes, 7041peptide

steroid hormones and c-fos expressionin breast cancer cells, 802

platelet-derivedret rovinii expression, transformed

cells, 4874stimulation of metastatic fibrosarcoma

transforming growth factor-/3, 6999Growth-inhibitory factor

low-molecular-weightcharacterization, V79 cells, 3737

Guaninemodulation of 6-thioguanine activity

HL-60 cells, 3648Guanine nucleotide-binding protein

identification in human neuroblastoma,2756

Guanosine triphosphateactivation of ornithine decarboxylase

human squamous cell carcinoma, 1252Guanylate

de novo synthesiscommitment to replication, hepatoma

3924A cells, 507Gynecological neoplasms


H

hCG: see Human chorionic gonadotropin11-2complex

Â¿V-ethyl-A'-nitrosourea-inducedtumori-genesis, 6634

Heartcardiotoxicity

acodazole hydrochloride, Phase I trial,4423

Heat shock protein synthesisdifferentiation and

HL-60 cells, 6715glutathione depletion

thermotolerance development, Chinesehamster ovary cells, 7033

premature chromosome condensationnuclear fragmentation, CHO cells,

6478suppression by glucose-deprived L929

cellsnucleoside restoration, heat resistance,

1442thermotolerance

bone marrow progenitors, 3630Height: see StaturelÃela cells


intranucleolar localization of p 120, 6523mitochondrial DNA mutagenesis, 4578phorbol ester-induced <. delay

time lapse photography, 1759potentiation of Adriamycin cytotoxicity

dipyridamole, 1208scraped

optimal loading, nucleolar antibodies,

7424




5246Hematological malignancies

a-difluoromethylomithinemethylglyoxal bis(guanylhydrazone)

and, Phase I study, 1367Hematopoiesis

suppressionLAK cell fraction, 534

Hematopoietic cellssuppressor molecules

effects, purified granulocyte-macro-phage progenitor cells, 1548

Hematopoietic progenitor cellscell cycle effects

deferoxamine, 3571differentiation antigens

anti-K562 monoclonal antibodies,5759

Hematoporphyrin derivativephotodynamic effect

bladder tumor, 6115photosensitizing effects

plasma membrane enzymes, mammaryadenocarcinoma, 3360

Hematotoxicityantitumor activity of FK973, 1166

Hemeeffect on fate of DNA ligase activity

differentiating erythroleukemia cells,6278

Heme oxygenasep32 cDNA clone isolation, 4795

Hemin-induced cell protection

anthracyclines, 3566Hemodynamics

systemicblood flow, galactose injection, 1476

Hemoglobinbinding to fluoranthene

major adduct formation, characterization, 4756

Superoxide disunitasi-erythroleukemia maturation, 6674

Hemopoietic cellshemin-induced cell protection

anthracyclines, 3566Hemopoietic growth factors, 5624Hepatitis

non-A/non-Bhepatocellular carcinoma, 7294

Hepatitis B virusduck

geographical pathology, 1319influence of aflatoxin Bi, 1559

Hepatocarcinogenesischemical

cellular distribution, c-myc transcripts,5522

a-naphthoflavone influenceethinylestradiol metabolism, liver mi-

crosomes, 5460peroxisome proliferation and DNA syn

thesis, 6739plasma membrane polarity, 6882purification and characterization

glutathione 5-transferase-P, liver nodules, 2805

HepatocytescÃs-bis-neodecanoate-frans-/Ã,/Ã-1,2-dia-

minocyclohexaneplatinum (II)cellular pharmacology, 1300

ditercalinium accumulation in cytoplasmmitochondria! damage, 6542

DNA replicationunscheduled DNA synthesis in hepato-

cytes, 1618effects of butyrate

epidermal growth factor receptor binding, 6560

formation of 5-adenosylethioninechronic feeding of DL-ethionine, 4464

genotoxicity of W-nitroso compounds,4144

hybridsdifferential regulation, a,-fetoprotein,

6371initiation

continuous administration of diethyl-nitrosamine and 1,2-sym-dimethyl-hydrazine, 988

intercellular communicationkinetics, phÃ©nobarbitalinhibition,

2519invasiveness in monolayers

metastatic potential, T-cell hybrido-mas, 3405

metabolism of ALnitroso-Ar-methyl-(2-ox-opropyl)amine

Z and E isomers, 3347phenotypic properties of altered foci

hepatic tumors, 4171preneoplastic

lack of albumin as marker, albumin-positive liver, 387


368tumor promoters

epidermal growth factor receptors,modulation, 1162

Hepatomaaldehyde dehydrogenase gene expression,

7009daunorubicin interaction

compromised DNA synthesis, 2404differentiated state

tumorigenicity, 3258dolichol kinase and phosphatase, 3418hepatocyte hybrids

differential regulation, Â«,-fetoprotein,6371

increased mannose-6-phosphatecathepsin D carbohydrate moiety, 362

Novikoffalterations in protein synthesis, 1554

nuclear proteinsisolation, monoclonal antibodies, 5495

selective accumulation3' ,5 '-dioctanoyl-5-fluoro-2 ' -deoxyuri-

dine prodrug, 4179thymidine incorporation

linoleic acid, arachidonic acid, 3106vitamin B,,metabolism

McA-RH7777 cells, 1080Hepatoma cells

commitment to replicationde novo guanylate synthesis, 507

energy substrate utilization, 602mitochondria! bound hexokinase, 913modulation of hormonal induction

tyrosine aminotransferase, glucocorti-coid receptors, 5188

rat ascitesfactor with antiinvasive potential in

liver, 3760role of folylpolyglutamate synthetase

methotrexate, 2426

Hepatotoxicitysaporin immunotoxins, 7072

Herbimycin-Aretinoic acid and

neuronal cell differentiation, neuroblastoma, 6530

reversal of transformed phenotypesire oncogene, rat fibroblasts, 1587

Herpes simplex virusinducible repair

xeroderma pigmentosum, 6054oncogenes of DNA tumor viruses, 493

Heterochromatinresistance to nickel(II) ions

characterization, mouse cell lines,6850

Hexamethylene bisacetamideheterogeneous responses

human colon carcinomas, 5487induction of differentiation

promyelocytic leukemia cells, 3613metabolism of

leukemic cells, 1712Phase I trial, 7304Superoxide dismutase

erythroleukemia maturation, 6674therapy by directing differentiation in

carcinoma, 1999Hexokinase

mitochondria! boundhepatoma cells, 913

l -Hexylcarbamoyl-5-fluorouracilcombined with hyperthermia

enhanced antitumor effects, Ehrlichascites tumor, 3977

Histamineantiestrogen binding site ligands

antiproliferative action, 3954L-Histidinol

5-fluorouracilmetabolism in a murine tumor system,

6664specificity, proliferation dependence,

1470Histone

variant synthesiscomparison, lymphocytic leukemia

and normal cells, 3670111.A complex

antigens in locoregional mÃ©tastasesmelanoma, 1019

class II antigens in retinoblastoma, 1633dexamethasone and interferons

tumoricidal effects, human leukocytecell lines, 567

effect on U937 cell differentiationendogenous and exogenous interfer

ons, 82human a-interferon genes and pseudo-

genefunctional properties, proteins, 1763

111.-6(1leukemia cellsactin polymerization, 6721alteration in tyrosine kinase phosphoryl-

ationgranulocytic maturation, 52

l -ÃŸ-D-arabinofuranosylcytosineactivation

bromodeoxyuridine enhancement, 5175-hydroxymethyl-2 '-deoxyuridine, me

tabolism, 3117bryostatin 1-induced phosphor yhition

pattern mimicryphorbol ester, 5984

7425




chemotactic peptide-induced elevation ofcalcium

inhibition, phorbol 12-myristate 13-acetate, 2707

differentiationtiazofurin effects, protooncogene

expression, 5965heat shock and differentiation, 6715induction of differentiation

hexamethylene bisacetamide metabolites, 3613

inhibitory effects of prostaglandin Ac-myc expression, cell cycle progres

sion, 2813interferon interactions

halogenated pyrimidine antimetabo-lites, 4868

low molecular weight factorgrowth inhibition, myeloid leukemia

cells, 4201maturation

cell cycle changes, retinoic acid, 5989mechanisms of multidrug resistance,

3959membrane-bound lectin

monocytic maturation, 280mitogenic responsiveness

granulocyte-macrophage CSF, 2683modulation of 6-thioguanine activity

guanine, 3648phorbol ester-induced changes

topoisomerase II DNA cleavage, 6625phorbol ester-induced differentiation

thioether phospholipid effects, proteinkinase C, 6669

protooncogene expression, 6733role of protein kinase C

vinculin phosphorylation, 3324tyrosine kinase and phosphotyrosine

phosphatasebiochemical characterization, 4299

variantsdifferent activities, protein kinase C,

2744Hodgkin's disease

molecular pathways of adhesionspontaneous rosetting, T-cells, 37

T-cell receptor gene rearrangementsimmunoglobulins, 3591

therapy-related acute nonlymphocyticleukemia

O*-alkylguanine DNA alkyltransferase,

3084Homocysteine

patterns of methionine dependencetumor cells, 6775

Hormones-dependent and -independent tumors

antitumor effects, CGS 16949A, 834growth of Sinclair swine melanoma,

1708prediagnostic serum

risk of prostate cancer, 3515HTLV-I

adult T-cell leukemia andneutral glycolipid, monoclonal anti

body, 3148polyclonal lymphocytosis of T-cells,

2585seroepidemiology in Taiwan, 5042

Human chorionic gonadotropindevelopment of highly sensitive inumi

noassaysapplication to malignancies, 1361

free 0-subunit and /3-core fragmentmarker for gynecological cancers,

1356Hybridoma, T-cell

metastatic potentialinvasiveness, hepatocyte and fibroblast

monolayers, 3405Hybridomas

human-humanmonoclonal antibodies, breast cancer

patients, 3208Hydantoins

tumor promotioncytochrome P-450 induction, liver and

thyroid, 2492Hydralazine

glucose andpH modification, air or carbon dioxide

mixture, 1543Hydrocarbons

polycyclic aromaticalteration, cholesterol biosynthetic

pathways, 2555cytochrome P-450c and -450d, ventral

prostate and liver, 3045detection of DNA adducts in foundry

workers, 2288fluoranthene-hemoglobin adducts,

characterization, 47564-Hydroperoxycyclophosphamide

cytotoxicity for blast progenitorsacute myeloblastic leukemia, 2348

effect on hemopoietic progenitors, 1223Hydroxyalkylnitrosamines

carcinogenicityF344rats, 1533

/3-Hydroxybutyrateenergy substrate utilization

Morris hepatoma 7777 cells, 6020-(/9-Hydroxyethyl)-rutoside

protection from renal injury<Â»illumini m-dÂ¡ehIdroplani! mud I), hy-

perthermia, 2239S-Hydroxymethyl-2'-deoxyuridine

mutagenicityChinese hamster cells, 5466

4-Hydroxy-jV-desmethyltamoxifenidentification as metabolite of tamoxifen

in human bile, 2304frani-4-Hydroxy-2-nonenal

1^-ethenodeoxyguanosine as markerDNA adduci formation, 3204-ci'j-Hydroxy-i .-proline

differential growth sensitivitytransformed rodent cell lines, 2483

3o-Hydroxysteroid-dihydrodiol dehydrogen-ase

oxidation of frans-3,4-dihydrodiol metabolites

7,12-dimethylbenz(a)anthracene, 1227Hydroxyurea

molecular mechanisms of drug resistanceribonucleotide reducÃase,2029

phenotypic changes in neoplastic cells,2440

-resistant leukemia I.I 2 Id cellscross-resistance patterns, 5796

transient exposureDNA replication, Syrian hamster cells,

6298Hypercalcemia

bone-resorbing activityinterleukin 1Â»,adult T-cell leukemia,

4284

Hyperglycemiablood flow and venous pH

Walker 256 carcinoma, 1201laser Doppler flow

murine tumors, 7102Hyperoxia

effects on growth characteristicsmetastatic lung tumors, 2779

Hyperplasiapreneoplastic

estrogen receptor complex, mouseLeydig cells, 14

Hypersensitivitydelayed-type

T-cells, effector cells in tumor rejection, 5922

Hyperthermiaacute pH 6.6 and 42.0Â°C

Chinese hamster ovary cells, 497bleomycin and

pH values, murine tumor cells, 615radiation, combination therapy devel

opment, 6291cell survival effects

protein synthesis patterns, endothelialcells, 2101

chronic pH 6.6 effectsChinese hamster ovary cells, 2417

combined with l-hexylcarbamoyl-5-fluo-rouracil

Ehrlich ascites tumor, Nakahara-Fu-kuoka sarcoma, 3977

cytotoxicityeffect, topoisomerase II inhibitors,

3932cÃº-diamminedichloroplatinum(II) and

protection from renal injury, o-(ÃŸ-hy-droxyethyl)-rutoside, 2239

rhodamine 1232, 2335squamous cell carcinoma line, 5101tumor growth delay, fibrosarcoma,

2693galactose effect on systemic hemody-


sues, 1476glucose-deprived L929 cells


glycosyltransferase activityChinese hamster ovary cells, 5717

hypoxia and acidosis effects on cytoxic-ity

platinum complexes, 2342irradiation and

lymphoblastic leukemia, 3576poly(ADP-ribose)

mechanism, metabolism alteration,4233

poly(ADP-ribose) glycohydrolase effect,4240

sensitizationnitrosourea-resistant Mer* tumor cells,

1086tumor necrosis factor and

synergistic effect, 650, 654whole body

advanced cancer, 6587cyclophosphamide, natural killer cell

activity, 4561cÂ»-diamminedichloroplatinum(II),

renal injury, 440Hypoxia

development of combination therapies

7426




bleomycin, hyperthermia and radiation, 6291

effect on cytotoxicityplatinum complexes, 2342

intracapillary o\> hemoglobintumor energy metabolism, 5440

kryptocyanine dye phototoxicitymitochondria, red cell membranes,

6794photodynamic therapy-induced

fluosol-DA (20%), carbogen breathing,3350

SR 4233 metabolismChinese hamster ovary cells, 5947

Hypoxie cellsmixed-function drugs

Mer cells, 798therapeutic attack

solid tumors, 775

I

ICRF-187effect of pretreatment

tolerated doxorubicin dose, 6918Idarubicin

monoclonal antibody conjugatesimmunochemotherapy, thymoma, 926

Phase I clinical trialchildren with refractory leukemia,

5348Ifosfamide

active metabolitescerebrospinal fluid penetration, 2113

Imidazole-induced tyrosinase expression

testosterone effect, B16 melanoma,3586

Immune complexesClq binding macromolecules

induction chemotherapy response,head and neck cancer, 5868

Immune responseCTL clone specific for stable antigen

LI210 cells, 6450enhancement by acrolein, 41mild immunodeficiency

papillomavirus-16, bladder carcinoma,7207

natural immunityinterleukin 2 effect, immunodeficiency

states, 6081restoration with new immunopotentiator

CL 259,763, cytolytic T-lymphocytes,2135

Immunityconcomitant

effector mechanism, murine plasmacy-toma, 1398

host effectors, isolation and reactivity,1153

Immunizationbacterial vaccines

muramyl peptides, tumor necrosis factor production, 5766

GMJIgG.i monoclonal antibody, inhibited

melanoma growth, 5680transfection with foreign gene

induction, immunogenic tumor variants, 2975

Immunochemotherapymurine thymoma

use of idarubicin mAb conjugates, 926Immunoconjugates

anti-CD5 radioimmunotoxinshuman tumors, nude mouse model.

7107anti-human CD3 monoclonal antibodies

endocytosis and degradation, T-cells,2249

daunorubicin-monoclonal antibodyacid-labile, compared to free drug,

6097increased antitumor effect

tumor necrosis factor, 3607monoclonal antibody-drug conjugates

dual label fluorescence technique,6211

Immunoelectronmicroscopyintranucleolar localization of p 120, 6523

Immunoglobulin Gdelivery of antibody and Fab fragments

osmotic blood-brain barrier disruption,4725

IgG2a monoclonal antibodymembrane sialoglycoprotein, small cell

lung carcinoma, 4318IgG3 monoclonal antibody

Tn antigen, blood group A antigen,4361

methotrexate conjugatenature of linkage, mode of action,

3330novel mouse monoclonal antibodies

reaction, mucinous type ovarian tumors, 4639

Immunoglobulin Mcarbohydrate epitope

human squamous lung cancer, 2125Immunoglobulins

gene rearrangement and immunopheno-type

clonal analysis, non-Hodgkin's lym-

phoma, 6272T-cell receptor gene rearrangements

Hodgkin's disease, 3591

Immunomodulationrecombinant murine and human tumor

necrosis factor, 544Immunoscintigraphy

gallium-labeled antibodiestumor targeting, drug-antibody conju

gates, 1189Immunotherapy

active specificmelanoma. Phase I trial, 5883

adoptivebrain tumors, LAK cells, 2047CTL activity, 7-interferon gene trans-

duction, 4730generation of antitumor effectors,

LAK cells, 3461interleukin 2, LAK cells, 4409, 5007OK-432, pantropic killer cells, 4163

biotechnology products in cancer therapy, 223

delayed-type hypersensitivity T-cellseffector cells, tumor rejection, 5922

establishment of childhood T-cell lym-phoma

growth in nude mice, 1312interleukin 2 and o-interferon

antitumor effects, hepatic mÃ©tastases,5810

interleukin 2 and LAK cellsmalignant brain tumors, 5011

production of monoclonal antibodymesothelioma cell lines, 5228

synergistic antitumor effectsinterleukin 2, tumor necrosis factor-Â«,

4011Immunotoxins

antibody-ricin A chain conjugateendocytosis, intracellular routing,

3822anti-CD5 radioimmunotoxins

human tumors, nude mouse model,7107

enhancement of activityovarian and epidermoid carcinoma,

3919preparation with deglycosylated ricin A

chainhindered disulfide linkages, 6396

ricin A chainclinical trial evaluation, CD 19 and

CD22 antigens, 2610mediation, pulmonary mÃ©tastasesre

duction, 3496monoclonal antibodies, 1119ricin and, kinetics of cell intoxication,

806tumor-reactive, pharmacokinetics,

2618, 2626ricin-monoclonal antibody conjugates

galactose binding activity, 4469inhibition, T-cell tumor growth, 4862

saporinhepatotoxicity, 7072

transplantation of non-T-leukemia cellstumor regression, 4673

Indium-Ill-labeled anti-melanoma monoclonal anti

body, 4417Indomethacin

augmented antitumor effecthuman interleukin la, 584

increased tumor radioresponse, 3008interleukin 2 and

cure of B16F10 melanoma lung metastasis, killer cells, 1072

prostaglandin productionpredictor for therapeutic response,

3002Inflammatory response

whole body protein turnover rateresting energy expenditure in cancer

patients, 2590Influenza virus

induction of immunogenic tumor variants

transfection, foreign gene, 2975Insulin

exogenousbody composition changes, cancer

cachexia, 2784-like growth factor 1

autocrine growth factor, lung carcinoma, 4976

membrane-associated phosphatidylinosi-tol kinase

mammary tumors, 6727phenotype and growth of melanomas

serum-free medium, 686Insulin-like growth factor I

autocrine mitogenic stimulationlung cancer cells, 3716

receptors in human breast cancer, 6429relation to steroid receptors in breast

cancer, 1343Insulin-like growth factor II

mRNA expression

7427




human breast cancer, 6691liver tumors, 6844

Insulin-like growth factorstwo types of receptors

human malignant glioma, 1233a-Interferon

A/D hybridseffect on tumor cell growth, 2366

human genes and pseudogenecoding, functional properties of pro

teins, 1763interleukin 2 and


ini rape-ritinu-aÃadministrationovarian cancer, 5853

modulationmajor histocompatibility antigens,

5818ar Interferon

escalating dose doxorubicin andPhase I trial, 2574

cr2a-Interferonaction in human mesothelioma xeno-

graftscw-diamminedichloroplatinum(II), mi

tomycin C, 64combined with a-difluoromethylorni-

thinePhase I study, 6584

a/j9-Interferoncombined with cyclophosphamide

response of P388 leukemia, 2329/9-Interferon

interleukin 2 andPhase I study, 3875

7-Interferonantiproliferative activity

tryptophan concentration, culture media, 346

circulating cytokines in metastatic cancerpatients

interleukin 2, LAK cells, 5864class II antigens in retinoblastoma, 1633clearance and distribution in mice, 2021cytotoxin release

bone marrow macrophages, 18081,25-dihydroxyvitamin 1), and

requirement of differentiative signals,interleukin 1 secretion, 1740

divergent dose-related effectscytotoxicity, human peripheral blood

monocytes, 1042effects of hematopoietic suppressor mol

eculesgranulocyte-macrophage progenitor

cells, 1548gene transduction

augmentation, CTL activity, 4730-mediated depression

hepatic cytochrome P-450 system,xanthine oxidase role, 2107

Phase II trialmonoclonal antibody CO 17-1A, colo-

rectal carcinoma, 2568synergy with tumor necrosis factor and

interleukin 2successful therapy, pulmonary mÃ©tas

tases, 2245Interferons

comparisons of combinationsmurine B- and I cell lymphomas,

4196dexamethasone and

tumoricidal effects, human leukocytecell lines, 567

endogenous and exogenousdifferentiation, U937 cells, 82

-induced revenants of transformedmouse cells

transcriptional inhibition, I la-rav.5157

interactions with antimetabolitesadenocarcinoma 38, HL-60 cells, 4868

interleukin 2 andantitumor activity, syngeneic murine

tumors, 260immunoregulatory effects, glioma-spe-

cific CTL, 2981Interleukin 1

endothelial cell-derivedchemotactic activity, tumor cells, 7041

receptor bindingcell growth response correlation, 5455

reduction of myelotoxicityradioantibody-induced, 5403

secretion7-interferon, 1,25-dihydroxyvitamin

D.,, 1740Interleukin la

antitumor activitymurine solid tumors, 6011

augmented antitumor effectindomethacin, 584

production of bone-resorbing activityadult I cell leukemia cells in humans,

4284Interleukin 2

activated lymphocyteslysis, drug-resistant tumor cells, 2372

active specific chemoimmunotherapytransplantation antigen, cyclophospha

mide, 101antitumor and antiviral natural immu

nityimmunodeficiency states, 6081

characterization of circulating Leu I1'cells, 6597

clinical and immunological effectsrepetitive weekly cycles to cancer pa

tients, 2561combined effects of chemotherapy

pulmonary tumors in mice, 122continuous vs. bolus infusion

cardiopulmonary effects in sheep,2221

indomethacin andcure of B16F10 melanoma lung metas

tasis, killer cells, 1072-inducible killer cells

asci lie fluid, pleural effusions, 6321a-interferon and


/3-interferon andPhase I study, 3875

interferons andantitumor activity, syngeneic murine

tumors, 260immunoregulatory effects, glioma-spe-

cific T-lymphocytes, 2981LAK cells and

activity, 1965adoptive immunotherapy, 2047, 3461,

4409, 5007antitumor effect, antibody-dependent

cellular cytotoxicity, 1173characterization, cytotoxic granules.

4681circulating cytokines, metastatic can

cer, 5864cytolysis enhancement, increased

yields to cancer patients, 5696giant autofluorescent lymphocytes,

2184malignant brain tumors, 5011mechanism, endothelial injury, 5528monoclonal antibody, B16 melanoma

lung mÃ©tastases,7140natural killer cells, tumor-infiltrating

lymphocytes, 1180rats, 878

local therapymammary tumors, various immuno-

genicities, 2193modulation

major histocompatibility antigens,5818

-stimulated lymphocytesmotility, tumoricidal activity, 3374

tumor-infiltrating lymphocytesrenal cell cancer, 206

tumor necrosis factor andactivation, cytotoxic lymphocytes, 788synergistic antitumor effects, 4011synergy with -y-interferon, pulmonary

mÃ©tastases,2245Interleukin 3

review of hemopoietic growth factors,5624

Intestinebiomarkers of increased susceptibility


bombesin-stimulated gastringastric cancer, 2296

A'-ethyl-Ar-nitrosourea-induced tumori-genesis, 6634

inhibition of 0-propiolactone-inducedneoplasia

4-mercaptobenzene, 2740restoration by polyethylene glycol

differentiation, colonie adenocarcinoma, 2498

significance of bacterial florainhibition, lung mÃ©tastases,3031

lodobenzylguanidinecytotoxic effects

neuroblastoma cell lines, 2993lododeoxyuridine

incorporation into granulocyte DNAfluorodeoxyuridine modulation, 2933

IproplatinCM-dichloro-bis-isopropylamine plati-

num(II) metabolite, 3533Iron

Adriamycin andreappraisal of association, 5645

neuroblastoma viability and proliferationinhibition of deferoxamine, 7189

Irradiationcancer family syndrome and cell survival,

2579hyperthermia and

lymphoblastic leukemia, 3576incidence and nature of tumors

induction, Sprague-Dawley rats, 2451-induced inhibition of lung mÃ©tastases

significance, bacterial flora, 3031-induced marker chromosomes

metastasizing murine tumors, 999inhibition of DNA damage repair

7428




2'-deoxycoformycin, chronic lympho-

cytic leukemia, 3981split low dosage total-body

curative effect, Friend virus complex,2399

X-ray combined with cu-diamminedi-chloroplatinum(II)

therapeutic gain, 3158Isoquinoline

peripheral-type benzodiazepine bindingglioma, diagnostic imaging, 5837

Italycomparative epidemiology of cancer,

7285

Japancancer of the prostate

case-control study, 1331case-control study of past history

nasal diseases, maxillary sinus cancer,1651

Jatropha curcasseed oil of

tumor promoter, 5800JB6 cells

transfer of pro gene transfectiontumor promoter-sensitive phenotype,

1195

K

Kallikreinglandular

prolactin, estrogen-induced pituitarytumors, 4158

Katacalcinmolecular forms

human medullary thyroid carcinoma,2412

K562 cellshematopoietic differentiation markers,

5759Keratinocytes

biosynthesis and secretion of laminin,5193

biphasic effects of TPAdown regulation, protein kinase C, 964

clonogenictwo-stage carcinogenesis, 6285

epidermalreversible induction, anchorage-inde

pendent growth, 1566growth modulation

transforming growth factors, 15968-methoxypsoralen-DNA photoadducts

flow cytometry, 7013oral

transforming growth factor-Â«,3130Keratins

13 and 16human breast epithelium, 5831

-like antigenmonoclonal antibodies, epithelial tu

mors, 4969sequential development of aneuploidy

skin papillomas, 3253subtypes

small cell lung cancer, 2724transcript ional control of gene expres

sionskin carcinogenesis, 3245

Ketoconazoleoptimal medical castration in male rats,

6063

KG-1 cellsphorbol ester-induced differentiation


Kidneyclearance and distribution

â€¢¿�y-interferonused in mice, 2021collagen chemoembolizationc/'j-diamminedichloroplatinum(II) and,

2446epithelial cells

epidermal growth factor, mitogenesis,4886

o-(/3-hydroxyethyl)-rutoside-mediatedprotection

r/.v-ilium mined ich loroplat in uin(l I) and

hyperthermia, 2239inhibition of estrogen-induced carcino

genesistamoxifen, 779

phosphoinositide turnoverserotonin as a major serum factor,

6697renal cell carcinoma

1,25-dihydroxyvitamin D, receptormeasurement, 2458

renal injuryci'i-diamminedichloroplatinum(II),

whole body hyperthermia, 440renal proximal tubule cells

cu-diamminedichloroplatinum(II),2538

Kidney neoplasmsactivated H-ras oncogenes, 5251estradiol-induced

biochemical analysis of development,971

estrogen-induceddrug metabolism enzymes, 5726

estrogen-sensitive proliferation pattern,3676

increased levelsfibroblast growth factor-like activity,

2083Killer cells

interleukin 2-inducibleascitic fluid, pleural effusions, 6321

metastasis cureindomethacin plus interleukin 2, 1072

pan tropicadoptive immunotherapy, OK-432,

4163Kryptocyanine dye

phototoxicitymitochondria, red cell membranes,

6794Kupffer cells

CM-bis-neodecanoato-frani-Ã„,/?-1,2-dia-minocyclohexaneplatinum (II)

cellular pharmacology, 1300

Lactatemetabolism in vivo

human breast cancer xenografts, 7264Lactation

risk factor for breast cancerChinese women in Shanghai, 1949

Lactoneimmunization

IgGj monoclonal antibody, inhibitedmelanoma growth, 5680

Lactoneotetraosylceramidedetection of patients with cancer

monoclonal antibody, 1512Lacto/V-fucopentaose II: see CA 19-9LAK cells

adoptive immunotherapybrain neoplasms, 2047generation, antitumor effectors, 3461pantropic killer cells, OK-432, 4163

alteration of activitymanipulation, protein kinase C and cy-

tosolic calcium, 635antitumor effect

antibody-dependent cellular cytotoxic-ity, 1173

cell fractionsuppression, hematopoiesis, 534

enhancement of cytolysisincreased yields to cancer patients,

5696fibrin coagulation

protection against cytotoxic cells,5216

generation and antitumor activityglioblastoma, 6069

injury of human endothelium, 5528interleukin 2 and

adoptive immunotherapy, 4409, 5007circulating cytokines, metastatic can

cer, 5864generation of cytotoxicity, tumor ne

crosis factor, 788induction of activity, 1965malignant brain tumors, 5011monoclonal antibody, B16 melanoma

lung mÃ©tastases,7140natural immunity, 6081tumor-infiltrating lymphocytes, 1180

isolation and characterizationcytotoxic granules, 4681

progenitor and effector phenotyperelationship to natural killer cells in

rats, 884selection of effectors

recycling intermediates, light-scattering properties, 2184

tissue and strain distributionontogeny in rats, 878

Lambert-Eaton myasthÃ©niesyndromeantagonism of voltage-gated calcium

channelsÂ«j-conotoxin,small cell carcinoma,

4719Laminin

biosynthesis and secretioncultured human keratinocytes, 5193

colon-derived substrata materialeffect on colon carcinoma cell line,

2825-dependent and -independent adhesion

sulfatides, melanoma cells, 3367induction of carcinoembryonic antigen

secretiontransforming growth factor-/3, colon

carcinoma, 4059Laryngeal neoplasms

occupational risk factors on the TexasGulf Coast, 1960

Laser Doppler flowhyperglycemia in murine tumors, 7102

L929 cellsglucose-deprived


I 12111cells: see also Leukemia, 1.12111CTL clone specific for stable antigen,

7429




6450cyclophosphamide-resistant

characterization of cytosolic aldehydedehydrogenase, 2963

cytokinetic effects of methotrexate, 4288DNA cross-linking by FK973, 5172DNA damage and cell kill

9-aminoacridines, 860DNA-directed actions of 3-deazaguanine,

2774effect of thymidine

nitrosourea activity, 4272hydroxyurea-resistant

cross-resistance patterns, 5796intracellular biotransformation of plati

num compounds1,2-diaminocyclohexane carrier ligand,

5136methotrexate effects

methylenetetrahydrofolate depletion,3398

methotrexate transport, 5995production of protein-associated DNA

breaks by PZE, 1404properties of resistant cells

a-difluoromethylornithine, 2678Lead chromate

mutagenesis in mouse embryo cells,5280

Lectins-binding proteins

nuclear preparations, rat liver and malignant tumors, 551

galactoside-bindingshared sequence homology, 645

monocytic maturationHL-60 cells, 280

Lentinandenaturation and renaturation

expression, T-cell-mediated responses,671

Leu 19* cells

appearance and phenotypic characterization

interleukin 2 treatments, 6597I-cucine

altered metabolismnoncachectic sarcoma patients, 1374

Leucovorin5-fluorouracil and

disseminated cancer treatment, pancreas, 5570

Leucovorin-5-fluoropyrimidineincreased levels of DNA lesions

colon adenocarcinoma, 4153Leukemia

acute nonlymphocyticpoint mutation, ras protooncogenes,

1812antitumor activity of quinocarmycin,

60298-deaza analogues of methotrexate and

aminopterincytotoxicity, polyglutamate formation,

1481doxycycline in combination chemother

apy, 6686Phase I evaluation

esorubicin, 5580proliferation-dependent cytotoxicity

methotrexate, 5638refractory

Phase I pediatrie trial, 4-demethoxy-daunorubicin, 5348

significancealtered a-2-i.-fucosyltransferase levels,

3998site-specific analysis of total serum cho


Nutrition Examination Survey, 452Leukemia, B-cell

lipopolysaccharide-activatedglucocorticoid effects, lipid lateral dif

fusion, 59Leukemia, I 12III: see also L1210 cells

(II clone specific for stable antigen,6450

polyamine uptake deficiencycurative effect, DL-2-difluoromethylor-

nithine, 4807resistance to ribonucleotide reducÃasein

hibitors, 839Leukemia, lymphoblastic

acutegrowth requirements, clonogenic as

say, 5901molecular heterogeneity, 866Philadelphia chromosome-positive,

2876radiobiological features, bone marrow

progenitor cells, 5788vincristine, methotrexate and other

agents, 351association of DNA ligase deficiency

I cell acute leukemia, 4038childhood acute

involvement, bovine leukemia virus,2919

interactionshyperthermia, irradiation, 3576

Leukemia, lymphocyticchronic

abnormal blood monocytes, 4812B-cells, distribution of doxorubicin

metabolites, 503DNA interaction of melphalan, 1972inhibited DNA damage repair, 2'-de-

oxycoformycin, 3981compared to normal lymphocytes

historic variant synthesis, 3670Leukemia, lymphoid

acuteautocrine production, malignant pre-B

cells, 6438Leukemia, myeloblastic

acuteblast progenitors, 4-hydroperoxycyclo-

phosphamide, 2348differentiation-induced MI.-1 cells

transformation, carcinogen target,4389

Leukemia, myelocyticPh-positive

sister chromatid exchange, normalbone marrow, 745

Leukemia, myelogenouscell line establishment

megakaryoblastic crisis, 6137chronic

discordant maturation, primary biological defect, 1035

Leukemia, myeloidcell cycle changes in maturing HL-60

cells, 5989chronic

sister chromatid exchange, busulfan,3435

Leukemia, nonlymphocyticacute

C^-alkylguanine DNA alkyltransferase,3084

Leukemia, P388antitumor activity of MX2

murine tumor cells, 6653mull Â¡factorialresistance to Adriamycin,

3595reversal of resistance to vincristine

quinacrine, 2064schedule-dependent response variations

cyclophosphamide, a//3-interferon,2329

Leukemia, T-cellacute

DNA ligase deficiency, 4038adult

bone-resorbing activity, interleukin la,4284

neutral glycolipid, monoclonal antibody, 3148

history, 4131tyrosine kinase YT16 expression, 856

Leukemia cellsAbelson virus-infected promonocytic

viral oncogene expression, 1702acute myeloblastic

growth potentiating factors, aiuologous blast cells, 6424

CCRF-CEMantileukemia agents, nuclear matrix-

bound DNA replication, 1850DNA cross-linking

influence of WR2721, nitrogen mustard, 6002

glucocorticoid receptor at protein level,2636

growth-promoting activitydesmopressin, 7055

inactivation of O^-alkylguanine-DNA al

kyltransferasenitrosourea potentiation, 1521

metabolism of hexamethylene bisacetam-ide, 1712

microtubule changes and cytotoxicity oftaxol, 4093

modulation of arabinonucleoside metabolism

arabinosylnucleotides, 329multidrug-resistant cell line

cytogenetic and molecular characterization, 393

murineaccumulation, ci's-diamminedichloro-

platinum(II) and platinum analogues, 9

myeloidlow molecular weight factor, differen

tiation and growth, 4201non-T-cell

anti-human immunotoxins, 4673phorbol ester-induced changes

topoisomerase II DNA cleavage, 6625phorbol ester-treated promonocytic

alteration, fibronectin receptors, 5730promyelocytic

1-jS-D-arabinofuranosylcytosine, 5-hy-droxymethyl-2'-deoxyuridine, 3117

resistance to drug-induced DNA cleavagelow levels, DNA topoisomerase II,

3537Leukemia virus

bovine

7430




childhood acute lymphoblastic leukemia, non-Hodgkin's lymphoma,

2919Leukocytes

DNA damagebenoxaprofen and phagocytes, 3094

tumoricidal effectsdexamethasone and interferons, 567

Lewis lung carcinoma tumorfibrinogen influx and accumulation

cross-linked fibrin, 1920growth and metastasis

1-/3-n-arabinofuranosylcytosine conjugates, lipids, 826

loss of factor X activator capabilitiesvitamin K, 6504

tumor-induced myelopoiesisregulation, prostaglandin I, 6826

Leydig cellsestrogen interactions

intracellular receptor complex, preneo-plastic hyperplasia, 14

Li-Fraumeni syndromecancer families

susceptibility to neoplasia, 5381cancer family syndrome in twenty-four

kindreds, 5358Ligands

antiestrogen binding siteantiproliferative action, 3954

bromine-SOm-labeled estrogenstherapy, ER-positive cancers, 899

LigaseDNA deficiency

association with I cell acute leukemia,4038

Light-induced DNA damage

4,5',8-trimethylpsoralen, Fanconi's

anemia, 2015Linoleic acid

arachidonic acid andthymidine incorporation, hepatoma,

3106effect of dietary eicosapentaenoic acid

azoymethane-induced colon carcino-genesis, 4790

Lipidsactivation of macrophages

alkylglycerols, cancerous tissues, 60441-/3-D-arabinofuranosylcytosine conju

gatesgrowth and metastasis, Lewis lung car

cinoma, 826Lipiodol

accumulation of 3',5'-dioctanoyl-5-flu-oro-2'-deoxyuridine prodrug

hepatoma, 4179Lipopolysaccharidc

-activated B-cell leukemia 1 cellsglucocorticoid effects, lipid lateral dif

fusion, 59production of tumor necrosis factor

mnraim I peptides, bacterial vaccines,5766

Liposomes-based therapy

human ovarian cancer, 5237entrapment of c/s-bis-neodecanoato-

frans-Ã„,Ã„-l,2-diaminocyclohex-aneplatinum(ll)

cu-diamminedichloroplatinum(II)cy-totoxicity, 4509

encapsulated Adriamycin

alterations, murine host defense functions, 130

-encapsulated immunomodulatorsAdriamycin therapy, monocyte activa

tion, 52568-Lipoxygenase

phorbol ester inductioncomparison, SENCAR and C57BL/6J

mice, 658Liver

albumin-positivelack of albumin as marker, preneoplas-

tic hepatocytes, 387biliary epithelial and hepatocytic cell

linesrelationships in embryonic rat liver,

4909biliary metabolites of fluoropyrimidines,

20105-bromo-2 '-deoxyuridine incorporation

pharmacodynamics, VX-2 tumors,6900

carcinogenesiscytochrome P-450 induction, hydan-

toins, 2492collagen chemoembolization

m-diamminedichloroplatinum(II),2446

cytochrome P-450 systeminterferon-mediated depression, xan-

thine oxidase role, 2107depletion of adenosine diphosphate-ribo-

syl transferaseexposure, /V-2-acetylaminofluorene,

3581differential expression

cytochrome P-450c and -450d genes,3045

DNA cyanoethylation3-(methylnitrosoamino)propionitrile,

6780duck

hepatitis B virus, geographical pathology, 1319

effect of aflatoxin Bglucocorticoid receptors, tyrosine ami-

notransferase, 5188effects of steroids

structure-activity studies, 2462elimination of 5-fluoro-2'-deoxyuridine,

3561epithelial cells

transforming growth factors, 850epithelial cell lines

chromium effects, transformation,6484

epoxide-metabolizing enzymeseffects of inducers, 1390

/V-ethyl-yV-nitrosourea-induced tumorigenesis, 6634

factor with antiinvasive potentialrat ascites hepatoma cells, 3760

formation of 5-adenosylethioninechronic feeding of Di.-ethionine, 4464

hepatocellular carcinomain vitro translation analysis, 2382


lack of DNA bindingmethapyrilene, 6475

late target proteinW-2-fluorenylacetamide, 6745

mÃ©tastasesantitumor effects, interleukin 2 and .â€¢â€¢

interferon, 5810mono- and bifunctional enzyme inducers,

4776normal and preneoplastic nodules

purification, glutathione S-transferase-P, 2805

nuclear preparationslectin-binding proteins, 551

organ cell specificityDNA mei IHlatimi, A'-nitrosomethyla-

mylamine, 5482peroxisomal /3-oxidation mRNAs in rat

tissues, 5316peroxisome proliferation and DNA syn

thesis in hepatocarcinogenesis, 6739preneoplastic

carbohydrate-metabolizing enzymes,profiles, 467

putative premalignant hepatic nodulesDNA adducts, 2-acetylaminofluorene

carcinogenesis, 5270rat model

etoposide metabolism and excretion,5692

regenerationphÃ©nobarbitaltreatment, cellular onco-

genes, 265specificity of cytochrome P-450 isozymes

metabolic activation, 2-amino-3-meth-ylimidazo[4,5-/]quinoline, 4513

tumor promotersepidermal growth factor receptor mod

ulation, 1162Liver microsomes

benzene-inducible cytochrome P-450,5387

inactivation of 4-methyl-5-amino-1 -for-mylisoquinoline thiosemicarbazone

inhibitor of ribonucleotide reducÃase,6375

metabolism of /V-nitrosodialkylamines,1499

tt-naphthoflavone influenceethinylestradiol metabolism, 5460

nitrosamine metabolismdiallyl sulfide effect, 5937

yV-nitrosopyrrolidine Â«-hydroxylaseactivity

reconstitution, 3987oxidative metabolism of 1-nitropyrene

cytochrome P-450 isozymes, 4261Liver neoplasms

comparative propertiesaltered hepatocyte foci, 4171

dose response study with jV-nitrosomor-pholine, 2089

7-glutamyltranspeptidasec-raf protooncogene expression, gap

junction protein, 1610glutathione-S'-transferase P mRNA

expression, peroxisome prolifera-tors, 4919

insulin-like growth factor II mRNAexpression, 6844

LLC-PK, cellsmodel for cisplatin nephrotoxicity

ihin! rescue agents, 6017Lonidamine

whole body hyperthermia in advancedcancer, 6587

Louisianacase-control study of diet and mesotheli-

oma, 2911L3T4* cells

7431




polycythemia-inducing strain of Friendvirus

curative effect, irradiation, 2399Lung

activation and DNA alkylation4-(/V-methyl-yV-nitrosamino)-1 -(3-pyri-

dyl)-l-butanone, 4215B16 melanoma mÃ©tastases

LAK cells, interleukin 2 and mAb,7140

cardiopulmonary effectsinterleukin 2 infusion, continuous vs.

bolus, 2221developing

stage-specific expression of SSEA-1-related antigens in, 7150

yV-ethyl-yV-nitrosourea-induced tumori-genesis, 6634

irradiation-induced inhibition of mÃ©tastases

significance of bacterial flora, 3031Kirsten-roj oncogene

clonal diversity, 4941metastasis

cure, indomethacin plus IL-2, 1072synergism of -y-interferon, TNF and

interleukin 2, 2245tissue inhibitor of metalloproteinases,

melanoma cells, 5539small cell cancer

characterization of cell lines, 6891timing of chemotherapy and surgery

murine osteosarcoma model, 5533tobacco-related tumors, 6912tumor tissue and

prntik's. prostaglandin biosynthesis,3140

Lung cellsChinese hamster

sister chromatid exchanges, antitumortopoisomerase II inhibitors, 512

Lung neoplasmsautocrine mitogenic stimulation

somatomedin-C/insulin-like growthfactor I, 3716

cancer in migrants to Australia, 751cancer morbidity and mortality among

phosphate workers, 7298colony formation

monoclonal antibodies, capillary endo-thelial cells, 4964

comparison of intrathoracic models,2880

cytokeratinschain-specific monoclonal antibodies,

3221estramustine-binding associated protein,

4615expression of a-amylase, 3292incidence by histolÃ³gica!type

population-based registry, 6580induction of tumoricidal activity

alveolar macrophages, monocytes,3949

long-lasting effects of tobacco smokingpulmonary drug-metabolizing en

zymes, 4695malignancy

activity of cytosolic isozyme, thymi-dine kinase, 5001

metastaticeffects of hyperoxia, growth character

istics, 2779non-small cell

antibody-guided targeting, 1977epidermal growth factor receptor

expression, 1132neuroendocrine markers, 4078prostaglandin biosynthesis, 4770

papillaryA'-nitrosoethylurea-induced, cell ori

gin, 148personal and family history

risk factors, adenocarcinoma, 7279selective growth inhibition

gpl60, radioimmunotherapy, 2768site-specific analysis of total serum cho


Nutrition Examination Survey, 452small cell

combined modality treatment, thymo-sin fraction V, 1663

epidermal growth factor receptorexpression, 1132

growth, bombesin antagonists, 4783longitudinal follow-up, 6891keratin subtypes, 2724myc family, DNA amplification, 5163

small cell neuroendocrine carcinomaspecificity, monoclonal antibody, 7319

smoking andwomen, 6951

squamouscarbohydrate epitope, 2125

SSEA-1-related antigensdeveloping human embryos, 7150

tumor size and morphologygestational development in the mouse,

379whole body protein turnover rate

resting energy expenditure, cancer patients, 2590

xenotransplantabilitymyc family gene abnormality, 6025

Luria-Delbruck fluctuation analysispitfalls and practice, 1060

Luteinizing hormoneoptimal medical castration in male rats,

6063Luteinizing hormone-releasing hormone ag

onistgonadotoxicity of cyclophosphamide,

2174inhibition of thymidine uptake, 7252

Lymnaea stagnali!model for testing

neurotoxic side-effects. Vinca alkaloids, 7184

Lymph nodesbreast cancer survival model, 5565fusion of lymphocytes

human-human hybridomas, breast cancer patients, 3208

metastasis of mammary adenocarcinomasoybean agglutinin binding cells, 1451

natural killer cell cytotoxicityhead and neck cancer, 5017

Lymphoblastoid cellstrimetrexate transport

lypophilic antifolates, 6986Lymphoblasts

inhibition of DNA damage repair2'-deoxycoformycin, chronic lympho-

cytic leukemia, 3981L5178Y murine

characterization, resistance to quinoneantitumor agents, 1727

T-celleffect of gallium, DNA synthesis, 3014

Lymphocytesactivated

lysis, drug-resistant tumor cells, 2372antibodies against 7-methyldeoxyguano-

sine, 5065clinical and immunological effects

interleukin 2 in repetitive weeklycycles, 2561

comparison of histone variant synthesislymphocytic leukemia cells, 3670

elevated sister chromatid exchangesethylene oxide-exposed primates, 5045

giant autofluorescentLAK cells as subset, 2184

human and mousesister chromatid exchange induction,

diaziquone, 27interleukin-2-stimulated

motility, tumoricidal activity, 3374intraperitoneal a-interferon administra

tionovarian cancer, 5853

lymph nodehuman-human hybridomas, breast can

cer patients, 3208macrophage potentiation and

host and tumor cell collagenolytic activity, 6832

regeneration of O'-alkylguanine-DNA al-

kyltransferasenitrosourea exposure, 5368

resistance to drug-induced DNA cleavagelow levels, DNA topoisomerase II,

3537role of metabolism and DNA adduct for

mationsister chromatid exchange, diethylstil-

bestrol, 335transferrin-like autocrine growth factor

T-lymphoma cells, normal T-cell proliferation, 3425

tumor-infiltratinganalysis of lymphoid infiltrates, glio-

blastoma, 6926depressed CD8+ responses, 6992

effects of interleukin 2, NK and LAKcells, 1180

interleukin 2, renal cell cancer, 206Lymphocytosis

polyclonalT-cells, human T-cell leukemia virus I,

2585Lymphoid cells

analysis of lymphoid infiltratesglioblastoma, 6926

Lymphokine-activated killer cells: see LAKcells

Lymphokinesbiotechnology products in cancer ther

apy, 223suppressor produced by T-cells

mammary adenocarcinoma, 943synergism of -y-interferon with TNF and

IL 2successful therapy, pulmonary mÃ©tas

tases, 2245Lymphoma cells

cell cycle and glutathione statuseffects, /V-methylformamide, 3389

Lymphomasantitumor activity of quinocarmycin,

6029

7432




B-cellcomparisons, combinations of interfer

ons, 4196xenogeneic tumor model, radioiodine-

labeled monoclonal antibodies, 2475incidence and nature of tumors

â€¢¿�Â»â€¢-irradiation,Sprague-Dawley rats,2451

large cellchromosome abnormalities, 5557nucleic acid flew cytometry, 6614

murinetumorigenicity, fluorescent cell sort

ing, 270non-Hodgkin's

clonal analysis, Ig gene rearrangement,6272

DNA content, proliferative activity,6608

involvement, bovine leukemia virus,2919

S49 wild type and eye"

tumorigenicity, adenylate cyclase, 641T-cell

amplification, c-myc oncogene, 4959comparisons, combinations of interfer

ons, 4196history of, 4131human, growth in nude mice, 1312

therapy-related acute nonlymphocyticleukemia

C^-alkylguanine DNA alkyltransferase,3084

thy miestages of, ras oncogenes, 5514

LymphosarcomaXenopus

transplantation studies, 954Lymphotoxin

distinctionnatural killer cell cytotoxic factor, tu

mor necrosis factor, 891gene expression

tumor necrosis factor, human tumorcell lines, 5417

Lynch syndromereduced genomic 5-methylcytosine con

tenthuman colonie neoplasia, 1159

Lysisdrug-resistant tumor cells

activated lymphocytes, 2372Lysosomes

intrinsic drug resistancepossible link, detoxification mecha

nism, 3025methotrexate conjugate with antitumor

antibodiesnature of linkage, mode of action,

3330milk fat globule membrane-associated

antigenendocytosis of monoclonal antibody,

MCF-7 cells, 3188Lyt-2* cells

importance in tumor rejection, 4834polycythemia-inducing strain of Friend

viruscurative effect, irradiation, 2399

M

Macromoleculesheterogeneous distribution

monoclonal antibodies, interstitial

pressure, 7022Macrophages

activationrole of tumor necrosis factor, tumori-

cidal activity, 5427activation by alkylglycerols, 6044alterations in murine host defense func

tionsAdriamycin or liposome-encapsulated

Adriamycin, 130alveolar

tumoricidal activity, lung cancer, 3949attached effector cells

antibody-mediated killing, human tumor cells, 624

c/5-bis-neodecanoato-Ãra/ii-A,/?-1,2-dia-minocyclohexaneplatinum (II)

cellular pharmacology, 1300bone marrow

cytotoxin release, -y-interferon, 1808effect of Â«A/D-interferon

tumor cell growth, 2366function of

clinical trial, tumor necrosis factor,5604

lymphocyte potentiation andhost and tumor cell collagenolytic ac

tivity, 6832tumor-infiltrating

detection by inAh. monosialoganglio-side, 2524

Magnesium-ATPasephotosensitizing effects

hematoporphyrin derivative, mammary adenocarcinoma, 3360

Magnetic resonance spectroscopyglucose metabolism

breast cancer cells, 870metalloporphyrin enhancement

human tumor xenografts, 4604Major histocompatibility complex

antigen modulation by cytokines, 5818class I

epithelial-like markers, mammary carcinoma, 7237

retrovirus transformation, rat celllines, 3816

class IIabnormal blood monocytes, chronic

lymphocytic leukemia, 4812retinoblastoma, 1633

effect on U937 cell differentiationendogenous and exogenous interfer

ons, 82A'-ethyl-A'-nitrosourea-induced tumori-

genesis, 6634Malignancy

activity of cytosolic isozymethymidine kinase, lung tumors, 5001

cell fusion, 3302cell kinetics

bromodeoxyuridine, flow cytometry,6238

Cora antigen expressiongastrointestinal epithelia, 2198

stages of gliomaclonal genomic alterations, 5546

Malignant cellstherapy by directing differentiation in

carcinoma, 1996Mammalian cells

bacteria andmutagenicity, CC-1065 and analogues,

32

DNA topoisomerase Idrug target, camptothecin, 1722

low-molecular-weight growth inhibitorcharacterization, 3737

molecular mechanisms of drug resistanceribonucleotide reducÃase,2029

resistance of noncycling cells to amsa-crine, 310

Mammary glandscarcinomatous and normal development

influence of caffeine consumption,2078

DNA alkylationestrous cycle modification, W-methyl-

A^-nitrosourea, 3090epithelial cells

DNA repair, arylamine metabolites,4227

epoxide-metabolizing enzymeseffects of inducers, 1390

hyperplastic alveolar nodulestransplantation, gland-free fat pads,

3197intervention of T-cells in transportation

mouse mammary tumor virus, 6555tumorigenesis

influence of caffeine, unsaturated fat,2074

influence of caffeine, coffee consumption, 2068

Mammary neoplasms7,12-dimethy lbenz(a)anthracene-induced

dietary flavonol quercetin, 5754DNA ploidy

flow cytometric analysis, 3411effect of exercise

induction of carcinogenesis, 2720fibrosarcoma growth

glucocorticoid-induced alterations,7212

mast cellsprolactin, binding and characteriza

tion, 3765membrane-associated phosphatidylinosi-

tol kinaseinsulin effects, 6727

mixed heterogeneousdominance, tumor subpopulation,

5747modulation of mitomycin C cytotoxicity

dicoumarol, 54711-nitropyrene derivatives and 1-amino-

pyrenecarcinogenic activities, 4256

yV-nitrosourea-induced tumorigenesiscalorie restriction and exercise, dietary

fat, 4276rat model for locally recurring tumors

sensitivity, chemotherapy and X-rays,4549

reconstitution of site preference, 3698response to endocrine therapy

NMR spectroscopy, rat tumors, 89tumorigenesis

adrenal regulation, 3801, 3808various immunogenicities

local interleukin 2 therapy, 2193Mammary serum antigen

detection in seramonoclonal antibody, breast cancer

patients, 7060Mammary tumor virus

intervention of T-cells in transportationmammary gland cells, 6555

7433




Mannitolrole of hypovolemic hemoconcentration

in flow decline, 7102Mannose-6-phosphate

elevated activitycathepsin D carbohydrate moiety, hu

man hepatoma, 362Mass spectrometry

pharmacokinetics of 5-fluorouracil, 6956Mast cells

mammary' tumorprolactin, binding and characteriza

tion, 3765McA-RH7777 cells

vitamin H. metabolism, 1080MCF-7 cells

endocytosis of monoclonal antibody,3188

estrogen action of 2-phenylindole derivatives, 784

inhibition of cell growthTPA and 1,2-dioctanoyl-sn-glycerol,

protein kinase C, 6943proliferation effects of melatonin, 6121regulation of growth and invasiveness

antiestrogens, 6764tamoxifen-stimulated growth

long-term antiestrogen administration,5183

VP-16-induced DNA strand breaksmechanism of action, 5096

Medroxyprogesterone acetateproliferation and cell cycle kinetics

mammary carcinoma cells, 5084Medulloblastoma


chemotherapybifunctional alkylating agents, 4189

melphalan transportglutathione levels, glutathione-S trans-

ferase, 5397Megakaryopoiesis

cell line establishmentchronic myelogenous leukemia, 6137

Melanocytesidentification

secreted M, glycoprotein, 1286Melanoma

activated ras genesdetection of low frequency genes, tu-

morigenicity assay, 950active specific immunotherapy

Phase I trial, 5883anionic form of glutathione transferase

presence in human tumors and celllines, 527

antibody-mediated killingattached effector cells, 624

-associated gangliosidesfish genus Xiphophorus, 3454

cancer in migrants to Australia, 751cell deformability and metastatic poten

tialcorrelation, 5124

cell surface cathepsin B-like activityidentification, butanol extraction,

1416cure of lung metastasis

indomethacin plus 112. killer cells,1072

cutaneoushistology, 5036

detection of monosialoganglioside

monoclonal antibody, tumor-infiltrating macrophages, 2524

early stages of tumor progressionmolecular cloning, ME491 antigen,

2955effect of ultraviolet-B radiation

cell growth, 4007effects of estradiol

estrogen and progesterone receptors,tyrosinase, 3720

estrogen receptor-positive170-estradiol effect on growth, 7093

hamsterinfluence of retinoids on growth, 1465

hereditary cutaneous malignantcell sensitivity, 4-nitroquinoline 1-ox-

ide, 5145highly pigmented variant

metastasis, skin and brain, 4897HLA antigens

locoregional mÃ©tastases,1019human malignant

cytotoxicity, catechol analogues, 5178identification

secreted M, glycoprotein, 1286immune system of cancer patients

low dose cyclophosphamide, 1671indium-111-labeled anti-melanoma mon

oclonal antibodysaturable clearance mechanisms, 4417

inhibited growthIgGi monoclonal antibody, GM1lac-

tone immunization, 5680interaction with murine mesentery, 5296M, 97,000 to 250,000 protein antigen

concentrations, autoradiography. 5475metastatic murine

pigmentation, influence of organ mlcroenvironment, 2258

multiceli spheroidsuptake kinetics, monoclonal anti

bodies, 1856multiple primary

association with dysplastic nevi, 1016murine

boron neutron capture therapy, 6313phenotype and growth

serum-free medium, 686progressive growth of fish tumors

transplantation, thymic-aplastic mice,741

retrovirus-associated antigenexpression, modulation, 4954

Sinclair swinegrowth as function of variables, 1708

site-specific brain metastasis, 3478thrombospondin binding

sulfated glycoconjugates, 6785tumor-specific metastasis, 4382wheat germ agglutinin-resistant

metastatic profiles, nude mice, 665Melanoma-associated antigen

molecular cloning of ME491early stages, melanoma tumor progres

sion, 2955mouse-specific epitope

metastatic ability, monoclonal antibody, 7173

recognitionLyt-2" and L3T4~ cytotoxic T-lym-

phocytes, 2730Melanoma cells

adhesion to sulfatideslaminin, 3367

bifunctional DNA-reactive cytostaticdrugs

cytotoxicity, D,L-buthionine-5,/Ã®-sul-foximine cells, 19

chromatinnerve growth factor receptors, colorec-

tal carcinoma, 7200multidrug-resistant

decreased drug accumulation, 6348murine

modulation of metastatic potential,urokinase, 1270

Melanoma cells, B16adhesive cell variant

loss of metastatic responsiveness, cellshape modulation, 1258

effect of testosteroneimidazole-induced tyrosinase expres

sion, 3586effects of folate deficiency

metastatic potential, 4529heat-induced vascular damage

thermosensitivity, 7226lung mÃ©tastases

LAK cells, interleukin 2 and mAb,7140

Melatoninproliferation effects

breast cancer cells, 6121Melphalan

D,i.-buthionine-S',/?-sulfoximine effect

cytotoxicity, human melanoma cells,19

chemosensitization by misonidazole,3528

effect of alkylating agent doseclinical correlation, 6417

enhanced cytotoxicityglutathione depletion, medulloblas-

toma xenograft, 2764resistance to nitrogen mustards

chronic lymphocytic leukemia, 1972transport in medulloblastoma

glutathione levels, glutathione-5-trans-ferase, 5397

unexpected toxicityuse of body surface for dosing in dogs,

288Meninges

site-specific brain metastasismelanoma and fibrosarcoma, 3478

4-Mercaptobenzeneinhibition of /3-propiolactone-induced

neoplasiaforestomach, large bowel, 2740

Mesenteryinteraction with B16 malignant mela

noma tumor cells, 5296Mesothelioma

anionic form of glutathione transferasepresence in human tumors and cell

lines, 527asbestos-induced

chromosome translocations, specificbreakpoints, 6455

diet andcase-control study in Louisiana, 2911

human malignantnonrandom chromosome alterations,

142human xenografts in nude mice

CM-diamminedichloroplatinum(II) andmitomycin C, Interferon action, 64

production of monoclonal antibody

7434




diagnostic and therapeutic potential,5228

Metal dustesophageal carcinoma, 3843

Metalloporphyrinenhancement of magnetic resonance im

aginghuman tumor xenografts, 4604

Metalloproteinaseshuman recombinant tissue inhibitor

metastasis, melanoma cells, 5539Metallopurpurins

photodynamic therapytransplantable bladder tumors, 194

Metallothioneininduction and deinduction

Adriamycin, prostatic carcinoma cells,4503

-like zinc-binding proteinzinc metabolism. Ehrlich cells, 3381

MÃ©tastases1-/3-D-arabinofuranosylcytosine conju

gates of lipidsinfluence, Lewis lung carcinoma, 826

augmentation of murine natural killercells

swainsonine, 1410B16 melanoma in lung

LAK cells, interleukin 2 and niAh.7140

bone marrowmurine model, 6876

breast cancercomparison, CA 15-3 and carcinoem-

bryonic antigen, 4107capacity

intercellular communication, mammary carcinoma, 5129

cathepsin B-like proteinasebiochemical study, colon cancer, 6855

circulating cytokinesinterleukin 2 and LAK cells, 5864

colon carcinomasialoglycoprotein expression, 2353

concomitant tumor immunityhost effectors, isolation and reactivity,

1153cure with indomethacin plus interleukin

2killer cells, 1072

determinants of tumor blood flow, 2641differential expression of WDNM1 gene

nonmetastatic mammary adenocarci-noma cells, 5203

differential NM23 RNA levels, 6550epithelial-like markers

class I MHC, mammary carcinoma,7237

fibroblast-mediated enhancement, 1457head and neck squamous cell carcinoma

two new cell lines, 2858hepatic

antitumor effects, interleukin 2 and in-terferon-a, 5810

immunotoxin mediation of reduction,3496

influence of retinoids on growthhamster melanoma in athymic mice,

1465irradiation-induced marker chromo

somes, 999locoregional

level of HLA antigens, melanoma,1019

loss of factor X activator capabilitiesvitamin K, Lewis lung carcinoma,

6504loss of responsiveness

cell shape modulation, B16 melanomaadhesive cell variant, 1258

lungeffects of hyperoxia, growth character

istics, 2779significance of bacterial flora, 3031

lymphaticsoybean agglutinin binding cells, mam

mary adenocarcinoma, 1451melanoma

tissue-specific, 4382orthotopic implantation of colorectal

carcinoma, 6863phenotypic changes in neoplastic cells

5-aza-2'-deoxycytidine, hydroxyurea,

2440platelet aggregation, 1460polypeptide markers

fibrosarcoma cells, 572pulmonary

mechanism of inhibition, sialicacid:nucleoside conjugate, 3728

synergism of-y-interferon, TNF andinterleukin 2, 2245

recombinant tissue inhibitor of metalloproteinases

melanoma cells, 5539role of tumor cell cytoskeleton

platelet adhesion, aggregation, 3787site-specific

brain, melanoma and fibrosarcoma,3478

skin and brainhighly pigmented melanoma variant,

4897synergistic effect

tumor necrosis factor, hyperthermia,650, 654

timing of chemotherapy and surgerymurine osteosarcoma model, 5533

tumor spread and DNA contentrenal cell carcinoma, 3165

wheat germ agglutinin-resistant humanmelanoma mutants

profiles, nude mice, 665Metastatic ability

cell motilityv-Ha-ros oncogene, prostatic cancer

cells, 6050down modulation of fibronectin messen

ger RNAprostatic cancer, 2042

mouse melanoma antigen, 7173radiation-induced injury

tumor bed stroma, sarcomas and carcinomas, 2116

stromal fibronectin staining patternbreast carcinoma, 6227

Metastatic cellsbasement membrane invasion

effects of inhibitors, 3307selection and overgrowth of primary tu

morsgenetic evidence, 6109

selection from surgical specimenscolon carcinomas, 1943

Metastatic potentialactivated ras oncogenes

thyroid cancers, 4459cell deformability and

correlation, melanoma cell variants,5124

cell surface cathepsin B-like activityidentification, butanol extraction,

1416effects of folate deficiency

murine melanoma cells, 4529invasiveness in hepatocyte and fibroblast

monolayersT-cell hybridomas in mice, 3405

modulation by cell surface urokinasemurine melanoma cells, 1270

multiplicity of transforming growth factors

human malignant effusions, 1792semisolid clonogenic medium

growth, mammary adenocarcinomacells, 399

stimulation of metastatic fibrosarcomatransforming growth factor-/3, 6999

visual grading systemcell motility, 4312

Meth A fibrosarcomarole of serotonin

antitumor effects, tumor necrosis factor-Â«,4250

Methapyrilenelack of binding

liver DNA, <2P-postlabeling, 6475

Methioninepatterns of auxotrophy

tumor cells, 6775Methotrexate

4'-(9-acridinylamino)methanesulfon-m-

anisidide andmetabolic interaction, 5106

blood-brain disruptionrat brain tumors, 694

bromosulfophthalein-sensitive effluxroute

vincristine action, LI210 cells, 5995conjugated with antitumor antibodies

nature of linkage, mode of action,3330

contribution of medicineprimary treatment, breast cancer, 2314

cytokinetic effectsL1210 cells, 4288

5-deazaaminopterin and 5-deazametho-trexate

5-alkyl derivatives of, comparison,5686

8-deaza analoguescytotoxicity, polyglutamate formation,

1481effects on methylenetetrahydrofolate

thymidylate synthesis inhibition,L1210 cells, 3398


59565-fluorouracil metabolites

plasma and urine, 1680growth inhibition

colon adenocarcinoma, 3319impaired polyglutamylation

resistance in CCRF-CEM cells, 2149yV'Â°-propargyl-5,8-dideazafolicacid and

accumulation, DNA strand breaks,2036

proliferation-dependent cytotoxicityleukemia, 5638

role of folylpolyglutamate synthetasehepatoma cells, 2426

7435




vincristine combinationother agents, acute lymphoblastic leu

kemia, 351Methotrexate-Y-aspÃ¡rtate

liposome-based therapyhuman ovarian cancer, 5237

9-(|2-Methoxy-4-|inethylsulfonyl)amino|-phenyljamino)-A',5-dimethyl-4-acridinecarbovamide: see CI-921

8-M ethoxypsora len-DNA photoadducts

flow eytometry, keratinocytes, 70134-Methyl-5-amino-l-formylisoquinoline

thiosemicarbazooeliver microsomal inactivation

inhibitor of ribonucleotide reducÃase,6375

Methylbenzylnitrosamine-induced formation of CX'-methylguanine

dietary ellagic acid, 7088Methyl bis(guanylhydrazone)

rhodamine 123anticarcinoma activity, murine renai

adenocarcinoma, 20613-MeIhylcholanthrcnc

-induced skin tumorigenesisprotection, tannic acid, 2361

Methylchrysene diol epoxide enantiomersSalmonella typhimurium

reactivity, DNA bases and mutagenic-ity, 1781

5-Methylcytosinegenomic

reduced content in human colonie neoplasia, 1159

7-Methyldeoxyguanosineantibodies

molecular epidemiology, 5065O6-Methyldeo\\Ruanosine

detection in human placenta! DNA,4184

Methylenetetrahydrofolatemethotrexate effects

thymidylate synthesis inhibition.LI210 cells, 3398

5,10-Methylenetetrahydrofolatescharacterization

xenografts, colon adenocarcinoma,3062

yV-Methylformamideeffects on cell cycle and glutathione sta

tuslymphoma cells, 3389

-induced radiosensitizationchromatin modifications, 5669

modulation of cytotoxic effect5-fluorouracil, colon carcinoma, 6193

Methylglyoxal bis(guanylhydrazone)a-difluoromethylornithine and

Phase 1evaluation, hematological malignancies, 1367

0*-MethylguanineDNA interstrand cross-link formation

chloroethylnitrosoureas, 3603esophageal

methylbenzylnitrosamine-induced formation, ellagic acid, 7088

repair ofoligodeoxynucleotides, 1184

Methyl methanesulfonateeffect on type 5 adenovirus DNA inte

grationembryo fibroblast cells, 3050

Methyl-n-amylnitrosaminehydroxy metabolites, 5663

3-(Methylnitrosoamino)propionitrileDNA cyanoethylation, 6780

yV-Methyl-nitrosoureaconversion of rat urinary bladder carci

nomaslow grade to high grade, 1265

stages of thymic lymphomasras oncogenes, 5514

yV-Methyl-/V'-nirro-yV-nitrosoguanidine

carcinogenesisproliferative response, gastric mucosa,

5275effect of cimetidine on inhibition by te-

tragastrincarcinogenesis in rats, 1591

gastric carcinogenesiscaerulein enhancement, 6332

-induced stomach carcinogenesisphenolic antioxidants, 5310

spontaneous transformationC3H 10T'/2 cells, 5977

-treated murine tumor cellsexpression of gp70, 1137

4-{Ar-Methyl-/V-nirrosamino)-l-(3-pyridyl)-1-butanone

activation and DNA alkylationcarcinogenicity, lung, 4215

jV-Methyl-iV'-nitrosoguanidine-induced colon carcinogenesis

effects, ammonium acetate and sodiumcholate, 3035

resistance of mitochondrial DNA to mu-tagenesis

HeLa cells, 4578/V-Methyl-/V-nitrosourea

estrous cycle modificationrat mammary gland DNA alkylation,

3090-induced skin tumorigenesis

protection, tannic acid, 2361Methylphosphonates

oligodeoxynucleotidesinhibitors, gene expression, 2659

Methylprednisolone acetatemammary tumorigenesis

adrenal regulation, 3801Methylxanthines

antitumor effects of pentoxifyllinethiotepa, human cancer cells, 4375

Metoprincantifolate drug interactions, 2421

Microsomeshepatic: see Liver microsomes

Microtubuleschanges and cytotoxicity

taxol, leukemic cell lines, 4093disorganizing-overstabilizing drugs

cell proliferation, 4892inhibitors

antiinvasive activity, estramustine,1842

role of tumor cell cytoskeletonplatelet adhesion, aggregation, 3787

Microwaveslow energy Ik-Ids

ornithine decarboxylase activity, phor-bol ester, 4222

Milk factorintervention of T-cells in transportation

mouse mammary tumor virus, mammary gland cells, 6555

Milk fat globule

radioimmunotherapybreast carcinoma, 4664

Milk fat globule membrane-associated antigen

endocytosis of monoclonal antibody,MCF-7 cells, 3188

Misonidazolechemosensitization

enhancement of melphalan activity,3528

Mitochondriaanticarcinoma activity

rhodamine 123, murine renai adenocarcinoma, 2061

damageditercalinium accumulation, hepato-

cytes, 6542energy substrate utilization

Morris hepatoma 7777 cells, 602hexokinase

hepatoma cells, 913kryptocyanine dye phototoxicity

red cell membranes, 6794loss of DNA

ditercalinium treatment, 4982picket-fence porphyrins

potential phototherapeutic agents,1148

proton stoichiometryelectron transport, mitoplasts, 628

resistance of DNA to mutagenesisHeLa cells, 4578

Mitogenesisepidermal growth factor-induced

kidney epithelial cells, 4886Mitogens

differential responsiveness of breast cancer cells

growth factors, 17/3-estradiol, 4083responsiveness to GM-CSF

III 60 cells, induced differentiation,2683

Mitomycin Ccompositional stability

artificial heterogeneous tumors, 2669m-diamminedichloroplatinum(II) and

interferon action, human mesotheli-oma xenografts, 64


3236modulation of cytotoxicity

dicoumarol, mammary tumor cells,5471

therapeutic attack of hypoxic cellssolid tumors, 775

Mitoplastsproton stoichiometry

electron transport, 628Mitoxantrone

Phase I clinical and pharmacokineticstudy, 5874

resistanceanalysis, human colon carcinoma cell

line, 1882ML-1 cells

differentiation-inducedtransformation, carcinogen target,

4389MO4 cells

antiinvasive activity of estramustine,1842

Monensinimmunotoxin mediation of reduction of

7436




mÃ©tastases,3496Monoclonal antibodies

ability to form ricin A chain-containingÂ¡ninninotoxins, 1119

aflatoxin H, ON A adductsin vivo immunological detection, 6328

antibody-dependent cellular cytotoxicityantitumor effect, LAK cells, 1173

anti-CDS radioimmunotoxinshuman tumors, nude mouse model,

7107antiglioma

therapeutic efficacy, 559antiidiotype antibodies

carcinoembryonic antigen, 4002anti-K562

hematopoietic differentiation antigens,5759

anti-ras M, 21,000 proteinstomach and thyroid cancers, 5503

anti-receptorprogesterone receptor localization,

breast cancer, 6462antitumor effect of immunoconjugates

tumor necrosis factor, 3607binding and endocytosis

milk fat globule membrane-associatedantigen, MCF-7 cells, 3188

binding to cell surface antigenlocalization, colon adenocarcinoma,

6573biotechnology products in cancer ther

apy, 223CA19-9andDU-PAN-2

expression in tumor tissue and serum,pancreatic cancer, 1435

CD3endocytosis and degradation, '1-cells,

2249cell surface glycoprotein expression

colorectal carcinoma, 7257chain-specific

cytokeratins, human lung cancer, 3221characterization of melanoma antigen

metastatic ability, mouse-specific epi-tope, 7173

CO17-1APhase II trial with 7-interferon in co

lorectal carcinoma, 2568combinations of interferons

therapy, murine B- and T-cell lympho-mas, 4196

comparison of tumor targetingcarcinoembryonic antigen, human tu

mor-hamster host model, 1823Cora antigen

differential expression, malignant andbenign gastrointestinal epithelia,2198

daunorubicin immunoconjugateacid-labile compared to free drug,

6097delivery across blood-brain barrier, 4725detection of different antigenic determi

nantshuman osteosarcoma-associated anti

gen, 2273detection of mammary serum antigen in

sera of breast cancer patients, 7060detection of monosialoganglioside

tumor-infiltrating macrophages, 2524detection of necrotic lesions in human

cancers, 5842detection of 06-methyldeoxyguanosine

human placenta! DNA, 4184detection of patients with cancer

lactoneotetraosylceramide, 1512diagnostic and therapeutic potential

mesothelioma cell lines, 5228discrimination of GM2ganglioside resi

dues, 6154disulfated glycosphingolipid

hepatocellular carcinoma, 6769-drug conjugates

dual label fluorescence technique,6211

fetal pancreatic protein as markerpancreatic carcinoma, 6906

fragmentglioma localization, 5701

gallium-labeled for scintigraphytumor targeting, drug-antibody conju

gates, 1189heterogeneous distribution

interstitial pressure in tumors, 7022heterogeneous responses

hexamethylene bisacetamide, coloncarcinomas, 5487

humantissue distribution, cellular localiza

tion, 7273human carcinoma-associated protein

complexquantitation, normal and tumor tissue,

816human-human hybridomas

breast cancer patients, 3208human milk fat globule

radioimmunotherapy, breast carcinoma, 4664

idarubicin conjugatesmurine thymoma, immunochemother-

apy, 926identification

papillomavirus type 18 E6 proteins,2969

identification of platelet-aggregating factor

colon adenocarcinoma, 6411IgG.,

GM3lactone immunization, inhibitedmelanoma growth, 5680

immunohistochemical characterizationprostate-specific antigen, 6938

immunotoxin preparationdeglycosylated ricin A chain, hindered

disillude linkages, 6396indium-111-labeled anti-melanoma

saturable clearance mechanisms, 4417interleukin 2 and LAK cells

combined therapy, B16 melanomalung mÃ©tastases,7140

isolation of hepatoma nuclear proteins,5495

keratin-like antigenepithelial neoplasms, 4969

keratins 13 and 16differential expression in human breast

epithelium, 5831M, 95,000 glycoprotein

identification, melanocytes and melanomas, 1286

M, 97,000 to 250,000 protein antigenconcentrations, autoradiography, 5475

M, 170,000-180,000 P-glycoproteinstrong expression, adrenal cortex,

4611

reaction, mucinous type ovarian tumors, 4639

mouse melanoma antigenrecognition, Lyt-2~ and L3T4" cyto-

toxic T-lymphocytes, 2730mucin-associated oncofetal antigen

early carcinogenesis in colon, 1571mucin-like carcinoma-associated antigen,

6799nerve growth factor receptors

chromatin, melanoma cells, 7200neutral glycolipid

HTLV-I infection and adult T-cell leukemia, 3148

new tumor-associated antigen ATM-1,4848

noncompetingenhanced cytotoxicity, colon carci

noma, 6303nlicitola r antigen p 150, 7159osteosarcoma-associated cell surface an

tigenexpression, characterization, 5302

PE-35immunohistological analysis, thymic

neoplasms, 1896plasma membrane polarity

hepatocarcinogenesis, 6882precursor of cathepsin D

breast cancer cells, 3709preparation

sialosyl-Tn epitope, 2214proliferation-associated nucleolar anti

genearly G i phase, 1244

pulmonary capillary endothelial cellslung tumor colony formation, 4964

purification of calcium-binding proteinmultidrug resistance, 3173

purification of TAG-72, 6811radiohalogenation

W-succinimidyl 3-(tri-/i-butylstan-nyl)benzoate intermediate, 1446

radioimmunotherapy of colonie cancerxenografts

carcinoembryonic antigen, 3270radioimmunotherapy treatment

intracranial human glioma xenografts,2904

radioiodine-labeledxenogeneic tumor model, human B-

cell lymphoma, 2475radiolabeled

localization, colorectal carcinoma,4324

reaction with high-molecular-weight glycoprotein

body fluid, gastrointestinal cancer,4053

reaction with human cervical adenocarcinoma

uterus, immunodiagnostic potential,6565

reactive with mucin glycoproteinsera of breast cancer patients, 2138

restricted specificity for tumor-associatedantigen

prostate and breast carcinoma, 4543retrovirus-associated antigen

modulation, melanoma cells, 4954retrovirus transformation in rat cell lines

modulation, MHC class I antigens,3816

ricin A-chain conjugates

7437




transplantation of non-T-leukemiacells, tumor regression, 4673

ricin A conjugatesdisulfide-linked, galactose binding,

4469scrape loading of nucleolar antibodies

HeLa cells, 5246second generation

radioimmunolocalization, carcinomaxenografts, 4597

tumor-associated glycoprotein 72 antigen, 4588

selective growth inhibitiongpl60 and radioimmunotherapy, lung

cancer, 2768specificity

small cell neuroendocrine carcinoma,lung, 7319

tissue distribution of P-glycoproteinmultidrug-resistant gene, 1926

transplantable carcinomasloss of M, 78,000 marker, 2265

tumor-associated antigenneuraminidase-treated cancer cells,

412tumor detection

colorectal cancer, 4348uptake

blood flow, Clouser and renal cell xenografts, 188

human malignant melanoma multicelispheroids, 1856

Monocytesabnormal blood

chronic lymphocytic leukemia, 4812activation by Adriamycin therapy

liposome-encapsulated immunomodu-lators, 5256

activity in vitrointravenous administration, granulo-

cyte/macrophage colony-stimulatingfactor, 2604

alteration of fibronectin receptorsphorbol ester-treated promonocytic

cell lines, 5730alveolar macrophages and

tumoricidal activity, lung cancer, 3949interleukin 1 secretion

7-interferon, 1,25-dihydroxyvitaminD,, 1740

maturationmembrane-bound lectin, III Mi cells,

280peripheral blood

7-interferon therapy, cytotoxicity,1042

platelet-derived growth factor 1 and 2gene expression, 4498

Mononuclear cells-derived factor

stimulation, tumor cell growth, 5411a-difluoromethylornithine

methylglyoxal bis(guanylhydrazone)and. Phase I study, 1367

generation of antitumor effectorsadoptive immunotherapy, LAK cells,

3461peripheral blood

LAK cell fraction, suppression of he-matopoiesis, 534

Monooxygenaseshepatic effects of steroids

structure-activity studies, 2462liver microsomal nitrosamine metabo

lismdiallyl sulfide effect, 5937

Monos ialogangliosidedetection by monoclonal antibody

tumor-infiltrating macrophages, 2524Morpholinyldoxorubicin

inhibition of ribosomal gene transcription, 4101

Morphometryheterogeneous populations of breast can

cer cells, 3276Mucin

-associated oncofetal antigenearly carcinogenesis, colon, 1571

colon cancercharacterization, xenografts, 6678

glycoproteinmonoclonal antibodies, sera from

breast cancer patients, 2138human model of gastric carcinogenesis,

3554-like antigens

monoclonal antibodies, pancreatic cancer, 3924

-like carcinoma-associated antigenmonoclonal antibodies, 6799

serum type 1 chain antigens, 3856TAG-72 purification

monoclonal antibodies, 6811Mucosa

colorectalpattern, epithelial cell proliferation,

4121Mucus

mucinous variant of colorectal carcinoma

cell culture, 3751Multidrug resistance

antitumor activity of MX2murine tumor cells, 6653

Chinese hamster cellschromosomal organization, amplified

genes, 3179decreased drug accumulation

melanoma cells, 6348cu-diamminedichloroplatinum(II)-resis-

tant sublinesovarian tumor cell lines, 3355

geneP-glycoprotein distribution, mono

clonal antibody, 1926gene overexpression, 5927HL-60 cells, 3959K562/ADM cells

ATPase activity, P-glycoproteins, 4926leukemia cell line

cytogenetic and molecular characterization, 393

myeloma cellsdoxorubicin concentration, DNA le

sions, 6360verapamil reversal, doxorubicin resist

ance, 6365partial reversal of doxorubicin resistance

forskolin, murine sarcoma S180 variants, 539

purification of calcium-binding proteinmonoclonal antibodies, 3173

resistance to mitoxantroneanalysis of human colon carcinoma

cell line, 1882RNA detection by in situ hybridization,

4334verapamil-hypersensitive Chinese ham

ster ovary cellsproperties of, 4477

Multilamellar vesiclesentrapment of cw-bis-neodecanoato-

trans-R,R-1,2-diaminocyclohexane-platinum(II)

m-diamminedichloroplatinum(II) cytotoxicity, 4509

Muramyl peptidesbacterial vaccines

tumor necrosis factor production innude mice, 5766

Mutagenesisevolution of cancer genes, 1697resistance of HeLa cell mitochondria!

DNAchemical carcinogens, 4578

transformation of mouse embryo cellslead eliminate. 5280

MutagenicityCC-1065 and its analogues

mammalian cells and bacteria, 32hypotheses for origin

colon cancer, 7323reactivity with DNA bases

Salmonella typhimurium, methylchry-sene diol epoxide enantiomers, 1781

role of fecapentaenes in colon cancer,7324

Mutagens2-amino-3-methylimidazo[4,5-y]quinoline

metabolic activation, cytochrome P-450 isozymes, 4513

-treated murine tumor cellsexpression of gp70, 1137

MX2antitumor activity in murine tumor cells,

6653Mycobacterium

-induced infectious granulomaXenopus, 958

Myeloid cellslow molecular weight factor

induction, differentiation, 4201platelet-derived growth factor 1 and 2

gene expression, 4498Myeloma

1,25-dihydroxyvitamin D., receptormodulation, 1213

multiplePhase l-II study of epirubicin, 6246

Myeloma cellscommon acute lymphoblastic leukemia

antigen-positiveultrastructure, 6234

multidrug-resistantdoxorubicin concentration, DNA le

sions, 6360verapamil reversal, doxorubicin resist

ance, 6365Myelopoiesis

tumor-inducedprostaglandin E? regulation, Lewis

lung carcinoma, 6826Myelosuppression

antitumor activity and hematotoxicity ofFK973, 1166

Myelotoxicityradioantibody-induced

reduction of, interleukin 1, 5403Myocytes

anthracycline cardiotoxicity modeladenosine triphosphate/protein ratios,

5222

7438




Myometriumheterogeneity of progesterone receptor

distributionhuman endemici rial adenocarcinoma,

1889Myosarcoma cells

self-induction of tumor necrosis factorhuman and murine cell lines, 5407

N

Nafarelingonadotoxicity of cyclophosphamide

luteinizing hormone-releasing hormone agonist, 2174

NaHCOjpromotion of bladder carcinogenesis

ascorbic acid amplification, 6317Nanospheres

polymethacrylateAdriamycin antitumor activity, U937

cells, 1835a-Naphthoflavone

influence on ethinylestradiol bindinghepatocarcinogenesis, liver micro-

somes, 5460Nasal diseases

maxillary sinus cancercase-control study of past history in

Japan, 1651Nasal mucosa

DNA cyanoethylation3-(methylnitrosoamino)propionitrile,

6780Natural killer cell cytotoxic factor

distinction from tumor necrosis factorrecombinant human lymphotoxin, 891

Natural killer cellsaugmentation by swainsonine, 1410cytotoxicity in head and neck cancer,

5017effects of interleukin 2

tumor-infiltrating lymphocytes, 1180interleukin 2 effect

natural immunity, 6081intraperitoneal a-interferon administra

tionovarian cancer, 5853

LAK cells in rats, 878progenitor and effector phenotype,

884modulation of activity by serum of can

cer patients, 2596transformation-associated cell surface

antigenidentification, fetus-derived fibroblast,

2798tumorigenicity of murine lymphomas

fluorescence-detected antibody binding, 270

whole-body hyperthermia and cyclophosphamide

activity in erythroleukemia, 4561Necrosis

detection of lesions in human cancers,5842

role in regulating growth saturationmulticellular spheroids, 2432

NeoplasiaN-myc expression

thyroid C-cells, 4073Neoplasia- cells

genetic convergence and divergencetumor progression, 5911

phenotypic changes


2440Neoplastic growth

target for chemotherapypolyamine metabolism, 759

Neoplastic rearrangementsgenomic

chromosomal bands, 7115Neoplastic transformation

cytogenetic changestrachea! epithelial cells, 702

dexamethasone effectsFujinami sarcoma virus, chick embryo

model, 7231Ar-methyl-yV'-nitro-Ar-nitrosoguanidine

induction of foci, C3H 10T'/2 cells,5977

ivirovirus associated antigenmodulation in melanoma cells, 4954

secreted phosphoproteins, 5770spontaneous

C3H 10T-/2cells, 5969Nephrotoxicity

cÃ»-diamminedichloroplatinum(II) effectskidney, renal proximal tubule cells,

2538thiol rescue agents, LLC-PK, cells,

6017Nerve growth factor

receptorchromatin, melanoma cells, 7200

Neuraminidase-treated human cancer cells

tumor-associated antigen, monoclonalantibody, 412

Neuroblastomaantiproliferative effect of verapamil,

3617cytotoxic effects of iodobenzylguanidine,

2993growth

inhibitory effect, adenosine dialdehyde,5933

I la-ras gene productscorrelation with prognosis, 1030

humanidentification, guanine nucleotide-

binding protein, 2756neuronal cell differentiation

retinoic acid, herbimycin-A, 6530Schwannian cell differentiation

induction by bromodeoxyuridine, 2531viability and proliferation

inhibition by deferoxamine, 7189Neuroblastoma cells

induction of differentiationM, 53,000 protein, 2226

induction of S-100 protein5-bromo-2'-deoxyuridine, 170

Neuroepitheliomapatterns of protooncogene expression,

4307Neurofibromatosis

-like diseasetransmissibility, damselfish, 3828

Neuroleukinphosphohexose isomerase characteriza

tiongastrointestinal carcinoma, 7018

Neurotoxicitysnail neurons as model

testing, antitumor agents, 7184Neutron capture therapy

boron

murine melanoma. 6313Neutrophils

actin polymerization in HL-60 cells,6721

actions of staurosporinccontrast with epidermal cells, 4646

Nickelalloyed with aluminum

decontamination and disposal, nitro-soureas, 522

Nickel(II)resistance to ions

characterization of mouse cell lines,6850

NIH 3T3 cellsdetection of activated oncogenes

human skin cancers, 3341interferon-induced revenants

transcriptional inhibition, Ha-ras,5157

phorbol ester-mediated associationprotein kinasc C, nuclear fraction,

1910ras-transfected

polyamine metabolism, interconversion, 3336

transformation by ras oncogenesincreased resistance, m-diamminedi-

chloroplatinum(II), 793/V-|4-(5-Nitro-2-furyl)-2-thiazolyl|formainidc

metabolite ofeffect of peroxidase inhibitors on uri

nary bladder, 304Nitrogen

bifunctional alkylating agentsmedulloblastoma, transplantable xeno-

grafts, 4189Nitrogen dioxide

nitrosamine formation from amines,1095

Nitrogen mustardeffect of alkylating agent dose

clinical correlation, 6417influence of WR2721

DNA cross-linking, bone marrow andleukemia cells, 6002

melphalanchronic lymphocytic leukemia, 1972

protection of Ehrlich asdics tumor cells5-AVV-dimethylamiloride, 2454

Nitroimidazoleschloroethylnitrosourea and

mixed-function drugs. Mer cells, 7981-Nitropyrene

derivativescarcinogenic activities, 4256

oxidative metabolismliver microsomes, cytochrome P-450

isozymes, 42614-Nitroquinoline 1-oxide

adduct formation andcell sensitivity, hereditary cutaneous

malignant melanoma, 5145Nitrosamine

antibodies against 7-methyldeoxyguano-sine, 5065

ÃŸ-and 7-hydroxylatedcarcinogenic-its in F344 rats, 1533

formation from aminesbefore and after nitrogen dioxide expo

sure, 1095liver microsomal metabolism

diallyl sulfide effect, 5937tobacco-related tumors

7439




lung and pancreas in rats, 6912Ar-Nitrosobutyl-(4-hydroxybutyl)amine

pharmacokinetic profile, 3666\~Nilroso compounds

genotoxicity in hepatocytes, 4144relevance to human cancer, 4711

/V-Nitrosodialkylaminesmetabolism by human liver microsomes,

1499iV-Nitrosodicthylamine

tumor promotion by hydantoinscytochrome P-450 induction, liver and

thyroid, 2492NÂ¡Irosmlimi-Ili)lamini-

activation and DNA alkylationcarcinogenicity in lung, 4215

jV-Nitrosoethylurea-induced papillary lung tumors

alveolar type II cell origin, 148induction of oligodendrogliomas

fetal lore-brain transplants, 2871Nitrosomethylalkylamines

comparative carcinogenesis, 6648/V-Nitrosomethylamylamine

organ and cell specificityDNA methylation, 5482

iV-Nitrosomethyl-(2-hydro\yethyl)amini'DNA alkylation

dose response, lesion persistence, 1537W-Nitrosomethylurea

-induced mammary cancerflavonol quercetin, 5754

-induced mammary tumor growthpolyamines, progesterone, 3058

-induced mammary' tumorigenesiscalorie restriction and exercise, dietary-

fat, 4276/V-Nitrosomorpholinc

dose response study in F-344 rats, 2089jV-Nitroso-/V-methyl-2-oxopropylamine

metabolism of Z and / isomers in rathepatocytes, 3347

jV-Nitrosopyrrolidine a-hydroxylasereconstitution of activity

liver microsomes, 3987yV-Nitrosothioproline

increase in urinary levelingestion of cod with vegetables, 4049

Nitrosoureaeffect of thymidine on activity, 4272induction of sister chromatid exchange

cytotoxicity, alkylating agents, 3100potentiation of cytotoxicity

leukemic cells, 1521regeneration of O^-alkylguanine-DNA al-

kyltransferasehuman lymphocytes, 5368

related A nitroso compounds anddecontamination, disposal, 522

-resistant Mer* tumor cells

thermal sensitization, 1086NMR: see Nuclear magnetic resonance

spectroscopyNoduligenesis

mammary hyperplastic alveolar nodulestransplantation into gland-free fat

pads, 3197NSC 308847

limited sampling modelspharmacokinetics, 4127

Nuclear magnetic resonance spectroscopy5-fluorouracil metabolites in plasma and

urine, 1680gliosarcoma, 5610

measurement of tumor blood flow andperfusion, 3449

monitoring of tumor physiologyflavone acetic acid-induced modula

tion, 4749Hp

cyclophosphamide response, RIF-1cells, 4736

profiles of neoplastic human breast tissues, 5112

response of rat mammary tumorsendocrine therapy, 89

tumor bioenergetics and histology, 676tumor energy metabolism

intracapillary oxyhemoglobin, 5440tumor metabolic changes with glucose,

5917Nuclear matrix

-bound DNA replicationantileukemia agents, CCRF-CEM leu

kemia cells, 1850Nucleic acids

oxygen-free radicals in carcinogenesis,3882

Nucleolar antigenpl20

intranucleolar localization, 6523optimal loading, scraped HeLa cells,

5246pl50

monoclonal antibodies, 7159proliferation-associated

early G, phase, cell cycle, 1244Nucleosides

inhibited salvagedipyridamole and acivicin. Phase I

clinical trial, 5585,5591restoration of heat resistance

protein synthesis, glucose-deprivedL929 cells, 1442

S'-Nucleotidase

photosensitizing effectshematoporphyrin derivative, mam

mary adenocarcinoma, 3360Nutrition: see also Diet

cancer cachexiaimprovement, exogenous insulin, 2784

parenteralbranched chain amino acids, Yoshida

sarcoma, 2698sodium-deficient diet

restriction, tumor growth, 3445

Obesityestrogens as cause of human cancer, 246

Occupational risksesophageal carcinoma, 3843foundry' workers

PAH-DNA adducts, white blood cells,2288

laryngeal cancerTexas Gulf Coast, 1960

motor exhaust-relatedbladder cancer, 1989

OK-432adoptive immunotherapy

pantropic killer cells, 4163Oleanolic acid

triterpenoid compoundsantitumor action, 12-O-tetradecanoyl-

phorbol-13-acetate, 5210Oligodeoxynucleotides

inhibitors of gene expression, 2659

repair of C^-methylguanine, 1184Oncogenes

activateddetection in skin cancers, 3341

activated rasthyroid cancers, 4459

cellularphÃ©nobarbitaltreatment, liver regener

ation, 265changes in expression

retroviral sequences, colon carcinogenesis, 3964

differential NM23 RNA levelsmetastatic potential, 6550

c-fos differential expressionfamilial polyposis coli, 4855

c-Ha-r<winterferon-induced revenants, tran-

scriptional inhibition, 5157malignant properties, bladder cancer

sublines, 4993polyamine metabolism, NIH 3T3 cells,

3336c-myc: see c-mycDNA tumor viruses, 493expression and tumorigenicity

pediatrie cancer, 2715growth factor expression and

mammary epithelial cells, 7041Ha-ros

cell line development, papillomas inskin grafts, 165

correlation with prognosis in neuro-blastoma, 1030

human kidney tumors, 5251mechanism of activation, mouse carci

noma, 556protein kinase C down-regulation,

C3H T 10'/2cells, 6535transformation, normal homologous

cells, 3470transforming growth factor-/?, meta

static fibrosarcoma, 6999human model of gastric carcinogenesis,

3554K-ras

activation, lung adenocarcinoma, 5738clonal diversity, 4941

malignancy by cell fusion, 3302molecular mechanisms of carcinogenesis

cancer prevention, treatment, 4135Â»IMfamily gene abnormality

lung cancers, xenotransplantability,6025

N-myc expressionneoplasia of thyroid C-cells, 4073

nonrandomness of chromosome aberrations, 7120

pp60'"r expressionprotein-tyrosine kinase activity, flow

cytometry, 4633ras

epidermal growth factor receptor,esophageal cancers, 5119

low frequency, human melanomas,950

resistance to m-diamminedichloropla-tinum(II), NIH 3T3 cells, 793

stages in thymic lymphomas, 5514ras/myc

role of chromosome loss, 1623ras p21

cAMP levels, salivary gland adenocarcinoma, 2898

7440




retrovirusestransformation, mammary epithelial

cells, 4689retrovirus transformation in rat cell lines


selective killing of transformed cellsintercellular communication, therapeu

tic applications, 3203src

reversal of transformed phenotypes,herbimycin A, 1587

transformation-associated cell surfaceantigen

identification, fetus-derived fibroblast,2798

\-fesneosynthesis of gangliosides, 1753

v-Ha-roscell motility, metastatic ability, 6050

viral expressionpromonocytic leukemia cells, Abelson

virus-infected, 1702Ontogenesis

evolution of cancer genesmutation-driven process, 1697

Oral contraceptivesborderline ovarian neoplasms

case-control study, 5849cervical carcinoma in Chile, 1011risk of colorectal cancer, 4399

Oral neoplasmshamster oral keratinocytes

transforming growth factor-Â«,3130pharyngeal cancer and

smoking and drinking, 3282Ornithine decarboxylase

activation by guanosine triphosphatehuman squamous cell carcinoma, 1252

increased activitymicrowave fields, phorbol ester, 4222

mechanisms of inductiontrachÃ©alepithelial cells, asbestiform

minerals, 709messenger RNA

retinoic acid inhibition, TPA-inducedsynthesis, 2168

polyamine levels andBarrett's esophagus, 3288

Osteosarcoma-associated antigen

expression, characterization, 5302monoclonal antibodies, antigenic de

terminants, 2273chick embryo model

dexameathasone effects, neoplastictransformation, 7231

developmentretinoblastoma susceptibility gene,

chromosomal reorganization, 3939liposome-encapsulated immunomodula-

torsAdriamycin therapy, monocyte activa

tion, 5256murine model

timing of chemotherapy and surgery,5533

Ouabainreduction of doxorubicin cytotoxicity,

725Oval cells

rat ductularpromotion of growth, primary culture,

368

Ovarian granulosa cell neoplasmsgene for susceptibility, 5092induction with dehydroepiandrosterone,

2788rapid induction

7,12-dimethylbenz(a)anthracene, neo-natally estrogenized mice, 425

Ovarian neoplasmsborderline tumors

case-control study, 5849cÂ»-diamminedichloroplatinum(II)-resis-

tant sublines, 3355DNA repair as mechanism of acquired

resistancem-diamminedichloroplatinum(II),

5713increased synthesis

prostacyclin and thromboxane, 2396inhibition of thymidine uptake

LHRH agonist, 7252a-interferon

intraperitoneal administration, 5853interleukin 2-inducible killer cells

ascitic fluid, pleural effusions, 6321liposome-based therapy, 5237mucinous type

reaction, novel mouse monoclonalantibodies, 4639

new growth factor in ascitic fluid, 1066prostaglandin biosynthesis, 4770tumor-associated galactosyltransferase

isozyme IIimmunoassay, 5325, 5335

Ovariectomyheterogeneous populations of breast can

cer cellskinetic and morphometric responses,

3276Ovary cells

Chinese hamsteracute pH 6.6 and 42.0Â°Cheating, 497camptothecin-resistant mutants, 6404cell cycle progression, cisplatin influ

ence, 6703cell survival and cycle, U-71,184, 109chronic pH 6.6 effects on response to

hyperthermia, 2417glutathione, Adriamycin tolerance,

4493glutathione depletion, thermotoler-

ance, 7033hyperthermia, glycosyltransferase ac

tivity, 5717polyamine-dependent recovery proc

esses, X-rays, 4881porfiromycin cytotoxicity, oxygen de

pendency, 5655premature chromosome condensation,

nuclear fragmentation, 6478SR 4233 metabolism, 5947verapamil-hypersensitive cells, 4477

Oxygenantioxidant enzymes

xeroderma pigmentosum fibroblasts,2132

-dependent regulationDNA synthesis and growth, Ehrlich

ascites, 2053effects of hyperoxia

growth characteristics, metastatic lungtumors, 2779

free radical formationAdriamycin-induced cardiotoxicity,

4766

carcinogenesis, 3882DNA damage induction, benzene me

tabolites, 4762squamous differentiation, bronchial

epithelial cells, 822intracapillary oxyhemoglobin

tumor energy metabolism, 5440porfiromycin cytotoxicity

Chinese hamster ovary cells, 5655

PAH: see HydrocarbonsPalmitate

effects of dietary retinoidsgrowth and differentiation, embryonal

carcinoma, 3772energy substrate utilization

Morris hepatoma 7777 cells, 602Pancreas

comparison of sialylated Le" antigens,

3834disseminated cancer treatment

leucovorin, 5-fluorouraciI, 5570fetal pancreatic protein as marker in car

cinoma, 6906tobacco-related tumors, 6912

Pancreatic neoplasmsexpression of blood group-related anti

gens, 5422expression of CA 19-9 and DU-PAN-2,

1435Le" and Ley antigen expression, 475mucin-like antigens

monoclonal antibodies, 3924site-specific analysis of total serum cho


Nutrition Examination Survey, 452tumor markers CA 19-9 and CA-50

carcinoembryonic antigen, 1985Papilloma

skinaneuploidy, â€¢¿�y-glutamyltransferase,

3253skin grafts on athymic nude mouse hosts

cell line development, ras"', 165

tumor progression in SENCAR miceinitiator dose, 7048

Papilloma virusanalysis of sequences

cell lines derived from cervical cancers,324

early gene expressiongrowth property correlation, cervical

carcinoma, 3780isolation of new type

transforming activity, cervical cancertissue, 7164

oncogenes of DNA tumor viruses, 493polymerase chain reaction analysis

forty-year-old paraffin sections, 4564type 16

mild immunodeficiency, bladder carcinoma, 7207

transformation, C127 mouse fibroblasts, 2505

types 16 and 18immortalization, exocervical epithelial

cells, 4620type 18

E6 proteins, cervical carcinoma cells,2969

types and localization in adenocarci-noma

7441




adenosquamous carcinoma, uterinecervix, 993

l'arai rim- growth factortransforming growth factor-j3

ER-negative breast cancer cells, 3898Paraffin sections

DNA sequence analysis by polymerasechain reaction of forty-year-old samples, 4564

Paragloboside: see Lactoneotetraosylceratn-ide

Paraneoplastic syndromesdorsal root ganglionopathy

antigen expression, small cell lung carcinoma, 430

Parasitesrare events as clues to cancer etiology,

3544Parvoviruses

DNA amplificationcellular genotoxic stress, 3123

Pediatrie neoplasmstumorigenicity and oncogene expression,

2715Pentoxifylline

antitumor effectsthiotepa, human cancer cells, 4375

Pepsinogen geneDNA methylation, 1603

Peritoneal cellsenhanced activity after aclacinomycin

respiratory burst, 3440Peritoneal exÃºdatecells

alterations in murine host defense functions

Adriamycin or liposome-encapsulatedAdriamycin, 130

Peroxidase inhibitorseffect on urinary bladder carcinogen, 304

Peroxisomal 0-oxidationmRNAs in rat tissues, 5316

Peroxisome proliferatorsDNA synthesis and

hepatocarcinogenesis, 6739lack of glutathione-5-transferase P

mRNA expressionâ€¢¿�y-glutamyltranspeptidasein liver tu

mors, 4919Perspectives in Cancer Research

breast cancer epidemiology, 5615changing concepts in cancer prevention

environmental carcinogenesis, 1381chromosomes in solid tumors, 1049contribution of medicine

primary treatment, breast cancer, 2314evolution of cancer genes

mutation-driven process, 1697genetic convergence and divergence

tumor progression, 5911glucocorticoid receptor at protein level,

2636human model of gastric carcinogenesis,

3554malignancy by cell fusion, 3302oncogenes of DNA tumor viruses, 493polyamine metabolism

neoplastic growth, chemotherapy, 759roles of cytochrome P-450 enzymes

chemical carcinogenesis. cancerchemotherapy, 2946

somatostatin analoguesoncological applications, 6977

tumors as caricaturesprocess of tissue renewal, 1996

P-glycoproteinamplified and overexpressed genes

multidrug-resistant cell lines, 5927chromosomal organization of amplified

genesmultidrug-resistant Chinese hamster

cells, 3179cytogenetic and molecular characteriza

tionmultidrug-resistant leukemia cells, 393

doxorubicin resistancediffering mechanisms, tumor cell lines,

2793M, 170,000 to 180,000

ATPase activity, multidrug resistant-K562/ADM cells, 4926

strong expression, adrenal cortex,4611

mechanisms of multidrug resistanceHL-60 cells, 3959

mull Â¡factorialresistance to Adriamycin,3595

tissue distributionmultidrug-resistant gene, monoclonal

antibody, 1926pH

ascorbic acid amplificationbladder carcinogenesis, NaHCO.i pro

motion, 6317chronic 6.6

hyperthermia response, Chinese hamster ovary cells, 2417

degradation of extracellular matrixcathepsin D, breast cancer cells, 3688

elevated temperatures andeffect of bleomycin, murine tumor

cells, 615intracellular

acute pH 6.6 and 42.0Â°Cheating,

Chinese hamster ovary cells, 497metabolism in vivo

human breast cancer xenografts, 7264mollification in normal and malignant

tissuehydralazine and glucose, air or carbon

dioxide breathing, 1543tumor metabolic changes with glucose

"P nuclear magnetic resonance, 5917uptake of WR-2721 derivatives

transported form of drug, 3634venous

Walker 256 carcinoma, hyperglycemia,1201

Phagocytesbenoxaprofen and

DNA damage, 3094human macrophage function

clinical trial, tumor necrosis factor,5604

Pharyngeal neoplasmsoral cancer and

smoking and drinking, 3282PhÃ©nobarbital

choline-deficient diet andmodulation, epidermal growth factor

receptors, 1162kinetics of inhibition

intercellular communication, mousehepatocytes, 2519

regeneration in rat liverretrovirus-like sequences, cellular on

cogenes, 265Phenolic antioxidants

gastric carcinogenesis, 5310

Phenol redestrogenic and antiestrogenic action

growth, breast cancer cells, 3693Phenols

tannic acidprotection against skin tumorigenesis,

23612-Phcn) lindÃ³le

estrogen action of derivatives, 784Phleomycin

bleomycin andinternucleosomal cleavage, yeast, 6837

Phorbol 12,13-dibutyratebryostatin 1 and

inhibition of cell-cell communication,epidermal cells, 447

Phorbol diestersdifferent protein kinase C activities

HL-60 leukemia cell variants, 2744Phorbol ester

adhesion and translocationprotein kinase C, U-937 cells, 3168

binding in mammary carcinoma cellsphospholipids, 1528

bryostatins andeffects, C3H 10T'/2 cells, 3702phosphorylation pattern mimicry, HL-

60 cells, 5984cAMP-dependent protein kinases

retinoic acid, teratocarcinoma cells,3993

changes in topoisomerase II DNA cleavage

leukemia cells, 6625differentiation in HL-60 cells


GÃ¬delayI Id a cells, time lapse photography,

17598-lipoxygenase induction

comparison, SENCAR and C57BL/6Jmice, 658

-mediated association of protein kinaseC

nuclear fraction, NIH 3T3 cells, 1910ornithine decarboxylase activity

low energy microwave fields, 4222-stimulated differentiation

retinoic acid, U937 cells, 5779-treated promonocytic cell lines

alteration, fibronectin receptors, 5730tumor promoters

protein kinase C as receptor, 1requirement, transformation, 7126

Phorbol I 2-nivrisiale 13-acetateinhibition of chemotactic peptide-in-

duced elevationintracellular calcium, HL-60 cells,

2707Phosphate

cancer morbidity and mortality amongphosphate workers, 7298

Phosphatidylethanolaminephosphatidylcholine and

phorbol ester binding, mammary carcinoma cells, 1528

Phosphatidylinositolnew growth factor in ascitic fluid

ovarian cancer, 1066Phosphatidylinositol kinase

membrane-associatedinsulin effects, mammary tumors,

6727

7442




Phosphohexose isomerasecharacterization

neuroleukin relationship, gastrointestinal carcinoma, 7018

isoelectric focusing patternsgastrointestinal and mammary carci

noma, 2998Phosphoinositide

turnover in kidney cellsserotonin as a major serum factor,

6697Phospholipids

toxicity to adenovirus 12 transformant,578

yV-(Phosphonacetyl)-L-aspartatebiochemistry and clinical activity, 4441

Phosphoproteinsglucocorticoid receptor at protein level,

2636secreted

neoplastic transformation, blood coagulation, 5770

Phosphoramide mustardbifunctional alkylating agents

medulloblastoma, transplantable xeno-grafts, 4189

Phosphorothioatesoligodeoxynucleotides

inhibitors, gene expression, 2659Phosphorylation

antiestrogen binding site ligandsantiproliferative action, 3954

different protein kinase C activitiesML 60 leukemia cell variants, 2744

M, 34,000 to 40,000 proteinsprotein kinase C, epidermis, 4018

Phosphotyrosine phosphatasetyrosine kinase and

biochemical characterization of HL-60cells, 4299

Photoactivationaflatoxin

DNA strand scission, apurinic sites,3070

Photodynamic therapyhematoporphyrin derivative

bladder tumor, 6115-induced hypoxia

fluosol-DA (20%), carbogen breathing,3350

metallopurpurin derivativestransplantable bladder tumors, 194

porphyrindifferential cell photosensitivity, 4539

Photosensitizationbiological effects of phthalocyanine dyes

transplantable tumors, 3040effects of pyronin Y and toluidine blue

O, 1295hematoporphyrin derivative

plasma membrane enzymes, mammaryadenocarcinoma, 3360

Phototherapeutic agentspicket-fence porphyrins, 1148

Phthalocyaninebiological effects of dyes in transplanta

ble tumors, 3040Pigmentation

influence of organ microenvironmentmetastatic murine melanoma, 2258

Pineal glandproliferation effects of melatonin

breast cancer cells, 6121Piriprost

ethacrynic acid andcytotoxicity effect, 3622

Pituitary growth hormonesomatostatin analogues

oncological applications, 6977Pituitary neoplasms

anterior pituitary dopamine receptorsestrogen-like effects, 7,12-dimethyl-

benz(a)anthracene, 6434compositional stability

artificial heterogeneous tumors, 2669estrogen-induced

glandular kallikrein. prolactin, 4158Placenta

detection of O6-methyldeoxyguanosine

human DNA, 4184Plasma

proteins cleaved during blood coagulation

secreted phosphoproteins, neoplastictransformation, 5770

urine and5-fluorouracil metabolites, 1680

Plasmacytomaeffector mechanism of tumor immunity,

1398Plasma membrane

enzymesphotosensitization, mammary adeno

carcinoma, 3360tnethotrexate transport in LI210 cells,

5995polarity

hepatocarcinogenesis, 6882tyrosine kinase and phosphotyrosine

phosphatasebiochemical characterization, HL-60

cells, 4299Plasminogen

levels of urokinase and its receptorcolon carcinoma, 3112

Plasminogen activatordifferential regulation

epidermal growth factor, urothelium,5552

effects of inhibitorsbasement membrane invasion, meta

static cells, 3307inhibitor activity and

human glioma cells, modulation by sodium butyrate, 291

modulation of activityendometrial adenocarcinoma cells,

growth factors, 6384profiles in neoplastic tissues

human colon, 4520relation to estrogen and epidermal

growth factorhuman breast cancer, 6603

tissue-typenew prognostic marker, breast cancer,

1348urokinase-type

modulation of metastatic potential,melanoma cells, 1270

Platelet-aggregating factoridentification of

monoclonal antibodies, colon adenocarcinoma, 6411

Platelet-derived growth factorexpression of mRNAs

glioma cell lines, 3910gene expression

myeloid cell lines, monocytes, 4498

-like proteinsconstitutive production, prostate carci

noma, 1930regulatory effects of cell density, 4266retroviral expression in transformed

cells, 4874Platelets

aggregationtumor cell cytoskeleton, IRGpIIb/IIIa,

3787aggregation in metastasis, 1460significance of Â«-2-i.-fucosyltransferase

serum of leukemic patients, 3998Platinum

-DNA adductsrepair, bladder and testicular tumors,

3019Platinum analogues

fi.s-diamminedicliloroplatinum(ll) andaccumulation in murine leukemia

cells, 9Platinum compounds

c/i-diamminedichloroplatinum(II) resistance

effect on hyperthermia, 5101effect of hypoxia and acidosis on cyto

toxicitynormal and hyperthermic tempera

tures, 2342intracellular biotransformation

1,2-diaminocyclohexane carrier ligand,L1210 cells, 5136

Polyadenosine diphosphoribosestimulation of synthesis by DNA lesions

sodium chromate, V79 cells, 1100Poly(ADP-ribose) glycohydrolase

effect of hyperthermia, 4240metabolism alteration by hyperthemia,

4233Polyamines

alterations in epidermal levelsDNA synthesis, chrysarobin, 6390

autocrine control of mammary tumorgrowth

progesterone, 3058-depleted Chinese hamster cells

inhibition, ionizing radiation recoveryprocesses, 4881

Â«-difluoromethylornithinemethylglyoxal bis(guanylhydrazone)

and, Phase I study, 1367importance of metabolism

neoplastic growth, chemotherapy, 759metabolism and interconversion

NIH 3T3 cells, ras transfection, 3336modulation of binding

progesterone receptor to DNA, 1217mutant LI210 cells

curative effect, m.-2-difluoromethylor-nithine, 4807

synthesis and interconversionresponse to blockade, normal and ma

lignant urothelium, 357Polycyclic aromatic hydrocarbons: see Hy

drocarbonsPolycythemia

erythropoietin-inducedtransplantation, renal carcinoma, 3430

-inducing strain of Friend virus complexcurative effect, irradiation, 2399

Polyethylene glycolrestoration

colon cancer cell differentiation, 2498Polyglutamates

7443




formation8-deaza analogues, methotrexate and

aminopterin, 1481Polyglutamylation

impairedmethotrexate, resistance in CCRF-

CEM cells, 2149Polyisoprenoids

dolichol kinase and phosphatasemicrosomal fractions, human hepato-

mas, 3418Polymerase

chain reaction analysisforty-year-old paraffin sections, 4564

Polymorphismsrestriction fragment length

epidermal growth factor gene, 4045Polypeptides

metastasis markersfibrosarcoma cells, 572

Polypsadenomatous

epithelial cell proliferation, colorectalmucosa, 4121

Porfiromycincytotoxicity

oxygen dependency, Chinese hamsterovary cells, 5655

Porphyrinphotodynamic therapy

differential cell photosensitivity, 4539potential phototherapeutic agents, 1148

Positron emission tomographyglioma imaging

isoquinoline, benzodiazepine binding,5837

Potassiumbreast cyst fluid

epidermal growth factor, 5860proteases in cyst fluid

human gross cyst breast disease, 6379Potassium tetrachloroplatinate

effect of hyperthermia, 2335Pregnancy

risk factor for breast cancerChinese women in Shanghai, 1949

Presidential Address, 775Princess Takamatsu Cancer Research Fund

eighteenth annual symposiumrare events, cancer etiology, 3544

Procarbazine-induced germinal cell aplasia

partial prevention, testosterone, 4354therapy-related acute nonlymphocytic

leukemiaCX'-alkylguanine DNA alkyltransferase,

3084Progenitor cells

bone marrowthermotolerance, heat sensitivity, 3630

fresh leukemic bone marrowradiobiological features, acute lympho-

blastic leukemia, 5788granulocyte-macrophage

effects of hematopoietic suppressormolecules, 1548

leukemicbone marrow purging, acetaldophos-

phamide, 339Progesterone

antagonism of actionepidermal growth factor, breast carci

noma, 5071estrogen action of 2-phenylindole deriva

tives, 784insulin-like growth factor I receptors in

breast cancer, 6429A'-nitrosomethylurea-induced mammary

tumor growthpolyamines, autocrine control, 3058

receptor binding to DNAmodulation by polyamines, 1217

receptor distributionheterogeneity in endometrial adeno-

carcinoma, 1889receptor localization

anti-receptor monoclonal antibodies,breast cancer, 6462

receptor structure and protease activityprimary human endometrial carci

noma, 1143receptors

hyperplastic and neoplastic endome-tria, 6132

Progestinhepatic effects of steroids

structure-activity studies, 2462steroid insensitivity

breast cancer cells, 4340Progestins

medroxyprogesterone acetate effectcell cycle kinetics, mammary carci

noma, 5084regulation of epidermal growth factor

gene expressionhuman breast cancer cells, 4555

Proglumidegastrin antibodies

colon carcinoma, 7179Prolactin

binding and localizationmammary tumor mast cells, 3765

estrogen action of 2-phenylindole derivatives, 784

glandular kallikreinestrogen-induced pituitary tumors,

4158somatostatin analogues

oncological applications, 6977A^-Propargyl-S.S-dideazafolic acid

methotrexate andaccumulation, DNA strand breaks,

20360-Propiolactone

11 rÂ«.\oncogene activationmouse carcinoma, 556

Prostacyclinthromboxane and

increased synthesis, ovarian malignancy, 2396

Prostaglandin A.,inhibited c-myc expression

cell cycle progression, HL-60 cells,2813

Prostaglandin analoguesethacrynic acid and piriprost

cytotoxicity effect, 3622Prostaglandin E

effects of hematopoietic suppressor molecules

granulocyte-macrophage progenitorcells, 1548

Prostaglandin Iregulation of tumor-induced myelo-

poiesisimmune suppressor cells, Lewis lung

carcinoma, 6826Prostaglandins

biosynthesis in human tumor cells, 4770effect of dietary eicosapentaenoic acid

azoxymethane-induced colon carcino-genesis, 4790

production by murine tumorspredictor for therapeutic response, in

dornet hucin. 3002profiles of biosynthesis

normal lung and tumor tissue, lungcancer patients, 3140

Prostatecadmium carcinogenesis

dose-response, 4656optimal medical castration in male rats,

6063-specific antigen

characterization, monoclonal antibodies, 6938

ventraldifferential expression, cytochrome P-

450c and -450d, 3045Prostatic neoplasms

cell motility and metastatic abilityv-Ha-ros oncogene, 6050

cytotoxic activitydiethylstilbestrol, 2867

dietary /3-carotene andcase-control study in Japan, 1331

down modulation of fibronectin messenger RNA, 2042

partial inhibition of growthSandostatin, 4651

Prostaglandin biosynthesis, 4770risk

prediagnostic serum hormones, 3515variation in tumor yield

3,2'-dimethyl-4-aminobiphenyl, 4629

Proteasescyst fluid

human gross cyst breast disease, 6379differential regulation of plasminogen ac

tivatorsepidermal growth factor, urothelium,

5552progesterone receptor structure

primary human endometrial carcinoma, 1143

Proteinadenosine triphosphate ratios

anthracycline cardiotoxicity model,5222

anti-ro?p21 monoclonal antibodiesstomach and thyroid cancers, 5503

branched chain amino acidsparenteral nutrition, Yoshida sarcoma,

2698estramustine-binding associated

lung cancer cell lines, 4615functional properties

human a-interferon gene, pseudogene,1763

glucocorticoid receptor, 2636induction of carcinoembryonic antigen

secretiontransforming growth factor-/3, colon

carcinoma, 405985-kDa

Adriamycin resistance, 7082lectin-binding

nuclear preparations from rat liver andmalignant tumors, 551

M, 53,000differentiation induction, neuroblas

toma cells, 2226

7444




M, 78,000loss of marker, primary pancreatic car

cinoma, 2265M, 97,000 to 250,000 antigen concentra

tionsmelanoma, quantitative autoradiogra-

phy, 5475p32 cDNA clone isolation, 4795P55

late target protein, ./V-2-fluorenylace-tamide in liver, 6745

pl20intranucleolar localization, 6523

pl50nucleolar antigen, monoclonal anti

bodies, 7159p 190

epidermal growth factor receptor, glio-blastoma cells, 5433

patterns of synthesishyperthermia, endothelial cells, 2101

retinoid-bindingretinoblastoma tumors, 1124

S-100induction by 5-bromo-2'-deoxyuridine,

neuroblastoma cells, 170synthesis alterations

Novikoff hepatoma, Yoshida sarcoma,1554

-tyrosine kinase activitypp60"~'" expression, flow cytometry,

4633whole body turnover rate

resting energy expenditure in cancerpatients, 2590

Proteinasecathepsin B-like

biochemical study of colon cancers,6855

Protein kinasecAMP-dependent

phorbol ester effect, teratocarcinomacells, 3993

Protein kinase Cantiestrogen binding site ligands

antiproliferative action, 3954colonie cancer cell differentiation

calmidazolium, 12-O-tetradecanoyl-phorbol-13-acetate, 6173

contrasting actions of staurosporineneutrophils, epidermal cells, 4646

cytosolic calcium andalteration, LAK cell activity, 635

different activitiesHL-60 leukemia cell variants, 2744

L-a-dioctanoylglyceroltumor promoter in mouse skin, 1736

DNA damagebenoxaprofen and phagocytes, 3094

effects of thioether phospholipidphorbol ester-induced differentiation

in HL-60 cells, 6669growth-promoting activity of desmopres-

sinleukemia cells, 7055

inhibition of MCF-7 cell growth1,2-dioctanoyl-i/i-glycerol, TPA, 6943

molecular mechanisms of carcinogenesiscancer prevention and treatment, 4135

ornithine decarboxylase mRNAretinoic acid inhibition, TPA-induced

synthesis, 2168partial down regulation

Ha-roj, C3H lOT'/z cells, 6535

phorbol 12,13-dibutyrate and bryostatin 1inhibition of cell-cell communication, epidermal cells, 447

phorbol ester-induced adhesion andtranslocation

U-937 cells, 3168phorbol ester-mediated association

nuclear fraction, NIH 3T3 cells, 1910phorbol ester-stimulated differentiation

retinoic acid, U937 cells, 5779phosphorylation of M, 34,000 to 40,000

proteinsmouse epidermis, 4018

receptorphorbol ester tumor promoters, 1

specific and direct bindingimmobilized tamoxifen analogue, 3626

translocation and down regulationTPA biphasic effects, keratinocytes,

964vinculin phosphorylation

HL-60 cells, 3324Proteoglycans

chondroitin sulfatedifferentiation-associated changes,

U937 cells, 6103thrombospondin binding

sulfated glycoconjugates in melanoma,6785

Protonstoichiometry

electron transport, mitoplasts, 628Protooncogenes

c-erbB-2gene copy number and protein in

breast tumors, 1238c-fos

steroid hormones and peptide growthfactors, breast cancer cells, 802

c-myc. see also c-mycepidermal growth factor receptor,

renal cancer, 6753infiltrating ductal carcinoma of the

breast, 199c-raf

7-glutamyItranspeptidase, liver neoplasms, 1610

expression in HL-60/MRI cells, 6733expression in normal and leukemic

erythroid cells, 3972HER2/neu

sporadic amplification, adenocarcino-mas, 1517

myc familyDNA amplification, small cell lung

cancer, 5163ras

point mutation, acute nonlymphocyticleukemia, 1812

tiazofurin effectsHL-60 cell differentiation, 5965

tumor expressionEwing's sarcoma, neuroepithelioma,

4307\-fms

inhibition of tumor growth, castanos-permine, 1091

Pseudomonascepharanthine and lysosomal function,

1307enhancement of immunotoxin activity

ovarian and epidermoid carcinoma,3919

Pulmonary neoplasms

combined effects of chemotherapy andinterleukin 2 in mice, 122

Furineantifolate drug interactions, 2421

Purine nucleoside analoguesmodulation of antibody response

natural killer cell activity, 4799Pyridoxal S'-phosphate

vitamin B6 metabolism in McA-RH7777cells, 1080

l'y rinudine

halogenated antimetabolitesinterferon interactions, adenocarci-

noma and HL-60 cells, 4868Pyronin Y

toluidine blue O andphotosensitizing effects, 1295

PZEproduction of protein-associated DNA

breaksLI210 cells, 1404

Quinacrinereversal of resistance to vincristine

P388 leukemia, 2064Quinocarmycin

antitumor activityleukemia, lymphoma cell lines, 6029

Quinoneantitumor agents

resistance of L5178Y murine lympho-blasts, 1727

Quinone reducÃaseestrogen-induced kidney neoplasms,

5726mono- and bifunctional enzyme inducers

in liver, 4776

Radiationbleomycin and hyperthermia

combination therapy development,6291

cancer morbidity and mortalityphosphate workers, 7298

fij-diamminedichloroplatinum(II) cross-resistance

human tumor cell lines, 5133tumor growth delay, fibrosarcoma,

2693increase in radioresponse

murine tumors, indomethacin treatment, 3008

-induced fibrosarcoma-1cyclophosphamide response, 3'P NMR

spectroscopy, 4736-induced injury

tumor bed stroma, sarcomas and carcinomas, 2116

ionizinginhibition of recovery processes,

Chinese hamster cells, 4881nul inani Â¡bodyinduced myelotoxicity

reduction of, interleukin 1, 5403rare events as clues to cancer etiology,

3544stages of thymic lymphomas

ras oncogenes, 5514ultraviolet-B

growth effect, melanoma cells, 4007Radiohalogenation

monoclonal antibodyyV-succinimidyl 3-(tri-/i-butylstan-

7445




nyl)benzoate intermediate, 1446Radioimaging

detection of necrotic lesions in humancancers, 5842

Radioimmunolocalizationantibody-guided targeting

non-small cell lung cancer, 1977Radioimmunotherapy

human colonie cancer xenograftsmonoclonal antibodies, carcinoem-

bryonic antigen, 3270monoclonal antibodies

human milk fat globule, breast carcinoma, 4664

selective growth inhibitionHP160. lung cancer cell lines, 2768

treatmentintracranial human glioma xenografts,

2904Radioimmunotoxins

anti-CD5human tumors, nude mouse model,

7107Radioiodine

-labeled monoclonal antibodiesxenogeneic tumor model, B-cell lym-

phoma, 2475Radiolocalization

polyclonal and monoclonal antibodiescarcinoembryonic antigen, 1823

Radioresponseincrease

indomethacin treatment in murine tumors, 3008

Radiosensitivitycancer family syndrome and cell survival,

2579Radiosensitization

Â¿V-methylformamide-inducedeliminatili modifications, 5669

Radiotherapycell kinetics in human malignancies

bromodeoxyuridine, flow cytometry,6238

combined modality treatmentthymosin fraction V, small cell lung

cancer, 1663Radiotoxicity

bromine-80mestrogen receptor-directed therapy,

Auger electrons, 5805Radon

cancer morbidity and mortalityphosphate workers, 7298

ReceptorsM

analysis, A-431 cells, 23881,25-dihydroxyvitamin D3

measurement, renal cell carcinoma,2458

modulation, human myeloma cell line,1213

dopamine7,12-dimethylbenz(a)anthracene, ante

rior pituitary, 6434epidermal growth factor

amplification, human glioma xenografts, 2231

characterization, A-431 cells, 2377c-myc expression, renal cancer, 6753cytotrophoblasts, A-431 cells, 11051,25-dihydroxyvitamin D,, breast can

cer cells, 2734effects of butyrate on hepatocytes.

6560expression in human lung cancer cell

lines. 1132gene amplification in esophageal can

cers, 5119glioblastoma cells, 5433growth of neoplastic thyroid cells,

3652human gastric and colonie carcinomas,

137modulation by liver tumor promoting

regimens, 1162overexpression in breast carcinoma,

161plasminogen activators in human

breast cancer, 6603relation to steroid receptors in breast

cancer, 1343restriction fragment length polymor

phisms, 4045selective amplification, glioblastoma

multiforme, 2711erythropoietin

induction, MEL cells, 1818estrogen

antiestrogen growth regulation inMCF-7 cells, 6764

bromine-80m radiotoxicity. Augerelectrons, 5805

17/3-estradiol effect, melanomagrowth, 7093

estradiol effects on melanoma, 3720hormone responsiveness, medullary

thyroid carcinoma, 2760localization, human breast tissue, 6517medicine and treatment, breast cancer,

2314medroxyprogesterone acetate, mam

mary carcinoma, 5084preneoplastic hyperplasia, mouse Ley-

dig cells, 14prostatic carcinoma, 3077SAMBA 200 analysis, breast carci

noma, 1578survival, epithelial ovarian carcinoma,

6222tamoxifen-stimulated growth, MCF-7

tumors, 5183transforming growth factor-/3, breast

cancer cells, 3905fibronectin

alteration of, phorbol ester-treatedpromonocytic cell lines, 5730

sarcoma virus-induced tumors, 5510gastrin

antibodies, colon carcinoma. 7179glucocorticoid

effects on fibrosarcoma growth, 2703protein level, 2636tyrosine aminotransferase modulation

of Reuber hepatoma cells, 5188insulin

diabetes and sex steroids, mammaryadenocarcinoma, 3742

insulin-like growth factor Ihuman breast cancer, 6429human malignant glioma, 1233

interleukin 1binding, cell growth response correla

tion, 5455nerve growth factor

chromatin, melanoma cells, 7200platelet-derived growth factor

mRNA expression in glioma, 3910

progesteroneanti-receptor monoclonal antibodies,

breast cancer, 6462epidermal growth factor, breast carci

noma cells, 5071estradiol effects on melanoma, 3720heterogeneity, endometrial adenocarci

noma, 1889hyperplastic and neoplastic endome-

tria. 6132medicine and treatment, breast cancer,

2314medroxyprogesterone acetate, mam

mary carcinoma, 5084modulation of binding to DNA by

polyamines, 1217structure and protease activity, endo

metrial carcinoma, 1143progestin

survival in epithelial ovarian carcinoma, 6222

protein kinase Cphorbol ester tumor promoters, 1

steroidsurvival in epithelial ovarian carci

noma, 6222T-cell

gene rearrangements, Hodgkin's dis

ease, 3591transforming growth factor-Â«

mRNA expression in glioma, 3910urokinase

levels, colon carcinoma cell lines, 3112vasoactive intestinal peptide

cellular processing, 6201Red blood cells

laser Doppler flowhyperglycemia, murine tumors, 7102

mitochondriakryptocyanine dye phototoxicity, 6794

Reed-Sternberg cellsmolecular pathways of adhesion

T-cell resetting, Hodgkin's cell line,

37T-cell receptor gene rearrangements

immunoglobulins, Hodgkin's disease,

3591Renal cell neoplasms

enhanced c-myc expressionepidermal growth factor receptor,

6753tumor-infiltrating lymphocytes

interleukin 2, 206Reproduction

borderline ovarian neoplasmscase-control study, 5849

factors and risk of canceruterine corpus, 6217

gestational choriocarcinomacase-control study, 1004

Respirationair or carbon dioxide mixture

pH modification, hydralazine and glucose, 1543

Respiratory burstenhanced activity of peritoneal cells

aclacinomycin, 3440Retinoblastoma

class II antigens, 1633susceptibility gene

chromosomal reorganization, osteosar-coma development, 3939

Retinoblastoma neoplasmsretinoid-binding proteins, 1124

7446




Retinole acidactin polymerization in HI, 60 cells,

6721cell cycle changes in maturing HL-60

cells, 5989cholesterol sulfate accumulation

esophageal epithelial cells, 5289chondroitin sulfate proteoglycan

differentiation-associated changes,U937 cells, 6103

effect of phorbol estercAMP-dependent protein kinases, ter-

atocarcinoma cells, 3993effect of sodium butyrate

ovarian adornÂ»carcinoma.6161effect on neoplastic salivary cells, 7219epidermal oxidation of retinol, 7038gap-junctional intercellular communica


3490herbimycin-A and

neuronal cell differentiation, neuroblastoma, 6530

inhibition of TPA-induced synthesisornithine decarboxylase mRN A. 2168

phorbol ester-stimulated differentiationprotein kinase C, U937 cells, 5779

protooncogene expressionHL-60/MRI cells, 6733

terminal differentiationgrowth inhibition, rhabdomyosarcoma,

5264therapy by directing differentiation in

carcinoma, 1999TPA and/or

modulation of transglutaminases, 74Retinoids

-binding proteinsretinoblastoma tumors, 1124

effect on xenoplanted human mammarycarcinoma

athymic mice, 3733growth and differentiation of tumors

murine embryonal carcinoma celllines, 3772

influence on growth and metastasishamster melanoma in athymic mice,

1465Retinol

risk of colorectal cancer, 4399vitamin intervention

precancerous lesions of esophagus inChina, 2280

Retroviruses-associated antigen

modulation, melanoma cells, 4954changes in oncogene expression

colon carcinogenesis, 3964evolution of cancer genes

mutation-driven process, 1697expression in transformed cells

platelet-derived growth factor, 4874history of human T-lymphotropic vi

ruses, 4131Kirsten-ra.s oncogene

clonal diversity, 4941-like sequences and oncogene expression

phÃ©nobarbitaltreatment, liver regeneration, 265

oncogenictransformation, mammary epithelial

cells, 4689transformation in rat cell lines


Rhabdomyosarcomachromosomal analysis, 983terminal differentiation

growth inhibition, retinoic acid, 5264Rhoads Memorial Award Lecture, 1Rhodamine 123

anticarcinoma activitymurine renal adenocarcinoma, 2061

m-diamminedichloroplatinum(II) resistance

effect of hyperthermia, 5101Rhodamine 12.ÃŒ

action of c/i-diamminedichloropla-tinum(II)

effect of hyperthermia, 2335Riboflavin

vitamin interventionprecancerous lesions of esophagus in

China, 2280Ribonucleosides

-restored heat resistancesuppressed protein synthesis, glucose-

deprived L929 cells, 1442Ribonucleotide reducÃase

effect of gallium on DNA synthesishuman T-cell lymphoblasts, 3014

hydro* yurea-resist ant leukemia LI 210cells

cross-resistance patterns, 5796inhibitors

leukemia LI210 cell lines, 839liver microsomal inactivation

4-methy 1-5-amino-1 -formylisoquino-line thiosemicarbazone, 6375

molecular mechanisms of drug resistance, 2029

Ml subunit in cellular proliferationquiescence, differentiation, 5151

Ricincytoplasmic suppression of tumorigenic-

ityreconstructed mouse cells, 830

Ricin Aability of niAh to form immunotoxins,

1119antibody conjugate

endocytosis, intracellular routing,3822

-containing immunotoxinsclinical trial evaluation, CD 19 and

CD22 antigens, 2610deglycosylated

immunotoxin preparation, hindereddisultidc linkages, 6396

enhancement of immunotoxin activityovarian and epidermoid carcinoma,

3919hepatotoxicity of saporin immunotoxins,

7072inhibition of T-cell tumor growth

T101, athymic mouse model, 4862kinetics of cell intoxication, 806-monoclonal antibody conjugates

disulfide-linked, galactose binding,4469

transplantation of non-T-leukemiacells, tumor regression, 4673

pulmonary metastasisimmunotoxin mediation of reduction,

3496tumor-reactive immunotoxins

pharmacokinetics, 2618, 2626

RIF-1 cellsthermoresistance

isolation and characterization, 1803RNA

amplified and overexpressed genesmultidrug-resistant cell lines, 5927

carcinoembryonic antigen familychromosomal localization, various tu

mors, 2550detection of drug resistance

enzymatic amplification, human tumors, 5775

detection of multidrug resistance genein situ hybridization, 4334

gene amplificationepidermal growth factor receptor,

esophageal cancers, 5119glyceraldehyde-3-phosphate dehydrogen-

ase gene expressionpancreatic adenocarcinoma, 6354

hepatocellular carcinomain vitro translation analysis, 2382

L-histidinol effect5-fluorouracil metabolism, 6664

inhibition of ribosomal gene transcription

morpholinyl anthracyclines, 4101interaction of second-generation anthra

cyclines with, 6962levels in metastasis

NM23 gene, 6550messenger: see RNA, messengertranscriptional inhibition of Ha-ras

interferon-induced revenants, mousecells, 5157

RNA, messengerfibronectin

down modulation, prostatic cancer,2042

genomic status of c-myc locusinfiltrating ductal carcinoma of the

breast, 199insulin-like growth factor II

human breast cancer, 6691liver tumors, 6844

oligonucleotidesinhibited gene expression, 2659

ornithine decarboxylaseretinoic acid inhibition, TPA-induced

synthesis, 2168p32 cDNA clone isolation, 4795peroxisomal .Â¿oxidation

rat tissues, 5316platelet-derived growth factor

transforming growth factor-a, 3910prostaglandin A: and c-myc expression

HL-60 cells, 2813protooncogene expression

HL-60/MRI cells, 6733Rosenthal Foundation Award Lecture, 5381RU 23908

optimal medical castration in male rats,6063

Salivary cellsneoplastic

effect of retinoic acid, 7219Salivary glands

adenocarcinomagrowth inhibition, normal human lÃ¬

broblasts, 2819ras p21, cAMP levels, 2898

Salmonella typHÃmurÃum

7447




i.-arabinose resistance testprimary tool in carcinogen screening,

907reactivity with DNA bases and mutage-

nicitymethylchrysene diol epoxide enantio-

mers, 1781Sandos tatin

partial inhibition of growthDunning rat prostate tumors, 4651

Sa porinimmunotoxins

hepatotoxicity, 7072Sapporo Cancer Seminar

primary and secondary prevention ofcancer, 4434

Sarcomacancer families

susceptibility to neoplasia, 5381cancer family syndrome

twenty-four kindreds, 53585-deazaaminopterin

5-alkyl derivatives, methotrexate comparison, 5686

Ewing's

patterns of protooncogene expression,4307

tumor-associated antigen, endocrinetissue, 6127

Glasgow osteogenicflavone acetic acid-induced DNA dam

age, 1279heat-induced vascular damage

thermosensitivity, 7226murine S180 variants

doxorubicin resistance reversal, for-skolin, 539

noncachectic patientsaltered leucine metabolism, 1374

radiation-induced injurytumor bed stroma, 2116

reproductive factorsrisk of cancer, uterine corpus, 6217

Yoshidaalterations in protein synthesis, 1554branched chain amino acids, paren

lerai nutrition, 2698Sarcoma cells

Nakahara-Fukuoka1-hexylcarbamoyl-5-fluorouracil, hy-

perthermia, 3977Sarcoma 180 cells

potentiation of Adriamycin cytotoxicitydipyridamole, 1208

Sarcoma virusFujinama

dexamethasone effects, neoplastictransformation, 7231

Gardner-Arnstein strain felineneosynthesis of gangliosides, 1753

-induced tumorstÃbroneciinreceptor expression, 5510

SchwÃ¤rmcellsdifferentiation of neuroblastoma cell

linesinduction by bromodeoxyuridine, 2531

neurofibromatosis-like diseasetransmissibility in damselfish, 3828

Seleniuminorganic

effect of dietary excess on colon carci-nogenesis, 1777

phenotype and growth of melanomasserum-free medium, 686

Seminomagerm cell neoplasms

blood group-related antigens, 5342Serine proteinases

effects of inhibitorsbasement membrane invasion, mela

static cells, 3307Serotonin

antitumor effectstumor necrosis factor-a, 4250

major serum factorphosphoinositide turnover, kidney

cells, 6697Serum

cancer patientsnatural killer cell activity, colorÃ©ela!

adenocarcinoma, 2596significance of a-2-L-fucosyltransferase

leukemic patients, 3998Shanghai

risk factors, breast cancer in women,1949

Sialic acidmono-, di, and tri-O-acetylated

normal and neoplastic colon, 483mucin-like antigens

monoclonal antibodies, pancreatic cancer, 3924

Sialic acidmucleoside conjugateinhibition of pulmonary metastasis

colon adenocarcinoma, 3728Sialoglycoprotein

expression on metastatic colon carcinoma, 2353

membraneIgG2a monoclonal antibody, small cell

lung carcinoma, 4318Sialosyl-Tn epitope

preparation of monoclonal antibodies,2214

Sialyl-fucosyl type 1 chaincancer-associated serum glycoprotein an

tigens, 3856Sialyltransferase

comparison of Le" antigens

human colon and pancreas, 3834expression correlated with human chro

mosome 11, 1489Simian virus 40

effects of transformationintercellular gap junctional communi

cation in fibroblasts, 3485human bronchial epithelial cells

T-antigen transformation, 1904-transformed uroepithelial cells

cytogenetic instability, chromosomechanges, 3215

Sinus cancermaxillary

case-control study in Japan, 1651Sister chromatid exchange

antitumor topoisomerase II inhibitorsChinese hamster cells, 512

assessment of cell cycle durationsomatic and spermatogonial cells,

5953cytotoxicity

alkylating chemotherapeutic agents,tumor cells, 3100

Ehrlich ascites tumor cells treated withcyclophosphamide

antineoplastic effect, caffeine, 1129induction by busulfan

chronic myeloid leukemia, 3435

induction by diaziquonehuman and mouse lymphocytes, 27

normal bone marrowPh-positive chronic myelocytic leuke

mia, 745persistently elevated

ethylene oxide-exposed primates, 5045role of metabolism and DNA adduct for

mationlymphocytes, diethylstilbestrol, 335

Skinalteration of cholesterol biosynthetic

pathwayspolycyclic aromatic hydrocarbons,

2555carcinogenesis

transcriptional control, keratin geneexpression, 3245

L-a-dioctanoylglyceroltumor promoter, 1736

inhibition of TPA-induced tumor promotion

curcumin, chlorogenic acid, 5941metastasis

highly pigmented melanoma variant,4897

nitrosamine formation from aminesbefore and after nitrogen dioxide,

1095papillomas

aneuploidy, 7-glutamyltransferase,3253

tumorigenesisprotection, tannic acid, 2361

tumor progression in SENCAR miceinitiator dose, papilloma, 7048

Skin neoplasmsalterations in epidermal polyamine levels

DNA synthesis, chrysarobin, 6390detection of activated oncogenes

sun-exposed body sites, 3341herpes simplex virus

inducible repair, xeroderma pigmento-sum, 6054

ultraviolet-inducedrejection, role of helper T-cells, 2325

Sodiumbreast cyst fluid

epidermal growth factor, 5860-deficient diet

restriction of tumor growth, 3445proteases in cyst fluid

human gross cyst breast disease, 6379Sodium bisulfite

chromosome alterationsSyrian hamster cells, 7246

Sodium butyrateeffect on ovarian adenocarcinoma, 6161modulation

plasminogen activator, glioma cells,291


368Sodium etiolate

effects on colon carcinogenesis7V-methyl-A''-nitro-./V-nitrosoguani-

dine-induced, 3035Sodium dirimÃate

-induced DNA lesionspolyadenosine diphosphoribose syn

thesis, V79 cells, 1100Sodium n-butyrate

modulation of calcitonin gene expression

7448




medullary thyroid carcinoma, 2096Sodium-potassium-ATPase

photosensitizing effects of hematopor-phyrin derivative

mammary adenocarcinoma, 3360Somatic cells

assessment of cell cycle durationsister chromatid exchange, 5953

Somatomedin-Cautocrine mitogenic stimulation

lung cancer cells, 3716Soma)ostatili analogues

oncological applications, 6977Sorcin

purificationmultidrug resistance, monoclonal anti

bodies, 3173Soybean agglutinin

binding cellslymphatic metastasis, mammary ade

nocarcinoma, 1451removal of breast cancer cells

model for purging human marrow,4573

Spermatogenesisprocarbazine-induced germinal cell apla

siapartial prevention by testosterone,

4354Spermatogonial cells

assessment of cell cycle durationsister chromatid exchange, 5953

Spermidinemetabolism and interconversion

NIH 3T3 cells, ras transfection, 3336Spheroids

diffusion and bindingantitumor antibodies, 4032

multicellularglucose diffusivity, 3905growth saturation, role of necrosis,

2432uptake kinetics of inAb. human malig

nant melanoma, 1856Spirohydantoin mustard

pediatrie Phase I and pharmacokineticstudy, 2292

SpleenT helper cells and accessory cells

tumor-specific CTL generation, 1422Sqiiamous SQCC/Y1 cells

differentiationchanges in glycosphingolipids, 2121

SR 4233metabolism by Chinese hamster ovary

cells, 5947Stature

adultrisk of cancer, 1658

breast cancer risk assessmentsanthropometry, 5363

Staurosporinecontrasting actions

neutrophils, epidermal cells, 4646Sterigmatocystin

effect on glucocorticoid receptorst>rosine aminotransferase, Reuber

hepatoma cells, 5188Steroids

dehydroepiandrosteroneinduction of ovarian granulosa cell tu

mors, 2788diabetes and

insulin receptor kinase, mammary ade

nocarcinoma, 3742effects of phenol red

breast cancer cell growth, 3693hepatic effects

structure-activity studies, 2462insensitivity

breast cancer cells, 4340peptide growth factors and

c-fos expression, breast cancer cells,802

risk of colorectal cancer, 4399Sterol

alteration of cholesterol biosyntheticpathways


Stomachbiomarkers of increased susceptibility


carcinogenesisphenolic antioxidants, 5310

gastric carcinogenesiscaerulein enhancement, 6332


Stomach neoplasmsanti-ros p21 monoclonal antibodies,

5503high risk of

diet, case-control study in China, 3518loss of chromosomal heterozygosity,

2988Streptomyces mediocidicus

teleocidins A and Btumor-promoting activity, 4211

Streptozotocindrug sensitivity assay

monolayer culture, colon carcinomas,3236

Stromafibrin-fibronectin degradation

ovarian carcinoma, 3507Strontium phosphate

human bronchial epithelial cellsT-antigen transformation, 1904

Subendothelial matrixinteraction of intravascular tumor cells

endothelial cells, 4065Substrates

effects of deoxycytidinethymidine kinase deficiency, deoxyri-

bonucleosides, 3681yV-Succinimidyl3-(tri-n-butylstan-

nyl)benzoate intermediateradiohalogenation of monoclonal anti

body, 1446Sudan III

mechanism of induced preventionchemical carcinogenesis in rats, 254

Sulfatideslaminin-dependent and -independent

adhesionmelanoma cells, 3367

Superoxide dismutaseeffect on Adriamycin tolerance

Chinese hamster ovary cells, 4493erythroleukemia maturation, 6674

Suppressor cellstumor-induced myelopoiesis

prostaglandin Kâ€¢¿�regulation, Lewislung carcinoma, 6826

Surface markersphenotype and growth of melanomas

serum-free medium, 686Surgery

chemotherapy andtiming of, osteosarcoma model, 5533

Swainsonineaugmentation of murine natural killer

cells, 1410Sweetners, artificial

squamouse cell carcinomabladder adenocarcinoma, 3853

Taiwanseroepidemiology of HTLV-1, 5042

Tamoxifendisparate actions

breast tumor growth, athymic mouse,812

endocrinologypremenopausal node-positive breast

cancer, 1026estrogen receptor and hormone respon

sivenessmedullary thyroid carcinoma, 2760

estrogens as cause of human cancer, 2464-hydroxy-A'-desmethyltamoxifen metab

olitehuman bile, 2304

inhibition of estrogen-induced renal carcinogenesis

DNA adduci levels, 779specific and direct binding

protein kinase C, 3626-stimulated growth of MCF-7 tumors

long-term antiestrogen administration,5183

vs. estradici effectsnormal breast cells, 7193

Tannic acidprotection against skin tumorigenesis,

2361Taxol

microtubule changes and cytotoxicityleukemic cell lines, 4093

T-cellsCD8+ depressed responses, 6992denaturation and renal unit ion of len-

tinan, 671early acting delayed-type hypersensitivity

effector cells, tumor rejection, 5922elimination of suppressor activity by

bleomycintumor-bearing rats, 6658

endocytosis and degradationanti-human CD3 mAb, 2249

helperrejection, ultraviolet-induced skin can

cers, 2325immune system of cancer patients

low dose cyclophosphamide, 1671inhibition of tumor growth

TlOl-ricin A-chain, athymic mousemodel, 4862

intervention in transportationmouse mammary tumor virus, mam

mary gland cells, 6555Lyt-2+

importance in tumor rejection, 4834polyclonal lymphocytosis

human T-cell leukemia virus I, 2585production of suppressor lymphokine

syngeneic mammary adenocarcinoma,943

spontaneous resetting

7449




molecular pathways of adhesion,Hodgkin's cell line, 37

tyrosine kinase YT16 expression, 8563T3 cells

disorganizing-overstabilizing drugscell proliferation, microtubules, 4892

Teleocidins A and Btumor-promoting activity, 4211

Icstii ulur neoplasmsdifferential repair of platinum-DNA ad-

ducts, 3019Testis

cadmium carcinogenesisdose-response, 4656

stage migrationgerm cell neoplasms, 3524

Testis neoplasmsestrogens as cause of human cancer, 246

Testosteronearomatization

epithelial tumor cells, ovarian carcinoma, 6491

imidazole-induced tyrosinase expressionB16 melnoma cell culture, 3586

increase in 5Â«-dihydrotestosteroneandrogen-independent prostate carci

noma, 609partial prevention

germinal cell aplasia, procarbazine-in-duced, 4354

2,3,7,8-Tetrachlorodibenzo-y>-dioxinAh receptor analysis

A431 squamous cell carcinoma, 2388Tetrachloro(</,/-fraiÂ»)l,2-diaminocyclohex-

ane platinum (IV)therapeutic and pharmacological studies,

1745l2-O-Tetradecanoylphorbol-13-acetate

alteration of cholesterol biosyntheticpathways


alterations in epidermal polyamine levelsDNA synthesis, chrysarobin, 6390

antitumor actionoleanane-type triterpenoid compounds,

5210biphasic effects on keratinocytes

down regulation, protein kinase C, 964calmidazolium and

differentiation modulation, coloniecancer cells, 6173

clonogenic keratinocytestwo-stage carcinogenesis, 6285

i,-a-dioctanoylglyceroltumor promoter in mouse skin, 1736

duration of exposurerequirement for transformation, 7126

effect on cAMP-dependent protein kin-ases

teratocarcinoma cells, retinoic acid,3993

-induced ( â€¢¿�delaytime lapse photography, HeLa cells,

1759-induced synthesis of ornithine decarbox-

ylase mRNAretinoic acid inhibition, 2168

induction of 8-lipoxygenasecomparison in SENCAR and C57BL/

6J mice. 658inhibition of chemotactic signals

intracellular calcium, HL-60 cells,2707

inhibition of induced tumor promotioncurcumin, mouse skin, 5941

inhibition of MCF-7 cell growthprotein kinase C activity, 6943

molecular mechanisms of carcinogenesiscancer prevention and treatment, 4135

nerve growth factor receptorschromatin, melanoma cells, 7200

ornithine decarboxylase activitymicrowave fields, 4222

retinoic acid and/ormodulation of transglutaminases, 74

reversible induction of anchorage-independent growth

normal mouse keratinocytes, 1566role of oxygen radicals

squamous differentiation, bronchialepithelial cells, 822

seed oil of Jatropha curcasnew tumor promoter, 5800

transfer of promotion sensitivitypro gene, 1195

Tetragastrininfluence of cimetidine on anticarcino-

genic effectAr-methyl-Ar-nitro-/V-nitrosoguanidine,

1591Tetrahydrofolates

characterizationxenografts of colon adenocarcinoma,

3062Tetrahydrouridine

clinical pharmacologyl-/3-D-arabinofuranosylcytosine, 1337

Tetraplatin: see Tetrachloro(i/,/-frfliÂ«)l,2-diaminocyclohexane platinum (IV)

Texas Gulf Coastoccupational risk factors, laryngeal can

cer, 1960T helper cells

accessory cells andtumor-specific CTL generation, 1422

ThermoresistanceRIF tumor cell strains

isolation, initial characterization, 1803Thermosensitivity

heat-induced vascular damage andmurine tumors, 7226

Thermotolerancedevelopment in Chinese hamster ovary

cellsglutathione depletion, heat shock pro

tein synthesis, 7033effect of hyperthermia

glycosyltransferases, Chinese hamsterovary cells, 5717

protein synthesisbone marrow progenitors, 3630

Thioether phospholipideffects on protein kinase C

HL-60 cell differentiation, 66696-Thioguanine

enhanced cytotoxicityADP-ribosyltransferase inhibitors,

5650HL-60 cells

mitogenic responsiveness to GM-CSF,2683

modulation of activity by guanine,3648

Thiolsexposure to A'-2-acetylaminofluorene

depletion of adenosine diphosphate-ri-bosyl transferase activity, 3581

rescue agentsLLC-Pk, cells as model, cisplatin

nephrotoxicity, 6017Thiotepa

antitumor effects of pentoxifyllinehuman cancer cells, 4375

Thrombospondininteractions with sulfated glycolipids and

proteoglycanshuman melanoma cells, 6785

laminin-dependent and -independentadhesion

sulfatides, melanoma cells, 3367Thromboxane

evidence for biosynthesislung adenocarcinomas, 2674

prostacyclin andincreased synthesis, ovarian malig

nancy, 2396Thymic neoplasms

immunohistological analysisPE-35 monoclonal antibody, 1896

Thymidineeffect on nitrosourea activity, 4272incorportion in hepatoma

linoleic acid, arachidonic acid, 3106increased levels of DNA lesions

leucovorin-5-fluoropyrimidine, colonadenocarcinoma, 4153

inhibition of uptakeLHRH agonist, 7252

Thymidine kinaseactivity of cytosolic isozyme

malignancy, lung tumors, 5001deficiency

substrate cycles, deoxyribonucleosides,3681

Thymidylateantifolate drug interactions, 2421synthesis inhibition

methotrexate effects on methylenete-trahydrofolate, LI210 cells, 3398

Thymidylate synthasedetection of drug resistance

enzymatic amplification, human tumors, 5775

mechanisms of innate resistance5-fluorouracil, 5894

proliferation-dependent cytotoxicitymethotrexate, leukemia, 5638

Thymidylate synthetaseinterferon interactions

halogenated pyrimidine antimetabo-lites, HL-60 cells, 4868

Thymomaimmunochemotherapy

use of idarubicin mAb conjugates, 926Thymosin fraction V

combined modality treatmentsmall cell lung cancer, 1663

Thymusglucocorticoid receptor at protein level,

2636Thyroid

carcinogenesiscytochrome P-450 induction, hydan-

toins, 2492C-cells

N-myc expression, neoplasia, 4073Thyroid cells

neoplasticepidermal growth factor receptor,

3652Thyroid neoplasms

7450




activated ras oncogenes, 4459anli-ru,v p2l monoclonal antibodies,

5503Tiazofurin

effects on protooncogene expressionHL-60 cell differentiation, 5965

T-lymphocytes: see T-cellsT-lymphoma cells

normal T-cell proliferationtransferrin-like autocrine growth fac

tor, 3425Tn antigen

IgG3 monoclonal antibodyblood group A antigen, 4361

Tobaccoeffects of timing and type

cigarette-induced bladder cancer, 3849esophageal carcinoma, 3843long-lasting effects of smoking

pulmonary drug-metabolizing enzymes, lung cancer, 4695

Toluidine blue Opyronin Y and

photosensitizing effects, 1295Topoisomerase I

camptothecin-resistant CHO cell mutants, 6404

mammaliandrug target, camptothecin, 1722

Topoisomerase IIantitumor inhibitors

sister chromatid exchanges, Chinesehamster cells, 512

effect of inhibitorshyperthermic cytotoxicity, 3932

effects of antileukemia agentsnuclear matrix-bound DNA replica

tion, CCRF-CEM leukemia cells,1850


5956-interactive antitumor drugs

estrogen and DNA damage, breastcancer cells, 297

phorbol ester-induced changesDNA cleavage, leukemia cells, 6625

production of protein-associated DNAbreaks

PZE, LI210 cells, 1404resistance of noncycling cells to anisa

crine, 310TPA: see 12-O-Tetradecanoylphorbol-13-

acetateTrachea) epithelial cells

cytogenetic changesearly stages, carcinogen-induced neo-

plastic progression, 702induction of ornithine decarboxylase ac

tivityasbestiform minerals, 709

Tranquilizersrisk of colorectal cancer, 4399

Transferringrowth requirements of colon carcinoma

monolayer and soft agarose, 2469-like autocrine growth factor

T-lymphoma cells, normal T-cell proliferation, 3425

phenotype and growth of melanomasserum-free medium, 686

Transformantsspontaneous

uniqueness, clone of BALB/c 3T3

cells, 2512Transformation

-associated cell surface antigenidentification, fetus-derived fibroblast,

2798characterization of chromium effects

liver epithelial cell lines, 6484gap-junctional intercellular communica

tionBALB/c 3T3 cells, 3490

normal homologous cellsHa-rfli oncogene, 3470

pro-l and pro-2 transfectantstumor promoters and antipromoters,

mouse cells, 6076requirement

duration of TPA exposure, 7126simian virus 40

intercellular gap junctional communication, fibroblasts, 3485

spontaneousC3H 10T'/2 cells, 5969A'-methyl-Ar'-nitro-Ar-nitrosoguanidine,

C3H 10T'/2 cells, 5977target

differentiation-induced Mil cells,4389

Transformed cellsselective killing

intercellular communication, therapeutic applications, 3203

Transformed growth-inhibiting factorlatency

human malignant effusions, 418Transforming growth factor-Â«

autocrine growth factorresponse, lung carcinoma cell line,

4976effusions from cancer patients

marker of tumor burden and prognosis, 5023

expression of mRNAsglioma cell lines, 3910

transformed hamster oral keratinocytes,3130

Transforming growth factor-/?biological activity

estrogen receptor-negative breast cancer cells, 3898

characterization of resistant subclonescolon carcinoma, 7120

enhancement of cell transformation,2832

induction of carcinoembryonic antigensecretion

fibronectin expression in colon carcinoma, 4059

modulation of plasminogen activator activity

endometrial adenocarcinoma cells,6384

regulatory effects of cell density, 4266stimulation

metastatic fibrosarcoma, 6999Transforming growth factors

growth modulation of mouse keratinocytes, 1596

4-as-hydroxy-L-prolinegrowth sensitivity of transformed ro

dent cell lines, 2483liver epithelial cells, 850multiplicity

human malignant effusions, 1792oncogene expression and

mammary epithelial cells, 7041therapy by directing differentiation of

carcinoma, 1996Transglutaminascs

tissue and epidermalmodulation, TPA and/or retinoic acid,

74Transplantation

fetal forebrain,/V-nitrosoethylurea induction, oligo-

dendrogliomas, 2871murine and human tumors into brain

subcutaneous tissues of mice, 6510non-T-leukemia cells

tumor regression, immunotoxins, 4673orthotopic implantation of colorectal

carcinoma, 6863progressive growth of fish tumors

thymic-aplastic mice, 741purging regimens

clonogenic assays in mice, 3394quantitative assays

spontaneous tumors in C3H mouse,4525

renal carcinomaerythropoietin-induced polycythemia,

3430studies of putative lymphosarcoma

Xenopus, 954Transplantation antigens

cyclophosphamide andinterleukin 2, active specific chemoim-

munotherapy, 101Trichothiodystrophy

DNA repair defectcellular response, ultraviolet light,

6090/V,/V',A'"-Triethylenethiophosphoramide

cyclophosphamide andcombination in vitro and in vivo, 94

I rifui ium pratenseassay for detection of anticarcinogens

natural products, 6257Trifluoperazine

ATPase activity of P-glycoproteinsmultidrug resistance, K562/ADM

cells, 49264,5',8-Trimethylpsoralen

repair of DNA damagenormal and Fanconi's anemia, 2015

Trimetrexateantifolate drug interactions, 2421characterization of transport

lymphoblastoid cells, lipophilic anti-folates, 6986

Phase I study, 5029Triphenylethylene

specific and direct bindingprotein kinase C, tamoxifen analogue,

3626Triterpenoid compounds

oleanane-type12-O-tetradecanoylphorboI-13-acetate,

antitumor action, 5210Tryptophan

concentration in culture mediaantiproliferative activity, 7-interferon,

346TSP-180

quantitation in normal and tumor tissue,816

Tubercidinmodulation of antibody response

natural killer cell activity, purine mi

7451




cleoside analogues, 4799Tuberculosis

risk factors for lung adenocarcinomapersonal and family history, 7279

Tumor-associated antigensATM-1

T-cell clone, sera of cancer patients,4848

autologous cytotoxic T-cell clonecharacterization, n-butyl alcohol, 3892

comparison of sialylated Le" antigens

human colon and pancreas, 3834Ewing's sarcoma

endocrine tissue, 6127gastrointestinal tumor-associated glyco-

proteinCA 19-9 expression, 1505

glycoprotein 72second generation monoclonal anti

bodies, 4588IgGj monoclonal antibody

( ÃŒM. lactone immunization, inhibitedmelanoma growth, 5680

monoclonal antibodyneuraminidase-treated cancer cells,

412monoclonal antibody with restricted

specificityprostate and breast carcinoma, 4543

Tumor-associated glycoproteinTAG-72

purification, monoclonal antibodies,6811

Tumor bed strinilaeffect of radiation-induced injury

metastatic spread, sarcomas and carcinomas, 2116

Tumor burdenprognosis and

transforming growth factor-a, cancereffusions, 5023

Tumor cellsantibody-mediated killing

attached effector cells, 624antiproliferative activity

ether lipid analogues, DNA-interactiveagents, 1788

autologous cytotoxic T-cell clonetumor antigen characterization, n-bu-

tyl alcohol, 3892blood How, 2641brain

sister chromai id exchange, alkylatingagents, 3100

cell growth and drug sensitivitysoluble tetrazolium/formazan assay,

4827collagenolytic activity

macrophage and lymphocyte potentia-tion, 6832

cytoskeletonplatelet adhesion role, platelet aggre

gation, 3787doxorubicin resistance

differing mechanisms, 2793drug-resistant

flow cytometric enumeration, 6037lysis by activated lymphocytes, 2372

effect of bleomycinelevated temperatures, two pH values,

615endothelial cell-derived interleukin 1

chemotactic activity, 7041extracellular matrix invasion assay

protein gels, 6933-fibroblast interaction

enhancement of metastatic capacity,1456

growth stimulationmononuclear cell-derived factor, 5411

humanprostaglandin biosynthesis, 4770

identification of platelet-aggregating factor

monoclonal antibodies, colon adenocarcinoma, 6411

interaction of melanoma with murinemesentery, 5296

intravascularinteraction with endothelial cells, sub-

endothelial matrix, 4065invasion

collagenase secretion blockade, estra-mustine, 6262

MDAY-D2collagen-binding glycoproteins, 4743

Mer" and Mer+ cellsmixed-function drugs, aerobic and hy-

poxic toxicity, 798mixed heterogeneous

dominance, tumor subpopulation,5747

MOPC-315tumor rejection, Lyt-2+ T-cells, 4834

murineantitumor activity, MX2, 6653

mutagen-treated murineexpression of gp70, 1137

nitrosourea-resistant Mer*

thermal sensitization, 1086patterns of methionine dependence, 6775protection against cytotoxic cells

fibrin coagulation, 5216rhabdomyosarcoma

terminal differentiation, retinoic acid,5264

RIFthermoresistance, isolation and char

acterization, 1803rodent and human

glutathione, various cell cycle phases,3661

glutathione levels, 3657synergistic cytotoxicity and DNA strand

break formationbromodeoxyuridine, bleomycin, 4244

tissue inhibitor of metalloproteinasesmelanoma cells, 5539

tumor necrosis factorlymphotoxin gene expression, 5417

viability and inoculum densitygrowth in agar, 3944

Tumor growthbreast

disparate actions, tamoxifen, 812Gompertzian model, 7067

delay with trimodality therapyFSalIC fibrosarcoma, 2693

effect of interferon-aA/D, 2366inhibition of T-cell line

T101-ricin A-chain, athymic mousemodel, 4862

mammarymast cells, prolactin binding and local

ization, 3765polyamines, progesterone, 3058reconstitution of site preference, 3698

restriction

sodium-deficient diet, 3445v-/ms-induced

inhibition by castanospermine, 1091I unioni Â¡ilalactivity

induction in alveolar macrophagesmonocytes, lung cancer, 3949

motility andinterleukin-2-stimulated lymphocytes,

3374Tumorigenesis

colonie cell proliferationstructural requirements, oxidized fatty

acids, 1771A'-ethyl-A'-nitrosourea-induced

major histocompatability complex(H-2), 6634

gene for granulosa cell tumors, 5092genetic convergence and divergence

tumor progression, 5911mammary

adrenal regulation, 3801dietary fat and caloric restriction, exer

cise, 4276influence of caffeine, unsaturated fat,

2074influence of caffeine, coffee consump

tion, 2068hyperplastic alveolar nodules, trans

plantation, 3197skin

protection by tannic acid, 2361Tumorigenicity

cytoplasmic suppressionreconstructed mouse cells, 830

dedifferentiated rat hepatoma line, 3258murine lymphomas

fluorescence-detected natural antibodybinding, 270

oncogene expression andpediatrie cancer, 2715S49 wild type and cyc~ lymphoma

adenylate cyclase, 641Tumor models

treatment-induced changesdrug sensitivity, 2749

xenogeneicradioiodine-labeled monoclonal anti

bodies, B-cell lymphoma, 2475Tumor necrosis factor

anticellular and DNA fragmenting activities

correlation, 6006antitumor effect of immunoconjugates,

3607breast cancer survival model, 5565circulating cytokines in metastatic cancer

patientsinterleukin 2, LAK cells, 5864

distinction from natural killer cell cytotoxic factor

recombinant human lymphotoxin, 891human macrophage function, 5604hyperthermia and

synergistic effect, 650, 654immunomodulatory properties, 544interleukin 2 and

activation, cytotoxic lymphocytes, 788lymphotoxin gene expression

human tumor cell lines, 5417mediator of cancer anorexia, 4567production in nude mice

muramyl peptides, bacterial vaccines,5766

role in macrophage activation

7452




tumoricidal activity, 5427self-induction of synthesis

human and murine cell lines, 5407synergy with -y-interferon and interleukin

2successful therapy, pulmonary mÃ©tas

tases, 2245toxic effect

tumor vasai hiturc in mice, 2179Tumor necrosis factor-a

antitumor effectsrole of serotonin, 4250

effects of hematopoietic suppressor molecules

granulocyte-macrophage progenitorcells, 1548

interleukin 2 andsynergistic antitumor effects, 4011

species preferencehuman and murine, 920

Tumor progressiongenetic convergence and divergence,

5911glioma malignancy stages

clonal genomic alterations, 5546Kirsten rov oncogene

clonal diversity, 4941phenotypic changes in neoplastic cells


2440retrovirus-associated antigen

modulation of melanoma cells, 4954SENCAR mouse skin

initiator dose, 7048Tumor promoters

antipromoters andpro-l and pro-2 transfectants, mouse

cells, 6076cytochrome P-450 induction

hydantoins, liver and thyroid carcino-genesis, 2492

L-a-dioctanoylglycerolmouse skin, 1736

duration of TPA exposurerequirement for transformation, 7126

-induced nuclear associationprotein kinase C, 1910

liverepidermal growth factor receptors,

modulation, 1162oxidation of retino! to retinoic acid

epidermis, 7038p32 cDNA clone isolation, 4795phorbol ester

comparison, SENCAR and C57BL/6Jmice, 658

ornithine decarboxylase activity, microwave fields, 4222

protein kinase C as receptor, 1phosphorylation of M, 34,000 to 40,000

proteinsprotein kinase C, epidermis, 4018

seed oil ofJatropha curcas, 5800teleocidins A and B

carcinogenesis, 4211transfer of pro gene transfection

JB6 cells, 1195transforming growth factor-/3, 2832

Tumorsaneuploid and diploid

tumor spread and DNA content, renalcell carcinoma, 3165

artificial heterogeneouscompositional stability, mitomycin C

as probe, 2669concomitant immunity

effector mechanism, murine plasmacy-toma, 1398

host effectors, isolation and reactivity,1153

detection of drug resistanceenzymatic amplification, 5775

detection of necrotic lesionsnovel method, human cancers, 5842

detection with monoclonal antibodiescolorectal cancer, 4348

endocrine and nonendocrineneuroendocrine markers, 4078

incidence and natureâ€¢¿�y-irradiation,Sprague-Dawley rats,

2451interstitial pressure

heterogeneous distribution, monoclonal antibodies, 7022

malignantnuclear preparations, lectin-binding

proteins, 551predictive value

MIvitro clonogenic assays, 5447primary

selection and overgrowth, genetics,6109

rat brainblood-brain barrier disruption, metho-

trexate, 694solid

antitumor activity, interleukin la,6011

CDS* tumor-infiltrating lymphocytes,

depressed responses, 6992chromosomes, 104910-ethyl-lO-deazaaminopterin, Phase I

trial, 5573glucose diffusivity in spheroids, 3905pathophysiology, cyclophosphamide

effect, 4206Ar-(phosphonacetyl)-i.-aspartate, bio

chemistry, 4434therapeutic attack of hypoxic cells,

775tobacco-related

lung and pancreas of rats, 6912transplan table

biological effects, phthalocyanine dyes,3040

vasculaturethermosensitivity, 7226

Tumor-specific antigensbutano! extraction

fibrosarcoma, ultraviolet light-induced,7004

lyrosinaseeffects of estradici

estrogen and progesterone receptors,melanoma, 3720

imidazole-induced expressiontestosterone effect, B16 melanoma,

3586influence of organ microenvironment

pigmentation, metastatic murine melanoma, 2258

Tyrosine aminotransferasemodulation of hormonal induction

glucocorticoid receptors, Reuber hepa-toma cells, 5188


368

Tyrosine kinasealteration in phosphorylation

granulocytic maturation, HL-60 cells,52

human T-cell-specific YT16 expression,856

phosphotyrosine phosphatase activitiesand

biochemical characterization, HL-60cells, 4299

protein activitypp60""irrexpression, flow cytometry,

4633

U

U-71,I84CC-1065 analogues

cell survival and cycle, Chinese hamster ovary cells, 109

U937 cellsdifferentiation-associated changes

chondroitin sulfate proteoglycan, 6103effect on differentiation

endogenous and exogenous interferons, 82

enhancement of Adriamycin antitumoractivity

polymethacr> late nanospheres, 1835phorbol ester-induced adhesion and

translocationprotein kinase C, 3168

phorbol ester-stimulated differentiationretinoic acid, protein kinase C, 5779

Ultraviolet Beffect of radiation on growth

melanoma cells, 4007Ultraviolet irradiation

antioxidant enzymesxeroderma pigmentosum fibroblasts,

2132detection of activated oncogenes

human skin cancers, 3341DNA damage

benoxaprofen and phagocytes, 3094DNA repair defect

trichothiodystrophy, 6090incidence of cutaneous melanoma

histology, 5036-induced fibrosarcoma

butano! extraction, tumor-specific antigens, 7004

-induced murine skin cancersrejection, role of helper T-cells, 2325

systemic effectsenhancement, chemical carcinogenesis,

620United States

comparative epidemiology of cancer,7285

incidence of cutaneous melanomahistology, 5036

Uric acidserum levels

cancer risk in humans, 2916Urinary bladder

carcinogeneffect of peroxidase inhibitors, 304

epithelial cellsDNA repair, arylamine metabolites,

4227papillary and nodular transitional cell

carcinoma, 2299Urinary bladder neoplasms

blood group-related antigens, 4113

7453




A'-nitrosobutyl-(4-hydroxybutyl)aminepharmacokinetic profile, 3666

Urinedeficient carboxyphosphamide excretion

cyclophosphamide administration,cancer patients, 5167

increased levelsfibroblast growth factor-like activity,

bladder or kidney cancer, 2083levels of A'-nitrosothioproline

ingestion of cod with vegetables, 4049plasma and

5-fluorouracil metabolites, 1680Uroepithelial cells

SV40-transformedcytogenetic instability, chromosome

changes, 3215Urokinase

determination of levelscolon carcinoma cell lines, 3112

modulation of metastatic potentialmurine melanoma cells, 1270

Urotheliumdifferential regulation of plasminogen ac

tivatorsepidermal growth factor, 5552

humanblood group-related antigens, 4113

normal and malignantglycosyltransferases, 4427response to blockade, polyamine syn

thesis and interconversion, 357Uterine cervix

carcinomahuman papillomavirus types, 993

Uterine corpusreproductive factors

risk of cancer, 6217Uterine curettage

risk of colorectal cancer, 4399Uterus

mAb reactive with human cervical ade-nocarcinoma

immunodiagnostic potential, 6565

Vascularityeffect of cyclophosphamide

pathophysiology, solid tumors, 4206Vascular leak syndrome

antitumor and antiviral natural immunity

interleukin 2, immunodeficiencystates, 6081

Vasculaturetumor

toxic effect, tumor necrosis factor,2179

Vasoactive intestinal peptidecellular processing

colonie carcinoma cells, 6201receptors

breast cancer cells, 5079V79 cells

bacteria andmutagenicity, CC-1065 and analogues,

32low-molecular-weight growth inhibitor

characterization, 3737mutagenicity

5-hydroxymethy 1-2' -deoxyuridine,

5466polyadenosine diphosphoribose stimula

tion

sodium chromate-induced DNA lesions, 1100

uptake of WR-2721 derivativestransported form of drug, 3634

Verapamilantiproliferative effect

brain tumor cells, 3617ATPase activity of P-glycoproteins

multidrug resistance, K562/ADMcells, 4926

-hypersensitive Chinese hamster ovarycells

properties of, 4477intrinsic drug resistance


reversal of doxorubicin resistancemultidrug-resistant myeloma cells,

6365Vimentin

diagnostic and therapeutic monoclonalantibodies

mesothelioma cell lines, 5228Vinblastine

effect on microtubulescell proiferation, 3T3 cells, 4892

Vinca alkaloidssnail neurons as model

testing, neurotoxic side-effects, 7184Vincristine


5956mechanisms of multidrug resistance

H L-60 cells, 3959methotrexate combination

other agents, acute lymphoblastic leukemia, 351

methotrexate transport in LI210 cells,5995

reversal of resistancequinacrine, P388 leukemia, 2064

verapamil-hypersensitive Chinese hamster ovary cells

properties of, 4477Vinculin

phosphorylationprotein kinase C role, HL-60 cells,

3324Virus

incidence and nature of tumorsâ€¢¿�Â»â€¢-irradiation,Sprague-Dawley rats,

2451rare events as clues to cancer etiology,

3544tumor

DNA, oncogenes, 493Vitamin A

dietary /3-carotenecancer of the prostate in Japan, 1331

oxidation to retinoic acidepidermis, 7038

Vitamin I!,,metabolism in McA-RH7777 cells, 1080

Vitamin Cdiet and high risk of stomach cancer in

China, 3518risk of colorectal cancer, 4399vitamin E and

prevention of recurrence, colorectalpolyps, 4701

Vitamin I>,chondroitin sulfate proteoglycan

differentiation-associated changes.

U937 cells, 6103Vitamin K

-dependent protein deficient serumfactor X activator capabilities, Lewis

lung carcinoma, 6504Vitamins

diet and mesotheliomacase-control study in Louisiana, 2911

intervention trial in Chinaprecancerous lesions of the esophagus,

2280Voronoi's method

proliferating area of human gliomaintercapillary distance, 2938

VP-16: see EtoposideVulvar neoplasms


VX-2 tumortissue-specific pharmacodynamics

5-bromo-2 '-deoxyuridine incorpora

tion, 6900

W

Walker 256 carcinomablood flow and venous pH

hyperglycemia, 1201effect of galactose on systemic hemody-


sues, 1476Wheat germ agglutinin

-resistant human melanoma mutantsmetastatic profiles, nude mice, 665

White blood cellspolycyclic aromatic hydrocarbon-DNA

adductsfoundry workers, 2288

\\ ilins' tumor

age distribution, 1653cancer families

susceptibility to neoplasia, 5381WR2721

derivativesuptake by cells in culture, 3634

influence on DNA cross-linkingnitrogen mustard, bone marrow and

leukemia cells, 6002radioprotection of cells, 3641

Xanthine oxidaserole in interferon-mediated depression

hepatic cytochrome P-450 system inmice, 2107

Xenograftscarcinoma

radioimmunolocalization, second generation monoclonal antibodies, 4597

characterization of colon cancer mucin,6678

Clouser and renal cellmonoclonal antibody uptake, blood

flow, 188colon adenocarcinoma

folate pools, 3062colon cancer

radioimmunotherapy, carcinoem-bryonic antigen, 3270

tumor targeting, second antibody,2005

gastric adenocarcinoma growtha-difluoromethylornithine, 3265

human

7454




cu-diamminedichloroplatinum(II)andmitomycin C, interferon action, 64

human breast cancermetabolism in vivo, 7264

human gliomaamplification, epidermal growth factor

receptor gene, 2231treatment, radioimmunotherapy, 2904

human glioma modelantiglioma monoclonal antibody, ther

apeutic efficacy, 559human tumor in nude mice

metalloporphyrin enhancement, magnetic resonance imaging, 4604

medulloblastomaenhanced melphalan cytotoxicity, glu-

tathione depletion, 2764rodent and human tumor cells

glutathione levels, 3657transplantable

chemotherapy, bifunctional alkylatingagents, 4189

tumor transplantabilitymyc family gene abnormality, lung

cancers, 6025quantitative studies in mice, 6510

variant forms of rat epidermal growthfactor

presence in urine of rats bearing human tumors, 1428

Xenopusmycobacterium-induced infectious granu

loma, 958putative lymphosarcoma

transplantation studies, 954Xeroderma pigmentosum

cancer in homozygotes and hÃ©tÃ©rozygotes in Britain, 2929

domain-oriented repair synthesis, 844fibroblasts

antioxidant enzymes, 2132formation and repair of cisplatin-DNA

adductsfibroblasts, 6058

inducible repairherpes simplex virus, 6054

ultraviolet light responseDNA repair defect, trichothiodystro-

phy, 6090X-ray

f;s-diamminedichloroplatinum(II) cross-resistance

human tumor cell lines, 5133recurrent tumor sensitivity

rat model, mammary tumors, 4549

Yeastinternucleosomal cleavage

bleomycin, phleomycin, 6837

Zincmetabolism in Ehrlich cells, 3381vitamin intervention

precancerous lesions of esophagus inChina, 2280

7455



1988;48:7401-7455. Cancer Res Subject Index

Updated version

http://cancerres.aacrjournals.org/content/48/24_Part_2/7401.citation

Access the most recent version of this article at:

E-mail alerts related to this article or journal.Sign up to receive free email-alerts

Subscriptions

Reprints and

[email protected] at

To order reprints of this article or to subscribe to the journal, contact the AACR Publications

Permissions

Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)

.http://cancerres.aacrjournals.org/content/48/24_Part_2/7401.citationTo request permission to re-use all or part of this article, use this link



http://cancerres.aacrjournals.org/cgi/alerts

mailto:[email protected]



Documents

Index to Volume 48 - Cancer Research · thylpsoralen, 2015 Aneuploidy sequential development â€¢¿y-glutamyltransferase,skin papillo-mas, 3253 Anorexia cancer tumor necrosis factor